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I 
 
Summary 
 
We have attempted to contribute to the arsenal of methods to modulate protein-
protein interactions, targets that are increasingly important for pharmaceutical 
applications. Minimalist α-helix peptidomimetics, scaffolds that can display amino 
acid side chains in a topologicaly similar way as an α-helix, were synthesized. The 
basic architecture consisted of a multimeric scaffold that was made using a 
modular synthesis strategy. This was accomplished via the assembling of 
(hetero)cyclic monomers using a palladium catalyzed aminocarbonylation amide 
bond formation. These monomers were designed in such a way that amino acid 
side chains can be attached to them, including those bearing reactive functional 
group. Additionally, the option to introduce other functionalities (for post-
modification) is also present.  
Flow chemistry was used to expand our repertoire of synthetic tools and several 
flow protocols were developed with a much wider applicability than just our target 
molecules. This includes a Negishi aryl-alkyl coupling method using a supported 
catalyst and a safer carbonylation method using carbon monoxide precursors. A 
novel unstable carbon monoxide precursor was also utilized in flow and when 
using a special tube-in-tube reactor design, interesting results were obtained that 
call for further research. 
The end result was the successful preparation of a variety of oligoaryl amide α-
helix mimetics displaying diverse amino acid side chains.  
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Samenvatting 
 
Proteïne-proteïne interacties genieten steeds meer belangstelling voor 
farmaceutische toepassingen. We hebben getracht om bij te dragen aan manieren 
om deze complexe interacties te moduleren door gebruik te maken van 
minimalistische α-helix mimetica. Deze moleculen hebben een basisskelet dat 
aminozuurzijketens kan projecteren op een topologisch gelijkaardige manier als bij 
een α-helix. De basisarchitectuur van dit skelet is een multimeer van kleinere 
hetero(cyclische) monomeren die via een modulaire synthesestrategie werden 
gekoppeld. Hiervoor werd gebruik gemaakt van een palladiumgekatalyseerde 
aminocarbonyleringsreactie om de nodige amidebinding te maken. De monomeren 
werden ontwikkeld zodanig dat aminozuur zijketens, ook deze met reactieve 
functionele groepen, eraan gekoppeld konden worden. Verder was ook de optie 
voorzien om andere functionaliteiten in te bouwen op het basisskelet met het oog 
op post-modificatie. 
Flowchemie werd gebruikt om ons arsenaal aan synthesetechnieken uit te breiden. 
In deze context werden verschillende syntheseprotocollen ontwikkeld die een 
breder toepassingsdomein hebben dan enkel onze doelmoleculen. Een Negishi 
aryl-alkylkoppeling met behulp van een geïmmobiliseerde  katalysator en een 
veiligere manier om carbonyleringen uit te voeren door gebruik te maken van 
koolstofmonoxideprecursoren waren het resultaat. Een onstabiele 
koolstofmonoxideprecursor werd gebruikt in combinatie met een nieuw reactor- 
concept om interessante resultaten te verkrijgen die momenteel nog verder 
onderzocht dienen te worden. 
Het eindresultaat was de succesvolle synthese van een reeks oligoaryl amide α-
helixmimetica waar diverse aminozuurzijketens aangehecht  zijn.
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1.1  The Interactome 
 
Imagine a metropolis, filled with people moving fluidly through the many streets 
and buildings. Every person with its own job, constantly working to sustain the 
city by interacting with other specific people. If the city is an analogy for the cell, 
then the people are the proteins populating it, each with a specific function and 
specific interactions with other proteins. If one were to draw the proteins as points 
and draw lines between those that interact, the interactome map will emerge: a 
complex network of interacting biomolecules which regulates the functioning of a 
cell.1 Although strictly speaking there are several types of interactome networks 
(such as metabolic and gene regulatory networks), the most relevant here is the 
protein-protein  interaction network (PPIN). In network theory terms,2 this model 
describes the proteins as nodes (or vertices) and the protein-protein interactions as 
edges connecting these nodes (figure 1.1). The total protein protein interactome of 
humans, estimated to entail approximately 130 000 to 650 000 binary interactions3, 
4
 remains mostly unmapped. Efforts are being made to resolve this using high-
throughput techniques such as yeast-2-hybrid (Y2H).5 But for now our city, it 
seems, remains mostly hidden in the dark.  
 
Figure 1.1: Graphical illustration of a part (~5500 PPI) of the interactome of C. Elegans. From 
reference 6. Reprinted with permission from AAAS. 
It bears no mentioning that protein-protein interaction networks are of vital 
importance. Indeed, when perturbations arise in the interactome network, disease 
and afflictions can begin to manifest.7 Some examples of pharmacologically 
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relevant PPIs are the Bak/Bcl-xL (cancer)8, CD4/gp120 (HIV)9, VWF-GPIbα 
(thrombosis).10 
Which naturally leads us to the questions: Can we modulate protein-protein 
interactions? And what are the advantages compared to more conventional targets 
(e.g. enzymes)? 
 
1.2  Protein-Protein Interactions (PPI) as Drug Targets 
 
Traditionally, drug development has been mostly targeted at classic druggable (the 
ability to modulate the target with a small molecule) proteins such as kinases, G-
protein-coupled receptors and enzymes.11 These targets usually have well defined 
binding sites or pockets, which can accommodate a small molecule. In addition, in 
many cases a small molecule partner is already available as a starting point in the 
form of natural substrates or a natural product.11 However, by focusing only on 
these types of targets a large, fertile field of  possible therapeutic applications was 
left untapped: the protein-protein interactions. With good reason: for a long time, 
PPI were considered undruggable because they differ so much in comparison to 
the more conventional targets. Some of the most important features of a PPI are: 
• Large (1200-4500 Å2) and shallow but dynamic interaction surfaces.12  
• Mostly driven by hydrophobic interactions, but with small functional 
epitopes which have a large influence on binding (hot spots).13 
The surfaces of PPIs are indeed quite large, considering that the average contact 
surface14 between a small molecule and protein is about 300-1000 Å2. So it would 
appear at first sight that we are looking for a shelter for our small molecule 
inhibitor in the outstretched, flat wasteland of the interaction surface. However, 
recent molecular dynamics experiments12, 15 revealed a different situation: the 
interaction surface is in fact dynamic, with transient pockets opening and closing 
in the space of nanoseconds (figure 1.2). Many of them are too small to 
accommodate a small molecule, but some have sufficient size. Because of their 
dynamic nature, they are not always visible in crystallographic structures of the 
free protein or protein-protein complex. So a better look reveals that the wasteland 
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is in fact shifting and moving and could form a cavity for a small molecule to 
embed itself in. 
 
Figure 1.2: Dynamic PPI surfaces. Left: molecule docked in dynamic surface as calculated using 
molecular dynamics. Right: The same binding area as determined by XRD. Reprinted with 
permission from reference 15a. Copyright 2007 American Chemical Society. 
But another challenge awaits: when two proteins come together, how can all of the 
interactions they make on the relatively huge surface be interrupted by something 
much smaller? Closer examination of general principles of PPI (based on alanine 
scanning of databases of known complexes) showed that in most cases, successful 
interaction is highly dependent on just a small amount of key amino acid 
residues.13,16 These are usually located close to each other on the interaction 
surface, forming a so called hot spot. This crucial area is usually surrounded by 
highly hydrophobic regions, forming a sort of seal (similar to an O-ring) against 
bulk solvent which would otherwise interfere (figure 1.3). Due to the lack of 
permanent clefts, which are protected by being buried inside the protein, this is an 
alternative way to keep the bulk solvent away from the crucial interacting area. 
This is good news for the prospective PPI inhibitor seeker, as binding to this much 
smaller hot spot is often sufficient to disrupt the whole complex. In addition, hot 
spots often have good adaptability to somewhat change their topology, which 
could for example lead to better accommodation (induced fit) of a small molecule 
binding to it.17 
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Figure 1.3: Interaction zones on NF-κB Essential Modulator/IKKβPPI. Hot spot regions 1 and 6 are 
complementary to regions 2 and 5 respectively. Regions 3, 4, 8 and 7 support the hot spot regions. 
From reference 18, Creative Commons license. 
So even though things looked rather bleak at the beginning, at least there is some 
consolation in these facts that PPI inhibition by small molecules is possible.  
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1.3  Strategies in Targeting PPI’s 
 
The opportunities that lie in PPI inhibition from a pharmacological point of view 
have been recognized by the scientific community for more than a decade. Thus, 
several strategies have been developed to address the difficulties in finding 
modulators of PPI (figure 1.4): 
 
Figure 1.4: Strategies to inhibit PPI. 
High-throughput screening (HTS),19 is a well known method where a large set of 
compounds is physically screened for inhibition of a certain PPI. Then 
optimization of hits can take place using medicinal chemistry approaches. It does 
require rather expensive equipment and a reliable, high-throughput biological 
assay protocol.20 This method has been used successfully in several cases, for 
example by Roche to develop a new class of compounds, the nutlins,21 which are 
active against the HDM2/p53 PPI. One derivative (RG7112, 1.1, figure 1.5) is now 
in phase I clinical trials as an anti-tumorogen.22 However, there are some caveats 
when applying high-throughput screening to PPI. It was quickly realized that 
traditional screening libraries are usually not suitable for PPI, as they were tailored 
towards activity against more conventional biological targets, such as enzymes.23 
Introduction -Chapter 1- 
  
-8- 
 
New compound libraries are needed, with chemotypes more suitable for PPI. This 
would include compounds with a more 3D character24 and somewhat larger than 
traditional medicinal molecules.  
Fragment-based screening25,26 takes a different screening approach. Instead of 
searching through large libraries of drug-sized molecules, smaller collections of 
only low molecular weight ( <300 Da) fragments are screened for weak binding 
(0.05 – 1 mM range) with the target protein.27 When such fragments have been 
found, they can then be combined (covalently) into larger molecules to hopefully 
result in a high affinity modulator. Again optimization using medicinal chemistry 
will be needed to obtain a lead structure. Such weak binding fragments usually 
cannot be detected using bioassays, rather, biophysical techniques such as NMR or 
XRD need to be used.28 The advantages are that the hit rate of this type of 
screening should, in theory, be higher than for normal HTS and that more 
chemical space can be covered with less effort. The challenges are in finding 
proper fragments and a suitable method of linking them. Fragment based screening, 
combined with computational methods, was used by our research group (in 
collaboration with several other research units) to find modulators of the VWF-
GPIbα protein-protein interaction29 (see Appendix). Another example is a small 
molecule developed by Sunesis (SP307, 1.3, figure 1.5), using fragment based 
screening, that is active against TNF-α, with applications in a host of autoimmune 
disorders.30 In another example, scientists at Abbott used high throughput NMR 
screening to obtain an inhibitor to Bcl-2.31 This inhibitor now goes by the name of 
Navitoclax (1.2, figure 1.5) and is currently in phase II clinical trials for cancer 
treatment. 
Virtual screening can be used to identify possible binding sites for a small 
molecule on the surface of a PPI in silico.32 As soon as such a prospective site has 
been found, computational models (such as pharmacophore queries) can be 
developed to screen databases of virtual molecules. The results can be combined 
with molecular docking algorithms to obtain a database of virtual hits to be tested 
in a bioassay for binding activity. Compared to other screening  methods, virtual 
screening is low-cost. However, accurate structural information of the target is 
required and binding pocket finding algorithms must be combined with molecular 
dynamics (MD) computations to take into account the dynamic nature of the 
interaction surface15b,33,34 (see 1.1.1). This method was used by our research group 
(in collaboration with, among others, the Laboratory for Molecular Modelling and 
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the Laboratory for Thrombosis Research) to identify a small molecule modulator 
of the VWF-GPIbα protein-protein interaction35 (see Appendix). 
Biological approaches utilize macromolecular ( > 5000 Da) modulators made by 
living systems, mostly in the form of antibodies or (fusion) proteins.36 This 
strategy also includes biopharmaceuticals (also called biologicals), an increasingly 
important class of drugs. Of the top 10 selling drugs of Q4 2013,37 four are 
biologicals (Humira®, Enbrel®, Remicade®, Neulasta®). In addition, in 2013, 
biologicals made up more than 10% share of the pharmaceutical market (>40 
billion dollar). Another demonstration of the commercial importance of PPIs. 
Biopharmaceuticals have the advantage of excellent selectivity against their target 
and slow clearance. However they need to be injected intravenously or 
subcutaneously and have very poor membrane permeability, limiting their range to 
extracellular targets. Moreover they are also rather expensive to produce compared 
to small molecules. Recent developments have tried to downscale the size of these 
macromolecules by grafting functional epitopes onto naturally occurring 
miniproteins.38,39 Technically, biological methods such as Yeast-2-Hybrid (Y2H) 
and phage display5 could also be considered as part of this approach. However 
they are often used to characterize or discover important binding epitopes of PPI, 
rather than actually deliver pharmacologically useful modulators.40,41,42 
Epitope mimicry/structure based design attempts to modulate a PPI by using the 
structure of the binding epitope (hot spot) as a starting point.20,43 Protein motifs 
which are known to interact with the binding epitope can be mimicked by 
stabilized peptides or peptidomimetics having the same secondary structure.44 
Another possibility is topology mimetics, molecules inspired by supramolecular 
chemistry that have a large, complementary interaction surface.45 Finally, small 
molecules can be used which mimic the spatial orientation of the motif residues.46 
Transferring a protein epitope to a small molecule was used to find a LFA-1 
antagonist,47 which provided a starting point for scientists at Shire to use medicinal 
chemistry (SAR) refining to develop Lifitegrast48 (1.4, figure 1.5). This molecule 
is currently past phase III clinical trials to treat dry eye disease.22   
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Figure 1.5: Some examples of small molecule inhibitors of PPI currently in clinical trials. 
 
1.4  Structure Based Design of Small Molecule PPI modulators 
 
The biological approach, while proven successful, is one that is reserved to the 
domain of biology and biochemistry. It also suffers from some disadvantages that 
comes with its macromolecular nature. The different screening strategies (high-
throughput, fragment-based and virtual) are very interesting alternatives, but from 
the perspective of a chemist the most interesting route is arguably the one purely 
based on rational design. It is here that synthetic chemistry can be used to the 
fullest by designing and preparing new scaffolds that can mimic protein secondary 
structures: the peptidomimetics.49,43,50,20 The field of peptidomimetics is vast and is 
usually subdivided based on the protein secondary structure that is being 
mimicked. Among them, one motif stands out above the others: the α-helix. 
 
1.4.1 The α-helix Motif 
 
Analysis of PPIs stored in the Protein Data Bank (PDB) has shown that α-helices 
are present on the interaction surfaces in 62% of the cases.51 It is thus quite clear 
that α-helices are a very important motif and that mimetics of this secondary 
structure could be used in a wide variety of PPI. The α-helix adopts a right-hand 
coiled structure, stabilized by hydrogen bonding between the backbone amide 
RG7112 (1.1) Navitoclax (1.2) 
SP307 (1.3) Lifitegrast (1.4) 
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C=O of the i residue and the backbone NH of an amino acid 4 residues higher up 
the helix (i+4 residue). Each turn of the helix contains 3.6 residues, which means 
that amino acid side chains are displayed on three ‘faces’ of the helix (figure 1.6). 
Each face being made up from an i, i+4 and i+7 residue. Analyzing known 
interactions has shown that roughly 60% of helices have hot spot residues on just 
one face, 30% on two faces and only 10% on all three.51 So peptidomimetics 
which can mimic even just one face already cover a large share of the known 
protein-protein interactions.  
 
Figure 1.6:left: α-helix, showing the Cβ in yellow. Right: Helix faces (view from top). 
With the structural characteristics of the α-helix known, the next step is to try and 
emulate its topography in order to design effective mimetics. 
 
1.4.2 α-Helical Constrained Peptides 
 
The most obvious way to mimic a peptide motif is quite simply to make the (short) 
desired sequence (based on the binding PPI epitope) and to use it. However, short 
peptides (<30 amino acids) made of proteinogenic amino acids are highly flexible 
and are usually unable to maintain a stable 3D structure by themselves.52 Methods 
are therefore needed to stabilize or constrain the desired conformation of these 
peptides which are sometimes referred to as Type I inhibitors53 in the context of α-
helix mimicry. Several possible strategies can be used to enforce an α-helical 
conformation: 
Helix inducing amino acids can be built into a functional epitope containing 
peptide, to increase its propensity to form a helical conformation. Natural amino 
acids such as alanine, leucine, methionine and glutamine for example are known 
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helix stabilizers,54,55,56 but usually not sufficiently effective in small peptides. Salt 
bridges between residues on the i and i+4 position on the other hand have
used to enforce helical conformations.57 Non-proteinogenic 
acids like Aib can also impart a helical conformation,
antibiotic Alamethicin59 (figure 1.7).  
Figure 1.7: Alamethicinα-helix, Aib α,α-substituents colored in yellow.
N-capping is a strategy that makes use of a specific template at the N
peptide to nucleate an α-helix conformation.60 This is done by mimicking the 
ordering of the carbonyl groups of the first turn of an 
demanding step in the folding process.61 Several different templates have been 
designed, some examples by Kemp et al.62(1.5) and Austin 
in figure 1.8. A special type of N-cap is the hydrogen bond substitution (HBS)
technique. In this case the hydrogen bonds of the first helix turn 
covalent bonds made via an alkene metathesis reaction
advantages, compared to template N-caps, are easier synthesis and less added 
hydrophobic bulk. 
N
N
O
N
O
O
HN
O
S
Peptide
N
H
O
COO
OO
O
N
H
R
Peptide
Figure 1.8: N-capping stabilization of α-helices. a: Triproline template by Kemp et al., b: 
Template by Austin et al., c: Start of helical turn, showing hydrogen bond between i and i+4 
residue. d: HBS technique, replacing the hydrogen bond by a metathesis crosslinki
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Stapled peptides have their secondary structure stabilized by crosslinking amino 
acid side chains,65 usually between the i and i+4 or i+7 residue (figure 1.9). 
Several approaches have been followed to accomplish this, including the use of 
disulfide66 and lactam67 bridges. Alternatively, rigid spacers can be used to connect 
two side chains68. Huisgen cycloaddition, forming triazole linkers, is also a 
possibility.69 Residues with alkene functional groups can be linked via ring closing 
metathesis70,71 (hydrocarbon stapling). This technique was used by Aileron 
therapeutics to produce a stapled peptide (ALRN-5281), a possible anti-cancer 
therapeutic that currently finished phase I clinical trials.72,22  
 
Figure 1.9: Peptide stapling. Left: Via introduction of a rigid linker. Right: By crosslinking 
reactions of the side chains. 
Constrained peptides are an interesting option in the field of peptidomimetics, 
cutting down a protein to just a (small) binding epitope. However it is possible to 
take an even more minimalistic approach and get rid of the peptidic backbone as 
well. In the end, it are mostly the amino acid side chains that contribute most to 
the binding anyway.73 This approach will give rise to molecules that have stripped 
the helix to its bare essentials, so they have been called minimalist mimetics.46 
 
1.4.3 α-Helix Minimalist Mimetics 
 
When an α-helix is regarded as simply a scaffold that projects amino acid side 
chains in particular directions in 3D space, it should be possible to make other, 
smaller scaffolds that can do more or less the same thing. This is the principle of 
minimalist mimetics, where the helix is replaced by a small molecule scaffold that 
can display amino acid side chains in the same spatial positions as an α-helix.65, 
74,75
 This class of peptidomimetics is also called type III or topographic mimetics.53  
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The first mimetic of this class to be developed is the 2,6-disubstituted indane 1.7 
skeleton (figure 1.10), reported by Rees et al.76 This scaffold is able to mimic the i, 
i+1 residues of an α-helix and showed binding affinity to the tachykinin receptor 
(a neuropeptide).  
 
Figure 1.10: The indane scaffold. 
After this initial success, the hunt was open for new, more diverse minimalist 
mimetics. A broad range of scaffolds has been developed since the humble indane, 
but most of them fit a general principle: they can adopt relatively well defined 
conformations with limited degrees of freedom. This property logically follows 
from the fact that the scaffolds must be able to reliable project the amino acid side 
chains in the same specific topology as an α-helix. It is also not surprising then 
that aromatics are often encountered in the scaffolds. To determine whether a new 
scaffold will be structurally suitable for helix mimicry, two methods can be used. 
The first and simplest method is to compare the distances of the side chain tethers 
on the mimetic to the separation between amino acid Cβ atoms of an α-helix 
(figure 1.11, left, table 1.1). While this method provides a quick way to identify 
possible mimetics, it disregards how the side chains are projected in space. To take 
this into account, a more stringent test would be to compare the Cα-Cβ vectors46 of 
the prospective mimetic to those of an α-helix (figure 1.11, right). This requires 
more computation however. A rigorous test requires thorough conformational 
analysis of the molecule under consideration, which is usually done by sampling 
minimal energy conformations and clustering them.77  
 
 
 
1.7 
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Figure 1.11: Minimalist scaffold design. Left: Based on Cβ distances. Right: Based on Cα-Cβ vectors.  
 
Table 1.1: Cβ-CβDistances of amino acid side chains in an α-helix. 
Seq. C
β
-Cβ 
(Å) 
i-i+1 5.2 
i-i+2 7.1 
i-i+3 5.6 
i-i+4 6.5 
i-i+5 9.8 
i-i+6 10.8 
i-i+7 10.7 
i-i+8 12.9 
 
The different minimalist mimetics can be subdivided according to the nature of 
their scaffold: 
Singular scaffolds have a core structure with substitutions at their periphery that 
are spaced in such a way that they have the correct distances for helix mimicry 
(figure 1.12). The indane scaffold 1.7, encountered earlier, is among this group. 
Anthracene core structures 1.8 were shown to be able to mimic i, i+2 residues of 
an α-helix and this scaffold was able to inhibit the Bcl-2/Mcl-1 PPI (relevant in 
antitumor applications) with submicromolar to micromolar affinity.78 Dömling et 
al.79 designed scaffolds (1.9) based on easily accessible van Leusen imidazoles, 
which can be made via a multi-component reaction (MCR). A pyridylpyridinone 
mimetic 1.10 was derived from the indane skeleton, to mimic the i, i+3, i+4 side 
chains.80 This mimetic proved to have improved water solubility and showed 
inhibitory activity against the estrogen receptor-coactivator PPI (relevant in cancer, 
osteoporosis and cardiovascular areas). Even old friends like the 
benzodiazepinediones (1.11) turned out to be able to have peptidomimetic 
properties.81 They were shown to be effective antagonists of the HDM2-p53 PPI.  
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Figure 1.12: Singular minimalist mimetics scaffolds 
Larger scaffolds (figure 1.13) can incorporate chirality82 (1.12) or extend the 
indane skeleton83 (1.13). More interesting cases are the benzoylurea systems of 
Hamilton et al. (1.14)84 that can display up to five residues and mimic two sides of 
an α-helix. 
 
Figure 1.13: Larger singular scaffolds. 
Unfortunately many of these scaffolds are hydrophobic, which hampers their water 
solubility. To address this issue, mimetics have been developed with higher 
intrinsic hydrophilicity, using thiazole heterocycles85 (figure 1.14, 1.15). Another 
interesting approach was taken by the group of Rebek.86 They first introduced the 
concept of ‘wet edge’: designing mimetics in such a manner that the side exposed 
to the solvent (not projecting residues) is as hydrophilic as possible (1.16). 
 
Figure 1.14: Peptidomimetics with improved solubility. 
1.10 
1.12 1.13 1.14 
1.9 1.8 
1.15 1.16 
1.11 
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Multimer scaffolds are composed of monomers, each displaying one or more 
amino acid side chains (figure 1.15). Their multimeric structure is an advantage 
because this makes them amendable for modular synthesis. In addition they can be 
extended to also mimic longer helices simply by adding more monomer units.87 
The terphenyl multimer by Hamilton et al.88 (1.17) fits this category and this 
scaffold has shown biological activity as a Bcl-xL antagonist (a protein involved 
in some types of cancer). A modular synthesis for this mimetic was also 
developed.89 This scaffold, and its heterocyclic counterparts such as 1.1890 and 
1.19,91 can mimic the i, i+3 and i+7 residues of the α-helix. An interesting 
modification replaces a benzene ring by an isosteric enaminone moiety92 (1.20), 
which has a better solubility profile and can be made in a modular fashion, 
ultimately leading to a 10-mer helix mimetic.93 
 
Figure 1.15: Terphenyl and derived multimer mimetics. 
The above mentioned terphenyl derivatives do not have strongly constrained 
conformations. They exist as multiple atropoisomers, with a relatively low 
rotational energy barrier.77 This can be advantageous in cases were an induced fit 
can result in better binding at a protein interface. However there is an entropic 
price to pay for this freedom. Rigid scaffolds on the other hand have little 
conformational freedom (figure 1.16). They make use of the same principles as 
foldamers,94 using intramolecular hydrogen bonding and trans preference of amide 
bond rotamers to stabilize the desired conformation. Most peptidomimetic 
foldamers are based on oligobenzamides95,96,97 (1.21, 1.22). The hydrogen bonds 
between the amide N-hydrogen and an aryl ether oxygen ensure a planar 
orientation, although in this case free rotation over the Caryl-(C=O)amide bond is still 
possible. A 3-O-alkylated benzamide trimer (1.21) has been shown to inhibit the 
p53/hDM2 PPI (a target for cancer chemotherapy).98  Similarly, the 2-O-alkylated 
regioisomer 1.22 was also able to inhibit this interaction.99 By virtue of their 
1.17 1.18 1.19 1.20 
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multimeric nature, a modular synthesis route could be developed to make large 
libraries of these mimetics.100 Even more strongly constrained systems use 
heterocyclic monomers that can form additional hydrogen bonds via their azine 
nitrogens101 (1.23). These scaffolds have been used successfully to retard the 
formation of amyloid deposits,102 that play a role in a plethora of degenerative 
diseases. It is possible to somewhat relax the rigid backbone of these multimers by 
introducing phenyl units into a heterocylic oligoamide multimer.103 This tactic 
resulted in better inhibitors of Bcl-xL. 
 
Figure 1.16: Rigid, foldameric minimalist peptidomimetics. 
The oligoarylamides shown in figure 1.16 are suitable if only one side of a helix 
needs to be mimicked. If a PPI requires interactions from two sides of an α-helix, 
systems such as the dimer of Marimganti et al.104 can be used (figure 1.17, 1.24). 
Another system (1.25), resembling the Marimganti one, was developed to mimic 
different positions.105 The synthesis of the latter compound unfortunately employs 
harsh reaction conditions which would not be compatible with reactive amino acid 
side chains. 
 
Figure 1.17: Rigid minimalist mimetics able to mimic two sides of an α-helix. 
1.24 1.25 
1.21 1.22 1.23 
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Universal mimetics are a recent trend46 in the field that diverge from the 
previously described systems in the sense that they have been designed to mimic 
any secondary structure.77 The group of Burgess developed this concept by 
asserting that a universal scaffold should be able to adopt different conformations, 
with each conformation mimicking a different secondary structure. The scaffold 
should then be designed such that these different peptidomimetic conformations 
are both kinetically and thermodynamically accessible at room temperature. In 
other words, the universal mimetic will continuously switch between different 
secondary structure topologies (such as an α-helix, but also a β-turn, β-sheet and γ-
turn). The hypothesis being that this way the mimic will be able to adapt to the 
protein and bind in its most favorable conformation (corresponding to a secondary 
structure). This is of course the concept of induced fit taken to the next level. To 
identify these universal mimetics, they did computational analysis on several 
molecular templates using molecular dynamics and density functional theory (to 
calculate the kinetic accessibility of the conformers). In this way clusters of stable 
conformations could be generated per template and the topological properties of 
each cluster was screened for peptidomimetic potential (using Cα-Cβ vector 
comparison, vide supra). They discovered several scaffolds that had the desired 
variety of secondary structure mimicking conformations and low barriers to switch 
between them. Figure 1.18 shows two such universal mimetics (1.26, 1.27) that are 
able to mimic an α-helix (as well as a β-turn, β-sheet and γ-turn).  
 
Figure 1.18: Universal mimetics able to mimic an α-helix, as well as a β-turn, β-sheet and γ-turn. 
This approach is a very interesting addition to the field of peptidomimetics. 
However the universal mimetics are mostly suitable for situations where the 
structure (or interaction epitope) of the PPI is not well known and their flexibility 
is put to good use. High throughput screening libraries seems to be an ideal 
application. When the target epitope is well known, it is usually better to use a 
mimetic with a well defined topology. 
 
1.26 1.27 
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1.4.4 Pyrazine Minimalist Peptidomimetics  
 
Now that we have familiarized ourselves with the field of minimalist 
peptidomimetics, opportunities for our own synthetic input should become 
apparent. Among the various systems described above, one heterocyclic core is 
remarkably absent: the pyrazine moiety. Pyrazine chemistry has been well studied 
by our group in the past, so we can rely on this expertise to guide us in the design 
of pyrazine based rigid minimalist peptidomimetics (figure 1.19). Besides 
developing a synthetic route towards these multimer scaffolds (trimers 1.28 and 
dimers 1.29), also ways need to be sought to introduce different functionalities on 
the scaffolds besides just amino acid side chains. In addition, ideally it should be 
possible to make mixed and hybrid multimers containing both pyrazine and for 
example phenyl monomers, which can be coupled via aryl-aryl (1.31) or amide 
bonds (1.28-1.29). This would not only increase diversity but also allow the option 
to introduce less rigidity in the multimer (vide supra). Finally, if monomers can be 
introduced with substitution patterns that allow the mimicking of different faces of 
the α-helix (1.30), even more versatile scaffolds could be made. 
 
Figure 1.19 Pyrazine mimimalist mimetic multimers, combined with other monomers.Y =  -COOR, -
NR2, -Aryl, -Alkyn. Z, Z’, Z”, X, X’, X”: -N, -CH-. Ri = AA sidechain, PG = amine protecting 
group. 
To develop such a mimetic, a modular synthetic approach will be required. 
Moreover, such a strategy will invite the use of a recent technological advance in 
the synthetic chemist’s toolbox, known as flow chemistry. 
 
 
 
1.28 1.29 1.30 1.31 
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1.5  Flow Chemistry as an Enabling Tool in Synthesis 
 
For more than 160 years, the synthetic chemist has set out to perform his craft in 
the laboratory. In his (or her) hands the venerable reaction flask is firmly clasped 
as one of the most essential items. In the last decade however, a new tool to 
perform reactions is working its way into the fumehood: the many shapes and 
varieties of flow chemistry. In the most basic sense, the main concept of flow 
chemistry is to perform a chemical process in a continuous manner. Continuous 
manufacturing has been used in industrial production of bulk chemicals for a long 
time, but flow chemistry seeks to apply its concepts on lab (or even smaller) scale 
for the production of much more complex molecules. While there are many 
exciting applications in the fields of biomedical, production and analytical science, 
the focus here will mostly be on lab scale flow systems as tools for organic 
synthesis. 
1.5.1 Tools of the trade 
 
Lab sized flow chemistry systems come in many shapes and sizes. Commercial 
systems are available in monolithic designs, where all components are integrated 
into one device (Thalesnano H-cube,106 FutureChemistry Flowstart,107 Uniqsys 
FlowSyn108). These have the advantage of having a more shallow learning curve, 
but do offer less freedom to customize. Completely modular systems can be 
custom built from loose parts like tubing, reactors, pumps, … from various 
suppliers (Dolomite,109 Chemtrix,110 Chemyx,111 Little Things Factory112). This 
allows for maximum flexibility in terms of process design and is in most cases the 
cheapest option. However, it can require significant effort to ensure compatibility 
between all combined components. Reproducing the exact same setup can also be 
challenging. Semi-modular systems are composed of a basic platform which can be 
expanded or allow separate functional modules to be attached to. Well known 
examples include Vapourtec E and R series113 and the Syrris Asia and Africa 
platforms.114 They are a tradeoff between monolithic and modular systems, but 
usually come at a higher price. The choice for a certain platform will ultimately 
depend on the desired goal, budget and available expertise.  
Any flow system is composed of some basic components working in unison to 
form one continuous process. A schematic overview is given in figure 1.20.   
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Figure 1.20: General flow setup scheme. 
• Reagent reservoir: contains solutions of chemicals to be fed into the 
reactor. The solutions can be stored in larger containers or syringes and 
gradually introduced into the system via (syringe) pumps. Alternatively, 
they can be introduced via loops, similar to HPLC. The latter approach 
allows the introduction of small amounts of reagents, ideal for screening 
reactions. It is also possible to introduce gasses as reagents into flow 
systems115 using mass flow controllers (MFC) or needle valves to regulate 
the flowrate. 
 
 
• Liquid pumps: these are responsible for the transport of reagent solutions 
through the system. They come in many varieties, from common HPLC 
piston pumps to advanced peristaltic designs. Small scale flow setups can 
also make use of syringe pumps, which are very user friendly. Miniature 
models are available for microflow applications,116 such as electro-osmotic 
pumps117 and piezoelectric pumps.118 In all cases, parameters such as 
chemical resistance, size, flow rate and stability, viscosity of solvent and 
pressure should be taken into account when choosing a pump. 
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• Mixing unit: this ensures adequate mixing between converging reagent 
streams (figure 1.21). They can be as simple as a T-tube fitting or as 
complex as special microfabricated static mixers.119 In some cases they 
can also be controllable valves which can regulate reagent streams. 
 
Figure 1.21: Mixing units. Left: T-tube fitting. Right: Micromixer on glass chip.109 
 
• Reactor: is the heart of any flow setup, where the actual reaction occurs. 
Heating or cooling can be applied, as well as energy input by other means 
such as UV-light,120,121 microwave irradiation122,123,124 or sonification.125 
Due to the nature of continuous processing126 (large surface areas, efficient 
heat exchange), they can operate at very high pressures and temperatures. 
Several types of reactors have been developed: Coil reactors (CR) are the 
most basic type, consisting of nothing more than a length of tubing, 
usually coiled up to remain compact (figure 1.22A). These can be made 
from stainless steel (high pressures/temperatures possible), fluoropolymers 
(chemical resistance), other (biocompatible) plastics or even catalytic 
metals.127 They are usually the cheapest and easiest to fabricate in the lab. 
Capillary reactors are also available with very small internal diameters for 
miniaturization purposes.128 Reactor chips129 are more complex devices, 
made by fabricating channels or other flow features (like mixers) onto a 
suitable 2D substrate (figure 1.22B). They are available in all sizes (µm to 
mm channel sizes) and materials (glass, borosilicate, quartz, PDMS, 
silicon, metal, …) depending on the desired application. They can be 
tailor-made for a desired application (like UV reactors) and are very 
suitable for miniaturization (Lab-on-a-Chip130). Packed bed reactors are 
convenient to introduce a heterogeneous catalyst to a flow process131 
(figure 1.22C). The insoluble catalyst or reagent is packed into a suitable 
vessel through which the reagent streams can be pumped. They do have 
more complex flow physics and require careful control of packing and 
particle sizes to ensure reproducibility. Several other, more exotic reactors 
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are reported in literature, like tube-in-tube reactors132 (see chapter 4.2.3), 
membrane reactors,133  enzymatic reactors,134… 
 
 
Figure 1.22: Flow reactors. A: Stainless steel coil reactor (SS-CR). B: Two glass reactor 
chips (GRC) of different dimensions. C: Packed bed reactor113 (PBR) loaded with a 
heterogeneous palladium catalyst and placed in a glass hot air heating jacket. 
 
• Pressure control: in case a process is performed at temperatures above the 
boiling point of the solvent used, the pressure must be raised. This can be 
done by backpressure regulators (BPR), which can have a fixed or 
controllable pressure. The simplest of these components comprise a spring 
loaded plunger which provides backpressure to the liquid flow (figure 
1.23). 
A B C 
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Figure 1.23: Principle of a BPR.135 
 
• Separation/purification module: with many recent developments in lab-
scale flow processing, the possibility to also perform purification or 
separation in flow is becoming more commonplace. These include 
scavengers136 to capture side products, continuous liquid-liquid extraction 
using membranes,137,138 solvent evaporation,139 distillation in flow,140,141 
crystallization142 and so on. 
 
• Product collection: the output flow of a flow process must be collected. In 
some cases it can also be led immediately into a quenching solution. It is 
also easily possible to automate collection so the output can be collected 
in fractions, for example to enable screening of reaction conditions (figure 
1.24). Alternatively, it can be led into another flow process to perform 
another reaction (cascading, vide infra). 
 
Figure 1.24: Syrris Asia automated fraction collector. 
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• Tubing: connecting all the separate flow components is done via tubes. 
These are available in many diameters, thickness and materials (figure 
1.25). Stainless steel (SS), fluoropolymers (Teflon, FEP, PTFE …) or 
(biocompatible) plastics. The choice again depends on the desired 
application: High temperature/pressure reactions will require SS tubing, 
while if chemical resistance is needed fluoropolymers are the material of 
choice. With any plastic tubing, the melting/softening temperature of the 
material should be checked before use. Integrated systems (especially on 
microscale) can replace tubing completely by channels made in the reactor 
chip. 
 
 
Figure 1.25: Tubing of different diameter and material (SS, copper, PTFE). 
 
• Inline monitoring: while it is possible (even automated) to take aliquots of 
a continuous process for analysis using any desired method, continuous 
measurements of reactions is the most interesting. To this end real-time 
FTIR,143,144 NMR,145,146 UV-VIS147,114 modules have been developed 
(figure 1.26). Immediate feedback of the reaction progress can be obtained, 
which can be very useful for optimization or quality control. 
 
Figure 1.26: Left: ReactIR inline infrared monitoring143. Right: Continuous flow 1H-NMR 
probe.148 Reprinted with permission from reference 143 and 148. Copyright 2010, 2009 
American Chemical Society. 
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• Control system: an enormous advantage of flow chemistry is the ability to 
easily integrate some or all components into an (automated) control 
system. This opens the way for a plethora of applications, especially when 
combined with monitoring, from fully automated processes to self-
optimization (vide infra). 
 
1.5.2 Assessing Flow Chemistry as a Tool in Synthesis 
 
Flow chemistry has many advantages compared to batch reactions, most notably: 
• Improved safety: due to the continuous rather than batch nature of 
(micro)flow procedures, the actual amount of hazardous reagents present 
in the reactor at any given time can be kept at a low level. It is therefore 
far more easy to keep these reagents contained than is the  case for a batch 
process. This can not only improve the safety profile of existing processes, 
but also enable in many cases the use of a reagents or reactions that would 
be considered too hazardous in batch. In this way, very useful reagents 
such as carbon monoxide,149 phosgene,150 hydrazoic acid151 or 
diazomethane132 (figure 1.27) can find their way back into the repertoire of 
reactions available to the synthetic chemist.  
 
 
Figure 1.27: Using diazomethane safely in flow.132 Reprinted with permission from 
reference 132. Copyright 2013 American Chemical Society. 
• Access to novel process windows (NPW): flow reactors can reach 
temperatures and pressures which are far beyond the normal limits found 
in discovery chemistry.152 This allows the development of new reactions 
in a previously inaccessible domain of chemical processes. Several 
examples demonstrate this principle, such as SNAr reactions with 
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unactivated substrates153 (at 200 bar and 270°C), Non-catalytic Claisen 
rearrangements154,155 (at 50 bar, 265°C) and hydrogenations156 (at 70 bar). 
 
• Control of parameters: flow reactors generally have excellent heat transfer 
capabilities due to their high surface area. This can be exploited by 
performing highly exothermic reactions at much higher temperatures then 
would be possible (safely) in batch processes. Combined with the ability 
to tightly control the reaction time by changing the flow speed and reactor 
volume, extremely fast reactions can be harnessed. This has given rise to 
the field of flash chemistry,157 which covers reactions with timescales of 
milliseconds to seconds that can be done on a preparative scale thanks to 
flow technology. Lithiation is an example of such a procedure and flow 
methods have been published that synthesize aryllithium compounds with 
highly sensitive functional groups in 0.06 seconds before using them in 
the next step158 (figure 1.28). Reaction times of just 0.8 seconds already 
reduced the yield drastically. 
 
 
Figure 1.28: Flash chemistry: Lithiation in flow with reaction times of 0.06 s.158 Reprinted 
with permission from reference 158. Copyright 2008 Wiley VCH. 
• Cascading/telescoping: a major topic in modern flow chemistry is the 
integration of multiple reaction steps into one uninterrupted reactor 
network.159,160,161 This can also be combined with inline purification 
methods such as scavengers,136 continuous extraction,162 distillation,141 etc. 
Such cascading reaction protocols can incorporate several (in some cases, 
all) of the synthetic steps needed to reach a target molecule in one 
continuous process. Complex molecules can be made in a continuous 
manner (figure 1.29). The applications are legion: unstable intermediates 
can be made and immediately used in the next step,151 radiolabeled 
 
t = 0.06s 
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molecules with short half-lives can be produced at the site of use163 and so 
on. 
 
 
Figure 1 29: Using cascading flow reactions and scavengers to synthesize a δ opioid 
receptor antagonist144. Reprinted with permission from reference 144 and 158. Copyright 
2010 Wiley VCH. 
• Automatisation: flow chemistry setups lend themselves well for computer 
control and feedback mechanisms. Combined with inline analysis tools, 
very interesting systems can be developed. An noteworthy example is the 
flow setup developed by Jensen et al. that self-optimizes a Heck reaction 
without human interference164 (figure 1.30). Even more advanced systems 
can also incorporate automated cascading reactions and purification. This 
results in devices such as pharmaceuticals-on-demand (PoD), a fully 
automated flow setup that starts from raw chemicals and outputs ready-to-
use medicine tablets.165  
 
Figure 1.30: Self-optimizing Heck reaction, A, B, C represent the different starting 
reagents.164 Reprinted with permission from reference 164 and 158. Copyright 2010 Wiley 
VCH. 
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Miniaturization: The same microtechnology that is used in semiconductor 
fabrication can be utilized to create very small flow reactors. This allows 
the design of very small, integrated microfluidic systems for preparation 
or analysis applications. The emerging Lab-on-a-Chip (LOC) concept,166 
where several chemical operations are carried out on a single small chip, is 
an example of the downscaling capabilities of flow chemistry. When 
combined with analysis, this technology is often referred to as µTAS or 
Micro Total Analysis Systems. These systems find many applications for 
example in medical diagnostics167 (figure 1.31) and biochemical 
analysis.168 
 
Figure 1.31: Lab-on-a-chip (LOC) device capable of concentration, lysis and qPCR of 
Salmonella spp. on one chip.169 Reprinted with permission from reference 169 and 158. 
Copyright 2007 SAGE publications. 
• Easier scalability: the excellent control of reaction parameters and the 
continuous nature of flow processes greatly facilitates scale up, compared 
to batch chemistry.152,126,170 There are three important ways to increase 
production in flow chemistry. Scaling out is the simplest solution, and 
consists of letting the process run for a longer time. While easy, especially 
for smaller reactors this is not always time efficient when large quantities 
are desired. Numbering up consists of running the same process in 
multiple (small) reactors in parallel. In one example, this technique was 
used to scale up a nitration reaction using 20 reactors in parallel.171 Finally, 
the reactor itself can be scaled up to handle larger throughput of reagents. 
This is the most difficult route, as it requires recalculation and scaling of 
the relevant parameters. 
 
Despite all these salient points, the decision to apply flow chemistry needs to be a 
rational one.172,173 Not all reactions are amenable for continuous processing. 
Especially in cases were precipitation or very viscous fluids are involved, batch 
procedures are still the best choice. In addition, any reaction or process that is 
considered for translation to flow should make optimal use of at least one of the 
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advantages stated above. Otherwise it is wiser to once more grab the flask and 
stirring bar. Especially in cases of hazardous conditions, very fast reactions, new 
process windows or on-demand synthesis the application of flow chemistry should 
be considered. 
To conclude, flow chemistry is not the answer to all problems, but it certainly is an 
extremely valuable tool that can significantly expand the synthetic repertoire. 
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1.6  Goals 
 
We have seen the complexity of protein-protein interactions, the virtues of 
structure based design (especially from a synthetic chemist point of view), the 
many faces of the α-helix peptidomimetics and flow chemistry as a modern tool. 
The goals of this work can now be clearly defined. 
Multimeric minimalist α-helix peptidomimetics will be developed, based on 
pyrazine monomers or in combination with other monomers to allow more 
diversity and tune backbone rigidity. These monomers should be designed in such 
a way that amino acid side chains can be attached to them, including those bearing 
reactive functional groups (alcohols, acids, free amide, …). Additionally, the 
option to introduce other functionalities (for post-modification) should exist 
(figure 1.32).  
 
Figure 1.32: General peptidomimetic architecture. 
To allow such a design, a modular synthetic strategy will be needed (Scheme 1.1): 
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Scheme 1.1: Modular synthetic strategy. 
The monomers, bearing amino acid side chains will be coupled stepwise in a 
modular fashion via a palladium catalyzed aminocarbonylation raction. This will 
require monomers which have both a halide group and an amine group to form the 
amide linking bond. The amine will need to be protected to avoid selectivity 
problems. The multimer can then be built using consecutive deprotection-coupling 
steps. In principle multimers of any desired length can be made this way, but we 
will stop at the trimer level.  
This strategy will be subdivided over the following chapters as follows: 
• Monomers will need to be synthesized with amino acid side chains 
attached via an aryl ether bond, to allow hydrogen bonding to the amide 
link (see chapter 1.4.3). In addition, a protected amine and a halide 
functional group must be present in a (pseudo)para orientation (figure 
1.33). This will be the topic of chapter 2. 
Figure 1.33: Monomer units, chapter 2. 
• The monomers will need to be functionalized, to allow post modification 
and to remove the halide functional group of the first monomer to avoid 
selectivity problems (scheme 1.2). Flow chemistry will be used to 
introduce alkyl chains. This will be further explained in chapter 3. 
 
Figure 1.34: Functionalization of monomers, chapter 3 
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• Finally, the monomers will undergo deprotection and subsequently linked 
together using the aminocarbonylation reaction. A safer alternative for 
gaseous carbon monoxide will be explored using flow chemistry. These 
are the topics of chapter 4, where the final mimetics will be prepared 
(figure 1.35). 
 
 
Figure 1.35: The final minimalist peptidomimetics, chapter 4. 
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2.1  Goals and General Strategy 
 
The monomers of the modular design scheme have rather stringent requirements to 
which they must comply (chapter 1). For the modular synthesis pathway of aryl 
peptidomimetics envisioned here, the monomers should be conform with the 
following archetype (figure 2.1): 
 
Figure 2.1: Monomer archetype. X = Br, Cl ; Y, Z = N, S, CH ; NPG = -NBoc2 , -NO2 
Therefore, it was desired for the monomer synthesis to have: 
• As few synthetic steps as possible. 
• Amino acid side chains which should be introduced via an alcohol 
functional group in a late stage in the synthesis to avoid side reactions. 
• A halogen –X (bromide or activated chloride), which is required for the 
coupling reaction. 
• A protected amine functionality –NPG, (pseudo)para with respect to the 
aforementioned halide, which must be present to form the amide bond. It 
must be orthogonal with the protection of the amino acid side chains. 
• Sensitive side chains must be protected using acid labile protecting groups. 
In addition, inspired by the mimetics described by Marimganti et al.,104 a 
monomer with an additional tether for a second amino acid side chain was planned 
(figure 2.2). 
 
Figure 2.2: Monomer based on Marimganti type peptidomimetics 
 
 
 
-Chapter 2- Monomers 
 
-39- 
 
2.2  Amino Acid Side Chains 
 
Attachment of amino acid side chains is possible via an ether bond (recall the ether 
oxygen is required to maintain the correct conformation of the foldamer, see 
chapter 1). Therefore alcohols were selected as the side chain precursors.  
 
Figure 2.3: Amino acid side chain strategy, X = Br, Cl, F 
Attaching the side chain can then be achieved by nucleophilic aromatic 
substitution (SNAr), using the alcohol as a nucleophile and displacing a halide 
function on the monomer precursor. Alternatively, via the Mitsunobu reaction,174 
it can be coupled to a phenol moiety on the precursor (figure 2.3). In cases where 
sensitive or interfering functional groups were present on the side chain, they were 
protected using an acid sensitive protecting group. Some of the side chains are 
commercially available as simple alcohols (figure 2.4): 
 
Figure 2.4: Commercially available alcohol amino acid side chains 
The side chains of tyrosine and methionine were replaced by bioisosteric 
analogues175 (figure 2.5). The former because of commercial availability and the 
latter due to the catalyst poisoning effects of sulphur in palladium catalyzed cross-
coupling reactions. 
2.1 2.2 2.3 
2.5 2.4 2.6 
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Figure 2.5: Commercially available bioisosteric analogues. 
Those that are not so readily available, mostly ones with more reactive functional 
groups, needed to be synthesized (scheme 2.1). In all these cases a protecting 
group was chosen which can be removed via acid treatment and which is resistant 
to base and hard (oxygen) nucleophiles. 
 
Scheme 2.1: Synthesis of amino acid side chains with reactive functional groups.176,177,178,179,180,181, 
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In first instance the Boc group was chosen as the protecting group of choice due to 
ease of synthesis and good solubility in organic solvents (compounds 2.14, 2.16 
and 2.18). The synthesis of these compounds was taken directly from literature. 
The Mitsunobu coupling reaction of these Boc protected substrates worked as 
expected, however attempts to use them in SNAr type reactions did not result in 
any conversion and monomer starting product was fully recovered, while no trace 
remained of the amino acid side chain reagent. Further literature search uncovered 
that N-Boc protecting groups are not always stable in combination with hard 
nucleophiles182 (scheme 2.2). They are known to be able to undergo a 
transcarbamation reaction, effectively removing the nucleophilic activity of the 
side chain. Alternatively, the N-hydrogen atom present on Boc protected primary 
amines can be deprotonated under the reaction conditions used here, which could 
also lead to side reactions (e.g. formation of isocyanates).  
 
Scheme 2.2: Side reactions of N-Boc protecting groups. a) Transcarbamation. b) isocyanate 
formation 
Therefore, for these side chains, the trityl protecting group was a more suitable 
choice (2.20, 2.22). While this approach proved satisfactory, a disadvantage is the 
lower solubility of trityl protected substrates. This was especially apparent in 
compound 2.20, which has a rather poor solubility in organic solvents used in the 
SNAr  reactions (THF, DMF, ACN, DMSO,… DMF being the best solvent). The 
solubility issue demanded longer reaction times (several days vs overnight) when 
using this substrate. For the tryptophan and arginine side chains however, making 
the trityl derivatives was not trivial, and all attempts to do so failed. 
Problems were also encountered with alcohol 2.3 (figure 2.4). Mitsunobu reactions 
utilizing this substrate only returned the monomer precursor starting product (vide 
infra), but with the disappearance of the alcohol. In all likelihood, the 
oxyphosphonium intermediate of the alcohol undergoes elimination to form t-
butyl-acrylate (although no evidence of this compound could be found, probably 
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due to its high volatility). Some other methods were attempted, but to no avail. An 
alternative was sought and found in the tetrazole bioisostere 2.27. 5-substituted 
tetrazoles are known to be able to act like carboxylic acids in bio-active 
molecules.175 They have similar abilities to form hydrogen bonds and a suitable 
pKa value (4.9, compared to the pKa of a carboxylic acid which is around 4.3). A 
first proposed synthetic pathway183 to this side chain, via metallation of a protected 
5-methyltetrazole 2.26, was attempted but failed. The second route utilizes the 
commercially available ethyl-1H-tetrazole-5-acetate (2.23), which was protected 
using trityl chloride to give intermediate 2.24 in quantative yield.184 Subsequent 
reduction of the ester to the desired alcohol, by means of LiAlH4, afforded the 
envisioned compound 2.27 (scheme 2.3). This side chain performed as expected in 
the Mitsunobu couplings. 
 
Scheme 2.3: Synthesis of the glutamic acid side chain bioisostere 
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2.3  Pyrazine Monomers 
 
The pyrazine heterocycle is an interesting choice to incorporate in a 
peptidomimetic. An advantage is the reduced hydrophobicity compared to, for 
example, the pyridine monomer. But perhaps more important: pyrazine-based 
helix mimetics have not yet been reported in literature. The synthesis of this 
monomer is relatively straightforward (table 2.1, scheme 2.4):  
Table 2.1, scheme 2.4: Pyrazine monomer synthesis. 
N
N NH2
N
N NH2
Br Br N
N NH2
Br OR
6
5 N
4
3
2N
1
NBoc2
Br OR
NBS
DMSO
ROH
Base
Boc2O
DMAP
Dioxane
95°C
72%
THF
SNAr
 
a: Isolated yield of unprotected monomer, b: Isolated yield of Boc protection step, c: Only starting 
product recovered, no trace of alcohol reagent. nt: not tried.  
Entry -OR Yield (2.30)a Boc Yield (2.31)b 
a 
 
83% 88% 
b 
 
81% nt 
c 
 
64% nt 
d 
 
35% nt 
e 
 
54% 25% 
f 
 
10% nt 
g 
 
88% 79% 
h 
 
-
c nt 
i 
 
-
c nt 
j 
 
-
c
 nt 
2.28 2.29 2.30 2.31 
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Using aminopyrazine (2.28) as the starting point, a double bromination was carried 
out using NBS in DMSO.185 Purifying the crude product is not straightforward 
however, several methods were tried: literature procedures usually recommend 
sublimation186, however this is rather inconvenient to scale up. A simpler 
alternative is to recrystallize 2.29 from hexane or water. This affords a product of 
sufficient purity for subsequent synthetic steps. However should a much more pure 
product be required, steam distillation was found to give the highest quality of 
product as beautiful white needle crystals. Again scale up is a problem in this case, 
though it is significantly easier still than sublimation. 
Following the bromination, the desired amino acid side chain was attached using 
SNAr in THF with NaH or NaHMDS as a base185, 187 (2.30). This step was not 
without difficulty. When using benzylic alcohols, the aminopyrazine substrate has 
a tendency to undergo alkylation on the amine nitrogen on the 2 position.188 Yields 
vary strongly depending on the amino acid side chain used (table 2.1, entries 
2.30a-g). Furthermore the products appear to have surprisingly similar Rf values  
as starting product 2.29 on TLC (silica gel) in all solvents tried (heptanes, EtOAc, 
CHCl3, DCM, THF, toluene, EtOH, MeOH, ACN and mixtures of these). It is 
recommended to utilize GC-MS or similar methods to follow the reaction progress. 
The glutamic acid side chain 2.3 (table 2.1, entry 2.30h) seemed to decompose 
under the reaction conditions, only starting product could be recovered. However 
it could be replaced by its tetrazole bioisostere (table 2.1, entry 2.30e). As 
mentioned previously, the Boc protected side chains did not result in the desired 
product (table 2.1, entries 2.30i, j).  
Lastly the free amine of precursors 2.30 were shielded using a Boc protecting 
group, introduced via Boc anhydride in THF or DCM, using DMAP as the catalyst 
(table 2.1, entries a, e, g). The Boc functional group is acid sensitive, like the 
protection scheme of the amino acid side chains. However it can be deprotected 
selectively by placing the product in boiling water189 (see chapter 4.3.2).  
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2.4  Phenyl Monomers 
 
The phenyl monomer is present in the first oligoaryl amide alpha helix 
peptidomimetics (see chapter 1.4.3) and therefore cannot be omitted. 
Table 2.2, scheme 2.5: Synthesis of the Phenyl monomer, R = amino acid side chain. 
 
Entry -OR Yielda 
a 
 
85% 
b 
 
Comm.b 
c 
 
-
c 
d 
 
-
d 
e 
 
-
d 
a: Isolated yield, b: commercially available, c: purification failed, d: Only starting product 
recovered, no trace of alcohol reagent 
There are surprisingly few simple procedures to prepare the desired 2-nitro-5-
bromophenol (2.33). Regioselective ortho nitration of meta-bromophenol, for 
example, is not a feasible route (there are few examples of this in literature190 and 
all attempts to do so failed). Fortunately, the strongly mesomeric electron 
withdrawing nitro group can be made of good use in the Vicarious Nucleophilic 
Substitution191 reaction, to obtain the target molecule in one step from 4-
nitrobromobenzene (2.32, scheme 2.5). This fascinating reaction (scheme 2.6) 
utilizes a hydroperoxide (cumyl hydroperoxide) which acts as a nucleophilic 
oxygen with a leaving group attached. On attacking the aromatic ring of 2.32, a 
Meisenheimer intermediate 2.35 is formed, from which a hydrogen atom can be 
abstracted by the base (KOtBu) to give a charged intermediate 2.36. This 
2.32 2.33 2.34 
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intermediate cannot undergo a second nucleophilic attack, leading selectively to 
the monosubstituted product 2.33 on acid workup. 
 
Scheme 2.6: Mechanism of the Vicarious Nucleophilic Substitution. 
Amino acid side chains can then be introduced via the Mitsunobu reaction192 (table 
2.2). Only some of the more complex side chains were introduced, as this 
monomer was already well explored in literature and therefore not a priority. 
Unfortunately, the tryptophan side chain (table 2.2, entry c) gave a mixture of 
products which could not be separated by chromatography, despite several 
attempts. Reactions with the arginine and glutamic acid side chains (table 2.2, 
entries d, e) returned only starting product, with no trace of the alcohol reagent.  
2.32 2.35 2.36 2.33 
-Chapter 2- Monomers 
 
-47- 
 
2.5  Thiazole Monomers 
 
Thiazole compounds are hydrophilic scaffolds which are widely applied in 
medicinal applications.11 They have also not been reported yet as part of an 
oligoarylamide alpha helical peptidomimetic. This particular monomer proved 
troublesome however. 
 
Scheme 2.7: Failed routes towards thiazole monomers 
The first attempted route (scheme 2.7) tried to make use of the strongly electron 
withdrawing nitro group to activate the 4-position. Either by introducing an 
oxygen atom (2.39  2.40) which could be further substituted via for example 
Mitsunobu chemistry (section 2.4) or a halogen (2.39  2.41 or 2.42) enabling 
SNAr  type of reactions. Starting with 2-aminothiazole (2.37), a consecutive 
nitration using mixed acid193 and a Sandmeyer reaction194 were successfully 
performed to give 2.39. The first possibility, using Vicarious Nucleophilic 
Substitution (using the same conditions as in section 2.4), failed to give the desired 
product 2.40. Instead decomposition of the starting material to an unidentifiable 
black substance was observed. Another attempt using metallation/halogenations 
(2.39  2.41, table 2.3) also resulted in similar decomposition of the substrate, 
despite the use of very gentle metallation methods195 (table 2.3: entries d, e).  
 
 
2.37 
2.38 2.39 
2.40 
2.41 
2.42 
Monomers - Chapter 2- 
 
-48- 
 
Table 2.3: Metallation attempts of 2-Bromo-5-nitrothiazole 
 
Entry  R-M Result 
a  LDA, -78°C Black tarry residue + diisopropylamine adduct 
b  LiTMPH, -78°C Black tarry residue + TMPH 
adduct 
c  BuLi, TMEDA, -78°C Black tarry residue 
d  TMP-MgCl.LiCl Black tarry residue 
e  TMP2Zn.2MgCl2.2LiCl Black tarry residue 
f  B2(Pinacol)2+[Ir(COD)(OMe)]2+dtbp No reaction 
 
It seems that the substrate 2.39 is unstable in the basic/nucleophilic environment 
needed for these methods. In some cases, in addition to unidentifiable side 
products, quite surprisingly the adducts of quite sterically hindered bases with the 
substrate were isolated (table 2.3: entries a, b). Although precise evidence of the 
decomposition mechanism or end products could not be obtained, some electron 
poor thiazoles are known to ring open in the presence of strong nucleophiles or on 
deprotonation.196,197 The ring opened product would be highly reactive and will 
lead to a plethora of side reactions, which could be an explanation for the black tar 
like nature of the residue isolated in these reactions. In this light, the final effort 
made use of a much more gentle procedure. A recently published CH fluorination 
technique198 using silver (II) fluoride is reported to be applicable to even highly 
complex nitrogen containing heterocycles. However no conversion was observed 
in this case and only the starting product was recovered. In all likelihood, substrate 
2.39 is too electron poor to participate in this type of reaction. Another synthetic 
pathway needed to be explored.  
 
Scheme 2.8: Alternative synthesis of thiazole monomers 
Using a similar strategy as for the pyridine monomers (vide infra), commercially 
available 2,4-dichlorothiazole (2.43) was nitrated using fuming nitric acid199 
2.39 2.41 
2.43 2.45 2.44 
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(scheme 2.8). It was then hoped the obtained precursor 2.44 could be selectively 
substituted in the 4-position with oxygen nucleophiles to give the desired 
monomer 2.45. Unfortunately, again decomposition of the thiazole to an 
unidentifiable tar like residue was observed. Due to lack of time and low estimated 
chance of success, further attempts to introduce side chains in this monomer were 
abandoned.  
 
2.6  Pyridine Monomers 
 
The pyridine ring is more hydrophilic than its carbocylic counterpart benzene, in 
addition the ring nitrogen can contribute to the foldamer structure of a rigid 
scaffold (see chapter 1.4.3). Two separate synthetic methods were explored, each 
producing the desired monomer with a different halide and amine protecting group. 
 
Scheme 2.9: First synthesis of the pyridine monomer 
The first pathway (scheme 2.9) is similar to the one for the pyrazine monomer: 3-
aminopyridine (2.46) is first brominated twice using NBS,200 giving intermediate 
2.47. Then the amino acid side chain can be introduced via SNAr  to give the 
unprotected monomer 2.48 using the same procedure as for pyrazine (see chapter 
2.3). Finally again the same Boc group protecting protocol was used to shield the 
amine and give the desired product 2.49.  
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Table 2.4, scheme 2.10: Alternative synthesis of the pyridine monomer. 
 
: Entry -OR Yielda 
a 
 
72% 
b 
 
74% 
c 
 
97% 
d 
 
94% 
e 
 
97% 
f 
 
Quant. 
g 
 
54% 
a: Isolated yields. 
An alternative, much shorter pathway was also developed (scheme 2.10). Starting 
from 2,6-dichloro-3-nitropyridine (2.50), a cheap commercially available 
compound, the amino acid side chain can be immediately introduced (table 2.4 
entries a-g). Using toluene as a solvent in the SNAr  reaction here is crucial, a more 
polar solvent such as THF would not give the required selectivity.201 While the 
chloride is sufficiently activated towards SNAr, it was also possible to change it to 
a bromide halogen (scheme 2.11). Simply refluxing the starting product 2.50 in 
AcOH and HBr to give the dibrominated product 2.52 in excellent yield.202 Then 
again a SNAr  reaction will give the bromide functionalized monomer (2.53).  
N
NO2
BrBr
2.7
Toluene
N
NO2
OBr
HBr
AcOH
93%
N
NO2
ClCl Reflux
NaH
69%
pF-Ph
 
Scheme 2.11: Synthesis of brominated nitropyrazine monomer. 
Due to the greater ease of synthesis, the second route (table 2.4, scheme 2.10) was 
chosen as the preferred way of making these monomers.  
 
2.50 2.51 
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2.7  Marimganti Type Monomers 
 
The previously mentioned monomers are only able to incorporate one amino acid 
side chain. In order to be able to mimic residues on more than just one side of an 
α-helix (see section 1.4.3), units which can contribute two side chains to the 
backbone are highly desirable (figure 2.2). The mimetic of Marimganti et al.104 
(1.24) fits this need (figure 1.17, section 1.4.3), however the original synthesis of 
this system is linear and lengthy (12 steps to make a dimer), so a monomer was 
sought that could be coupled in a modular fashion and is compatible with the 
methodology described here. 
What was needed to accomplish this was a phenyl ring conforming to the general 
scaffold (section 2.1). In addition, it requires two tethers which allow alcohols to 
be coupled sequentially in the final stages of the synthesis. The first attempt at 
such a molecule is presented in scheme 2.12. 
OH
O
OAc
O
OAc
O
Br
OH
O
Br
O2N
OH
O
Br
NO2O2NAcCl
Al2O3
EtOAc
99%
Br2
DCM
84%
OH
O
Br
KOH
H2O/MeOH
Ortho-
Nitration
quant.
45%
OAc
O
Br
O2N
OAc
OH
Br
O2NHNO3
Ac2O
Demethylation
59%
1) Mitsunobu coupling
2) Deprotection
3) Mitsunobu coupling
 
Scheme 2.12: First failed synthetic route towards Marimganti type monomers. 
Table 2.5: Attempts at regioselective nitration of 2.57. 
Reagent Result 
HNO3 in AcOH Dinitration 
HNO3 in Ac2O Dinitration 
 
Table 2.6: Attempts at demethylation of  2.60. 
Reagent Result 
BBr3 in DCM Diphenol formation 
LiCl in DMF at 100°C No reaction 
Me3SiCl in CHCl3 No reaction 
Pyridine.HCl at 180°C Decomposition 
2.54 2.55 2.56 2.58 2.57 2.59 
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Para-methoxyphenol (2.54) was protected by the introduction of an acyl group 
using a very high yielding protocol based on alumina as a base203 (2.55). This 
allowed for a selective bromination, using a conventional bromination 
procedure,204 in the desired position (compound 2.56). The phenol 2.57 can then 
be recovered in quantitative yield via a simple saponification reaction. The 
envisioned selective ortho nitration failed however. Despite several attempts, 
unexpectedly only the double nitrated product could be obtained (table 2.2). 
Attempting the (regioselective) nitration from the acylated intermediate 2.56 failed 
when using standard HNO3/AcOH nitration mixtures.193 However when using a 
more delicate procedure,205 with Ac2O as the solvent, the correct regioisomer 2.60 
was obtained in fair yield. Despite this minor success, demethylating this 
compound failed with all methods tried (table 2.6) either by not reacting at all or 
giving the diphenol. Discouraged by these results, another route was sought. 
 
Scheme 2.13: Second failed route towards Marimganti type monomers. 
Table 2.7: Attempts at regioselective nitration of 2.63. 
Reagent Result 
Fuming HNO3 Decomposition 
H2SO4/HNO3 (70%) Deacylation 
H2SO4 on silica gel + Bi(NO3)3 No reaction 
Fuming HNO3 in Ac2O No reaction 
Fuming HNO3 in Ac2O 
(high concentration) Decomposition 
 
Another possible route (scheme 2.13) started from benzoquinone (2.62), which 
could be acylated and brominated efficiently in one step using ZnBr2 in acetic 
anhydride206 (compound 2.63). If this easily accessible molecule could be 
selectively nitrated in the 4-position, hydrolysis of one of the acetate groups to the 
desired precursor 2.65 should have been easily accomplished. Then a Mitsunobu 
coupling of the first side chain, deprotection of the second acyl group and finally 
another Mitsunobu coupling should give the target monomer. Unfortunately, it 
2.62 2.63 2.64 2.65 
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proved impossible to perform the regioselective nitration, despite several attempts 
using different methods (table 2.7).  
 
Scheme 2.14: Third failed route towards Marimganti type monomers. 
Still not discouraged by the previous failures, another route (scheme 2.14) begins 
by nitrating para-bromophenol (2.66) to the ortho nitro product 2.67. Protection of 
the phenol using acylation afforded compound 2.68 in excellent yield, which was 
envisioned to be able to react in a palladium catalyzed C-O coupling207 to tert-
butanol (giving 2.69). A selective bromination (2.70), followed again by a short 
sequence of deprotection/Mitsunobu coupling steps would be expected to deliver 
the desired molecule. Despite the, at first sight favorable, electronic properties of 
intermediate 2.68 the C-O coupling failed. Only dehalogenated product could be 
found in the reaction mixture. Therefore also this attempt was abandoned. 
 
Scheme 2.15: Synthesis of the Marimganti type monomer. 
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Table 2.8: Marimganti type monomer synthesis. 
Entry -OR Yielda Entry -OR’ Yielda 
a 
 
78% 
a 
 
47% 
b 
 
52% 
b 
 
94% 
a 
 
51% 
b 
 
37% 
c 
 
44% a 
 
49% 
d 
 
46% a 
 
91% 
e 
 
-    
f 
 
76%    
g 
 
46% a 
 
-
b 
h 
 
31%    
a: Isolated yields, b:Decomposition of starting product. 
A successful synthetic route was finally found in the pathway depicted in scheme 
2.15. The inexpensive 4-fluoroanisole (2.71) is treated with Br2 in DCM to give 
the monobrominated product 2.72. Then a demethylation using an excess of 
BBr3,208 again in DCM, will deliver phenol 2.73. It should be mentioned that this 
compound is in fact also commercially available (CAS 496-69-5). To permit a 
nitration in the correct (4) position, the electron donating tendency of the phenol 
functional group needed to be tempered by transforming it into a carbonate 
(2.74)209 by simple treatment with an alkyl chloroformate. Here ethyl 
chloroformate was used but the methyl derivative for example is also a viable 
option. The nitration is then best carried out using a nitrate salt/sulphuric acid 
nitration method,193 which gives superior yields when compared to the mixed acid 
reaction (HNO3/H2SO4). Simple saponification210 of the carbonate 2.74 with KOH 
in MeOH then delivers the nitrated phenol compound 2.75 in an overall yield 
(from 2.73 in 2 steps) of 62%. It should be noted that no column chromatography 
is needed in any of the previous steps, making the synthesis of 2.75 easily scalable. 
2.75 is however not stable for longer periods at room temperature and should be 
placed in a freezer (-20°C). When stored in this way, no degradation of the 
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compound was observed after 6 months. Decorating this scaffold with amino acid 
side chains can then be accomplished by first using a Mitsunobu reaction to give 
the monosubstituted derivatives (table 2.8, entries a-h). Again here, the glutamic 
acid side chain decomposed under the reaction conditions (table 2.8, entry e), 
requiring the use of its tetrazole bioisostere (table 2.8, entry d). Subsequently the 
fluorine, which is highly activated towards substitution due to the close proximity 
of the nitro group, can be replaced by the second side chain using a by now well 
known SNAr  reaction at room temperature211 to result in the finished monomers 
2.78 (table 2.8, entries aa, ab, ba, bb, ca, da). In this way side chains can be 
introduced in any desired order at the very end of the synthesis of this unit without 
any extra deprotection steps. However, when using Boc protecting groups on the 
first sidechain (-OR), the following SNAr  reaction will result in decomposition of 
the starting product(table 2.8, entry ga) and this situation should be avoided by 
using a trityl protection scheme (table 2.8, entry ca).  
 
2.8  Conclusions 
 
• Synthetic routes were developed to synthesize pyridine, phenyl, pyrazine 
and bisubstituted monomers conforming to the desired archetype.  
 
• Examples with amino acid side chains were made for each scaffold. These 
side chains were introduced as alcohols that were either commercially 
available or easily synthesized. Side chains with Boc protecting groups 
could not be used in SNAr  substitutions and needed to be replaced with 
trityl. The arginine side chain proved to be troublesome and all attempts to 
introduce it on a monomer failed. 
 
• Unfortunately, the side chain functionalized thiazole monomers could not 
be made due to the instability of the scaffold under the tried conditions.  
 
With the monomers in hand, the next step is to functionalize them in preparation 
of the carbonylative coupling. 
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3.1  Functionalization Strategies 
 
The monomers are endowed with a halide functional group to permit carbonylative 
coupling with other units to form the peptidomimetics. However the first monomer, 
from where the modular synthesis starts, needs to have this halide group replaced 
with a moiety that cannot participate in the following palladium catalyzed 
coupling. Otherwise selectivity issues would no doubt arise. It is here that another 
virtue of the modular architecture becomes evident: aryl halides are synthetically 
extremely versatile, therefore this starting functionalization provides even more 
freedom in the design of the peptidomimetics. This can  allow post-modification of 
the multimers, e.g. Huisgen cycloaddition reactions212 to couple them to a wide 
variety of other chemical entities. 
Because the potential transformations of aryl halides are so vast,213 only a few are 
demonstrated and discussed further (scheme 3.16). It should be kept in mind 
however, that this is by no means an exhaustive list of their synthetic potential. 
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Scheme 3.1: Some functionalization possibilities of monomers (X= Br, Cl). 
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3.2  Nucleophilic substitution 
 
The halide moiety in the pyridine monomers is highly activated towards 
nucleophilic substitution. This is due to both the fact that it is in the α-position of 
the azine nitrogen and due to the presence of a very electron withdrawing nitro 
functional group in the para orientation (with respect to the halide) on the 
heterocyclic ring.214 It is not surprising then, given these favorable elements, that 
the introduction of secondary amines such as morpholine in this way is 
exceedingly facile. It suffices to mix the monomer with morpholine and 
triethylamine while stirring and heating the mixture at 80°C to give the desired 
product in excellent yields (scheme 3.2, table 3.1). In some cases, it was even 
possible to perform the reaction at room temperature (table 3.1, entry b). While 
here morpholine was chosen as a model amine, in principle any primary or 
secondary amine of sufficient nucleophilicity could be used. 
Table 3.1, scheme 3.2: SNAr substitution of the pyridine monomer with morpholine. 
 
Entry -OR Yielda 
a 
 
93% 
b 
 
72%b 
c 
 
78% 
d 
 
91% 
a:Isolated yields, b: reaction conducted at room temperature. 
The other monomers are not so predisposed towards nucleophilic substitution. 
They either lack an azine nitrogen (phenyl 2.34 and Marimganti 2.78 monomer 
units) or don’t have sufficiently electron withdrawing substituents (pyrazine block). 
However in these cases transition metal catalyzed methods could offer solace. 
Using well established reactions such as the Buchwald-Hartwig amination215 
(palladium catalyzed) or the Ullmann coupling216 (copper catalyzed) should allow 
for the introduction of the desired amines (scheme 3.3). While not attempted here, 
2.51 3.1 
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examples of amination reactions on the pyrazine,217 phenyl218 and Marimganti-
like219 substrates can be found in literature.  
 
Scheme 3.3: Hypothetical monomer funtionalization without SNAr 
 
3.3  Ester Synthesis via Carbonylation 
 
In a similar manner as the modified carbonylative coupling by Martinelli et 
al.220can be used to make amide bonds between the monomers (see chapter 4), it is 
also possible to make esters (scheme 3.4). Using alcohols as coupling partners in 
palladium catalyzed reactions is a little more difficult due to their higher 
propensity to undergo the alpha elimination side reaction.221 The same 
Xantphos/Pd(OAc)2 catalyst system can be utilized (in a 2/1 ratio this time), but a 
large excess of alcohol (10 eq) is required as well as conducting the reaction in 
triethylamine as the solvent. For the pyrazine and Marimganti monomers the 
reaction proceeded as expected (3.5, 3.5 and 3.7), however the pyridine block 
proved more troublesome. Instead of a clean conversion to the desired ester, a 
complex reaction mixture was obtained. Probably, these problems are related to 
the highly activated nature of the scaffold. 
2.31 
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Scheme 3.4: Ester functionalization of monomers. 
Fortunately, a method was found using a simpler catalytic system222 (Pd(PPh3)2Cl2) 
which did perform the desired functionalization as required (scheme 3.5: 
compounds 3.8, 3.9). Though it remains speculation, perhaps the complex 
obtained after oxidative insertion to Xantphos-Pd(0) is unstable and decomposes 
before carbon monoxide can coordinate.  
 
Scheme 3.5: Ester functionalization of pyridine monomer. 
 
3.4  Alkyne attachment via Sonogashira coupling 
 
The alkyne functional group is an interesting functionality to add to the 
peptidomimetic architectures, its most obvious use being as a partner in the 
Huisgen cycloaddition reaction212 (often referred to as ‘click reaction’) and its 
2.31 
2.78 
2.51 
2.51 3.8 
3.9 
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variant: the Copper(I)-catalyzed Azide-Alkyne Cycloaddition (CuAAC). The 
ubiquitous presence in the scientific literature223,224,225 of this reaction as a method 
of attaching a wide array of molecular entities via a triazole bridge justified the 
implementation of this functionality. It was introduced via a Sonogashira coupling 
reaction226 with a protected acetylene (scheme 3.6). 
 
Scheme 3.6: Alkyne functionalization of pyrazine and pyridine monomers. 
 
3.5  Alkylation via Negishi Coupling in flow 
 
This section is based on: 
Egle, B., Muñoz J.M., Alonso, N., De Borggraeve, W.M., de la Hoz, A., Díaz-Ortiz, 
A., Alcázar, J. (2014). First Example of Alkyl-Aryl Negishi Cross-Coupling in 
Flow: Mild, Efficient and Clean Introduction of Functionalized Alkyl Groups. 
Journal of Flow Chemistry, 4 (1),p22-25. 
Another possibility to functionalize the monomers via a carbon-carbon bond is to 
attach substituents via an sp3 carbon. However, C(sp3)-C(sp2) coupling reactions 
are not so trivial. One method which can accomplish these kind of connections is 
the Negishi coupling reaction,227,228 named after the Nobel prize laureate. In 
cooperation with Janssen Pharmaceutica (Toledo, Spain), a method was sought to 
perform such Negishi C(sp3)-C(sp2) coupling reactions. In addition, it was 
attempted to also harness the elegance of flow chemistry during the development. 
Negishi couplings in flow were not described in literature, but whenever flow 
2.51e 
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chemistry is considered, the first question to ask must be whether is actually 
necessary to utilize this more advanced technology to perform a synthetic 
operation (chapter 1.5). There must be a necessity or at least a significant added 
value to legitimize the higher complexity of a methodology development when 
compared to batch chemistry. In the case of Negishi coupling, we argued that flow 
chemistry indeed offers significant advantages: 
• The use of a heterogeneous catalyst in flow greatly simplifies purification 
and work-up.229,131 In our case this also led to reduced palladium 
contamination of the final compound, a strong merit for medicinal 
applications.230 
• Scale up of the reaction is more straightforward.129 Considering that the 
coupling might be needed for a precursor (as is the case here), easier 
increase of production rate is desirable. 
• The alkyl zinc reagents are reactive and pyrophoric substances.231 In the 
interest of safety, having only small amounts of these reagents in a reactor 
at any given time increases the acceptance of experimenters to actually 
utilize them. This holds especially true in the case of large scale reactions. 
• The coupling can be performed much faster, thus increasing throughput 
and conserving energy. 
• Aside from scaling up, translating the methodology to flow paves the way 
for cascading or integrating the method in a larger synthetic flow 
pathway.232 Indeed, the Janssen research group recently published just 
such a cascading synthesis using the Negishi method here described as the 
final step.233 
To begin the methodology development, first a model compound must be chosen. 
The choice went to 4-nitrobromobenzene (3.13) as aryl halide, to be alkylated 
using dimethyl zinc as the organozinc species (which can be bought conveniently 
as a solution). This compound resembles the monomers to some degree, but more 
importantly, the methylated product 3.14 is not volatile (as is the case when using 
for example bromobenzene) but still easily visible on GC-MS. Before introducing 
unknown reaction conditions to flow, it needs to first be tested in batch. Flow 
systems do not handle precipitates well, so it is vital to check for any formation of 
solids in the batch reaction. If precipitation is observed, the conditions should be 
changed. For these batch reactions, microwave heating was used to operate at 
similar heat transfer efficiency as in a flow reactor. 
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The starting point of the screening was a rather simple in-house procedure, 
utilizing homogeneous Pd-tetrakis in toluene at high concentration and 
temperature (table 3.2 entry a). While these conditions yielded the desired product, 
large amounts of black precipitate were also formed. Firstly the concentration of 
aryl halide was lowered, while the reaction time was increased to 1 minute (table 
3.2, entry b). This increased the conversion somewhat, but did not solve the 
precipitation problem. It was then assumed that the precipitate was, in all 
probability, various zinc salts which are not soluble in the apolar toluene. Attempts 
to use the more polar THF in first instance did indeed result in a homogeneous 
solution (table 3.2, entry c), however conversion also suffered significantly. If the 
reaction time was increased to 5 minutes, full conversion could be achieved, but 
still a light precipitate was observed. Although in much less quantities then was 
the case for toluene, this was still considered not optimal. The logical next step 
was then to simply use a mixed solvent system consisting of equal amounts of 
THF and toluene (table 3.2, entry e). As predicted, this resulted in full conversion 
in just 1 minute reaction time, at the price of again a mild amount of precipitation 
occurring. However these conditions were deemed suitable to now utilize for the 
screening of several types of heterogeneous catalysts. A first attempt using 
essentially the same catalyst (Pd-tetrakis), but on a polymer support, did not result 
in an acceptable conversion (table 3.2, entry f). However in the flow chemistry 
research unit at Janssen, good results had been obtained when using palladium 
catalysts immobilized on silica gel in previous flow protocols.234 These types of 
heterogeneous carriers have especially low catalyst leaching levels and do not 
swell on organic solvents, making them very interesting for this application as well. 
Out of the three silica catalysts screened (table 3.2, entries g-i), both Siliacat-Pd0 
and Siliacat-DPP-Pd (figure 3.1) turned out to give good conversions.235 These 
were then tested at lower temperatures but higher 
concentration (to increase throughput) and 
corresponding higher reaction times (table 3.2, entries 
j-k). Of these, Siliacat-DPP-Pd gave the best results 
and was therefore selected as the catalyst of choice to 
use in flow. 
Figure 3.1: Siliacat-DPP-Pd.  
The fact that the conversion is not complete is of little concern: in these batch 
experiments only 1 mol% of catalyst was used, while in a packed bed reactor in 
3.12 
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flow, there will be a large excess of catalyst present compared to the amount of 
substrate in the reactor at any given time. This will greatly boost conversion. 
Table 3.2: Screening experiments of the Negishi coupling reaction in a microwave reactor. 
 
 Solvent T 
[°C] 
Conca
[M] 
Catalyst  Time 
[s] 
Ppt
? 
Conv.
b 
a Toluene 100 0.75 Pd Tetrakis  10  Yes 60% 
b Toluene 100 0.1 Pd Tetrakis  60 Yes 77% 
c THF 100 0.1 Pd Tetrakis  60 No 17% 
d THF 100 0.1 Pd Tetrakis  300 Yes 100% 
e Toluene/THFd 100 0.1 Pd Tetrakis  60 Yes 100% 
f Toluene/THFd 100 0.1 Polymer-Pd(TPP)4c 60 No 6% 
g Toluene/THFd 100 0.1 Siliacat-Pd0 c 60 No 70% 
h Toluene/THFd 100 0.1 Siliacat-S-Pd0 c 60 No 20% 
i Toluene/THFd 100 0.1 Siliacat-DPP-Pd0 c 60 Yes 85% 
j Toluene/THFd 60 0.5 Siliacat- Pd0 c 300  No 50% 
k Toluene/THFd 60 0.5 Siliacat-DPP-Pd0 c 300  No 60% 
Conditions:1 mol% of catalyst, a: Concentration of 4-nitrobromobenzene, b: As determined by GC-
MS, c: Heterogeneous catalyst, 1 mol% based on Pd loading, d: 1/1 toluene/THF. 
 
Figure 3.2: Flow setup diagram. P1, P2: Liquid pumps, TTF: T-Tube Fitting, PBR: Packed Bed 
Reactor with Heterogeneous Catalyst, CV: Collection Vessel. 
3.13 3.14 
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Figure 3.3:Flow systems for Negishi coupling in flow: A) Vapourtec R2+R4 module B)
assembled setup. a: Syringe pump, b: Syringes with organozinc and aryl halide solutions, c: Mixing 
chip, d: Heated reactor column, e: product collection flask.
The transition to flow was made on the Vapourtec R2+R4 system,
automated flow chemistry platform (figure 3.3A). The general flow setup is 
represented schematically in figure 3.2: The aryl halide and dialkylzinc reagents 
are pumped separately (pumps P1, P2) at flow rates of 0.2 ml/min each (dependent 
on desired residence time) through Teflon tubes. These reagent streams are then 
mixed in a T-piece (TTF) before being forced over a glass reactor packed with 1g 
of Siliacat-DPP-Pd, heated in an oven (integrated in the Vapoutec). Afterwards the 
product stream is collected in a collection vessel (CV) for work
All these components are incorporated in the Vapourtec system, however it is also 
possible to utilize a self assembled setup using common lab apparatus (figure 
3.3B). In this case, the reagents were loaded in syringes and pumped using a 
syringe pump. The mixing was effected by a commercially available mixing chip, 
although a simple T-piece would also suffice. The mixed reagent
then passed over the Siliacat-DPP-Pd reactor, which was heated 
module. However, for self assembled systems
alternative heating elements such as for example 
oven. Then the product can again be collected in a suitable receptacle. These 
setups were used to further develop the Negishi coupling in flow.
The first attempt, using the conditions obtained from the batch reactions, afforded 
the product in full conversion (table 3.3, entry a). Encouraged to test the limits of 
the catalyst system, the temperature was lowered to 40°C and later to ambient 
A) B) e 
d 
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(table 3.3, entries b and c). At the latter temperature, conversion was still complete. 
A lower concentration of 0.1M achieved complete conversion at all temperatures 
tried (table 3.3, entries d-f). Raising the concentration to 0.25M still allowed full 
conversion at room temperature(table 3.3, entry g). To check the influence of the 
amount of organozinc reagent, its ratio was also lowered (table 3.3, entries h-i). 
The conversions dropped to 40% when half an equivalent of Me2Zn was used. 
Again in the interest of throughput, the reaction time was lowered as much as 
possible, while varying the temperature or concentration accordingly(table 3.3, 
entries j-l). From these results, the conditions of entry j were chosen as general 
starting parameters to be used with other substrates (3 min, 60°C, 0.25M). Even 
though the reaction is possible with higher concentrations/lower reaction time, it 
should be kept in mind that the model substrate is quite reactive. Therefore the 
middle ground was chosen. 
Table 3.3: Optimization of Negishi coupling in flow. 
 
Entry Ratioa Rt [s] T [°C] Conc. [M]b Conv.c 
a 1/1.3 300 60 0.5 100% 
b 1/1.3 300 40 0.5 100% 
c 1/1.3 300 RT 0.5 85% 
d 1/1.3 300 60 0.1 100% 
e 1/1.3 300 40 0.1 100% 
f 1/1.3 300 RT 0.1 100% 
g 1/1.3 300 RT 0.25 100% 
h 1/1 300 40 0.1 90% 
i 1/0.5 300 40 0.1 40% 
j 1/1.3 180 60 0.25 100% 
k 1/1.3 60 40 0.1 100% 
l 1/1.3 60 40 0.5 100% 
a: Ratio of 3.13/Me2Zn, b: concentration of ArX, c: as determined by GC-MS. 
Armed with a general method, it was time to indulge our eagerness to test the 
protocol on different substrates (table 3.4). 
As could be expected, various aryl bromides and electron deficient aryl iodides did 
not cause any trouble and resulted in very good to excellent isolated yields (table 
3.13 3.14 
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3.4, entries a-c and e-h). When more electron rich substrates were used, the 
homocoupling (forming biaryl compounds) side reaction was observed (table 3.4, 
entries d, i, j). Performing the reaction at higher dilution (0.1M) reduced the 
amount of homocoupling to an acceptable level of below 10%. Aryl chlorides with 
electron withdrawing substituents or with a halide in the α-position of the azine 
nitrogen can also be used as a substrate for  the reaction (table 3.4, entries k-n). To 
reach acceptable yields, higher temperatures (80°C) were often required however. 
Encouraged by the positive results for the aryl chlorides, aryl nonaflates were also 
tested as possible substrates (table 3.4, entry o). Unfortunately, even with a 
strongly electron withdrawing functional group present, they proved recalcitrant 
under these conditions. The same negative result was obtained for aryl triflates 
(not shown). Finally, a test was performed to check whether a bromine substituent 
could be selectively alkylated preferentially to a chlorine (table 3.4, entry p). This 
proved to indeed be the case, with only minor amounts of dialkylated product 
detectable. Note the functional group compatibility, as the protocol leaves nitro, 
ester, aldehyde, nitrile and ketone substituents untouched. The presence of 
substituents ortho to the reacting halide likewise did not diminish reactivity. An 
added advantage is the convenient work up procedure, which in most cases 
consisted of en aqueous quench and subsequent extraction with DCM or EtOAc. 
The crude product thus obtained usually required no further purification. The 
catalyst also proved recyclable, indeed many of these small scale reactions were 
run using the same reactor. Periodic checking of the catalyst activity using a 
standard reaction indicated no appreciable loss of function after more than 20 runs. 
Table 3.4: Scope of aryl halides in the Negishi coupling in flow. 
 
Entry Substrate Conc [M] T [°C] Rt [s] Conv.
a
 Yieldb 
a 
 
0.25 60 180 100% 97% 
3.15 
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b 
 
0.25 60 180 100% 83% 
c 
 
0,25 
0.5 
60 
60 
180 
300 
100% 
100% 
83% 
- 
d 
 
0.5 
0.1 
0.1 
60 
80 
60 
300 
300 
180 
60%c 
100%d 
98%d 
-
 
- 
66% 
e 
 
0.25 60 180 100% 87% 
f 
 
0.25 60 180 100% 82% 
g 
Br
O
 
0.25 60 180 100% 81% 
h 
 
0.25 60 180 100% 73% 
i 
 
0.25 
0.1 
60 
60 
180 
180 
100%c 
100%d 
- 
71% 
j 
 
0.1 
0.25 
0.1 
60 
60 
40 
180 
180 
180 
100%d 
100%c 
80%d 
81% 
- 
- 
k 
Cl
O
OEt
 
0.5 
0.1 
0.25 
60 
80 
80 
300 
180 
180 
95% 
80% 
100% 
- 
- 
73% 
l 
N ClO
 
0.25 60 180 50% 35% 
m 
 
0.25 
0.25 
60 
80 
180 
180 
10% 
40% 
- 
43% 
-Chapter 3- Functionalization 
 
-71- 
 
n 
 
0.25 
0.25 
60 
80 
180 
180 
85% 
100% 
- 
87% 
o 
 
0.25 
0.1 
60 
80 
180 
180 
4% 
10% 
- 
- 
p 
 
0.25 60 180 100%e 75% 
a: Determined by GC-MS, b: Isolated yield, c: >25% homocoupling detected, d: <10% 
homocoupling detected, e: 5% dimethylated product detected. 
However interesting these results may be, if the protocol would be restricted to 
methylation only it would be of limited use. Therefore also the scope of the 
organozinc reagents was explored further (table 3.5). Simple replacement of 
dimethyl zinc by the ethyl derivative gave similar results as expected (table 3.5, 
entry a). When attempts were made to react a secondary diorgano zinc reagent 
(diisopropyl zinc, table 3.5 entry l-m), the results were not favorable. A complex 
reaction mixture was obtained, containing amongst other unidentified substances 
the starting product, dehalogenated and homocoupled substrate. In addition it 
completely destroyed the activity of the catalyst. It is likely that secondary 
organozinc reagents are simply too reactive to participate in this protocol in a 
controlled manner. Relatively complex organozinc bromides are usable however, 
which caused no small delight since these compounds are also easier to prepare 
then their diorganozinc counterparts.236,237,238 Although in most cases it was 
necessary to change the solvent to pure THF, to eliminate blockage of the reactor. 
In this way it was possible to introduce heteroaryl (table 3.5, entry b, e), small 
carbocyclic (entries c,d), benzyl (entry f), alkyl nitrile (entry g), alkyl ester (entries 
i, k) and protected aldehyde (entries h, j) substituents. All in fair to excellent 
yields. 
 
Table 3.5: Scope of organozinc reagents in the Negishi coupling reaction in flow. 
 3.16 
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Entry Substrate Organozinc Product Yielda 
a 
 
Et2Zn 
 
85% 
b 
 
 
 
50%b 
c 
Br
O2N
 
 
 
62%b 
d 
 
 
 
94%c 
e 
 
 
 
90%c 
f 
 
 
 
74%c 
g 
 
 
 
55%c,d 
h 
 
 
 
68%c,e 
i 
 
 
 
51%c,e 
j 
 
 O
O
O
 
81%c 
k 
 
 
 
81%c 
l 
Br
O2N
 
iPr2Zn Complex mixture - 
m 
 
iPr2Zn Complex mixture - 
Conditions: 0.25 M ArX, THF/Toluene 1/1, 60°C, 3 min. a:isolated yield, b: THF as solvent, 80°C, 5 
min residence time, c: 2 eq. organozinc reagent used, THF as solvent, 2-5 min residence time, d: 
>25% homocoupling detected, e: <10% homocoupling detected. 
So it was possible to apply the protocol to a wide array of aryl halides and with a 
varied arsenal of organozinc reagents. However, in the arguments concerning the 
use of flow chemistry the easy of scale up was also considered as an important 
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advantage. This assertion was put to the test in a large scale run using the Negishi 
flow protocol (scheme 3.7). The exact same conditions were used as for the small 
scale runs, only now the reaction was run for a much longer time. After 4 hours of 
continuous reaction, conversion was still close to 100% (figure 3.4), indicating 
that the catalyst is stable under these conditions. The product were produced in 
this way at a rate of 7.5 mmol/hour (corresponding to approximately 1 g/h for 
these substrates) using a packed reactor containing about 1 g of catalyst. The 
palladium content of the crude product was also determine
ppm Pd present. This proves the catalyst does not suffer from leaching, as hoped.
Br
THF/Toluene 1:1
60°C, Rt = 3 min
Me2Zn
Siliacat-DPP-Pd
R
O
R
O
Scheme 3.7: Scale up run of the Negishi flow protocol, isolated
Figure 3.4: Evolution of the conversion of the
The Negishi flow protocol was then applied to some model monomers (
2.51c, 2.78aa) to establish proof of principle (scheme 3.8). As 
reaction proceeded in every case (3.20-22), however yields of the pyridine 
monomer 3.21 were somewhat low (10%). A number of unidentified side products 
were formed in this case, arousing the suspicion that the high reactivity of this 
scaffold was causing trouble. Due to lack of time no further optimization was 
attempted.  
3.17 
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d, indicating only 0.025 
 
CH3
7.5 mmol/h
R = Me : 83%
R = H : 84%
 
 yields. 
 
 scale-up reaction in time. 
2.31a, 
expected the 
3.18 
3.19 
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Scheme 3.8: Negishi coupling in flow of selected monomers. 
 
3.6  Suzuki Aryl-Aryl Coupling. 
 
The Suzuki reaction is an extremely versatile and robust method to make aryl-aryl 
bonds.239 It was therefore the method of choice to couple phenyl groups to the 
pyrazine monomers. In addition, if phenyl groups are used that can have AA side 
chains, it presents an opportunity to make peptidomimetics that are a hybrid of the 
terphenyl (1.17) and oligoarylamide (1.21) scaffolds (figure.3.5).  
This requires a benzene unit that has a boronic ester functional group and the 
ability to introduce AA side chains ortho to the boron 
moiety. A short synthesis for such a unit was developed 
(scheme 3.9), again making use of the amino acid side 
chain alcohols described in chapter 2.2.  
2.31a 
2.51c 
2.78aa 
3.20 
3.21 
3.22 
X
Z N
O
H
O X'
Z' PG
O
Ri+7
Ri+4O
Ri
1.31 
Figure 3.5: Hybrid peptidomimetic. 
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Scheme 3.9: Synthesis of the benzene unit  for hybrid peptidomimetics. 
An aspartic acid amino acid side chain (from alcohol 2.12) was attached to 2-
iodophenol (3.23) via the Mitsunobu reaction. The iodide group of iodoarene 3.24 
could then be transformed into the desired boronic pinacol ester 3.25 using a 
Miyaura protocol.240,241  
This substituted aryl boronic ester (3.25, table 3.6 entries a, b) or commercial 
available boronic acids and ester (table 3.6, entries c, d) could then be used in a 
Suzuki coupling reaction on the pyrazine monomer. A protocol was used that 
allowed this reaction to take place even without protection of the amine 
function.242 
 
Entry Boron species -OR2 Yield 
a 
 
-OCH3 68% 
b 
 
 
55% 
c 
 
-OCH3 70% 
d 
 
-OCH3 80% 
Table 3.6: Suzuki coupling reaction on unprotected pyrazine monomer. 
3.23 
3.24 3.25 
3.26 2.30 3.27 
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Note that instead of the Suzuki coupling reaction, the Negishi flow protocol 
(chapter 3.5) could also be used (see for example table 3.5 entries b, e). This 
would require the preparation of the required aryl zinc bromide unit instead of an 
aryl boronic acid or ester. However, due to lack of time and the good results 
obtained via the Suzuki coupling, this route was not explored. 
 
3.7  Conclusions 
 
To make the required monomers described in chapter 2 ready for carbonylative 
coupling, their halide functionality needed to be replaced. Rather than simply 
rendering them inert, the opportunity was seized to utilize the versatility of aryl 
halide chemistry to add extra functionality to the monomers (and thus the 
prospective peptidomimetics as well). 
• Proof of principle was given for the addition of amines to pyridine 
monomers using the SNAr reaction. 
 
• Simple esters could be introduced using carbonylation chemistry. 
 
• Alkyne functionalities were added via Sonogashira coupling to pyridine 
and pyrazine monomers 
 
• An extensive flow protocol was established for Negishi coupling using a 
heterogeneous catalyst. This was applied to some selected monomers. 
 
• The Suzuki reaction allowed the coupling of phenyl units to the pyrazine 
monomers. In this way it is possible to make hybrid peptidomimetics, 
which are a combination of terphenyl and oligoaryl amide scaffolds (see 
chapter 4.3.5). 
Now that methods are found to prepare the monomers for subsequent coupling 
with other monomers, the foundation is laid for the modular construction of the 
actual peptidomimetic multimers.   
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4.1  Carbon Monoxide Insertion Coupling 
 
4.1.1 General Considerations 
 
The key reaction in the modular synthetic strategy is the formation of a linking 
amide bond via a carbon monoxide insertion coupling (chapter 1.6). This is a 
rather unconventional method to form an amide bond, which is more traditionally 
made by condensation of an (activated) carboxylic acid and an amine (scheme 4.1). 
Our alternative approach uses carbon monoxide as a C1 synthon to deliver the 
carbonyl moiety. Note that the polarities of the other synthons remain the same, i.e. 
the aryl reagent is an acceptor and the amine reagent is a donor.  
 
Scheme 4.1: Retrosynthetic analysis of amide bond formation 
The reaction which can enable such a disconnection is the palladium catalyzed 
aminocarbonylation reaction.243,244,245,246 Reactions of this type have been known 
for a long time,247 but the earlier simple catalytic systems used to require high 
carbon monoxide pressures. The obvious safety hazard presented by using a highly 
toxic and flammable gas under pressure had pushed these reactions towards the 
realms of obscurity for lab scale organic synthesis. On an industrial scale on the 
other hand, carbon monoxide is used extensively to make various bulk chemicals 
such as aldehydes (hydroformylation248), alcohols (e.g. methanol249), hydrocarbons 
(Fisher-Tropsch process250) and acetic acid (Monsanto process249), to name a few. 
Fortunately, the development of more advanced catalytic systems (using bidentate 
ligands) allowed the aminocarbonylation (and carbonylations in general) to be 
performed at lower and often atmospheric pressure.220 With the proper safety 
precautions (see Appendix), carbon monoxide can now claim its righteous place as 
an accessible and versatile C1 building block for the organic chemist. For the 
Peptidomimetics -Chapter 4- 
 
-82- 
 
synthesis of oligoaryl amide peptidomimetics, the aminocarbonylation reaction 
offers strong advantages: 
• Aryl halide substrates can be used, which allows for very diverse and easy 
functionalization, resulting in more synthetic freedom (chapter 3). 
• The reaction conditions are mild and therefore compatible with the 
sometimes sensitive amino acid side chains present on the 
peptidomimetics (chapter 2). 
• Aminocarbonylation allows the use of substrates which are very difficult 
to use in conventional amide bond formation reactions. The prime 
example in this case is the pyrazine monomer. Aminopyrazines have a 
very low nucleophilicity and are notoriously difficult to couple using 
conventional methods251 (for a few of our own attempts, see appendix). 
They require harsh methods which would not be compatible with the 
amino acid side chains. Using aminocarbonylation however, they 
performed well and gave the desired amides under mild conditions 
(chapter 4.4).  
In addition, the hazards posed by carbon monoxide gas can be further reduced by 
generating it in situ in a flow chemistry setup, which will be the topic of chapter 
4.2.  
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4.1.2 Mechanism of the Palladium Catalyzed Aminocarbonylation 
 
The mechanism of the palladium catalyzed aminocarbonylation reaction is 
relatively complicated. Several steps are also still under debate and are dependent 
on the exact nature of the substrate, ligand or other reaction conditions. Scheme 
4.2 describes the generally accepted catalytic cycle221,244,243 using bidentate ligands 
(such as Xantphos, the ligand of choice in this work).  
 
Scheme 4.2: Mechanism of palladium catalyzed aminocarbonylation with bidentate ligands. 
Initially, palladium is added to the reaction mixture as a Pd(II) salt, which needs to 
be reduced first to Pd(0).252,253 There are several possibilities to achieve this both 
the most prominent ones are reduction via either β-elimination of amine bases or 
oxidation of the phosphine ligand (scheme 4.3).  
4.1 
4.2 
4.3 
4.5 4.4 
4.6 
4.7 
4.8 
4.9 
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Scheme 4.3: Mechanisms of formation of Pd(0) species. 
The most likely mechanism is the oxidation of phosphine ligands, as this is usually 
the fastest.221 The Pd(0) then associates with 2 bidentate ligands, forming a stable 
18 electron complex 4.1. This stable complex is not reactive, so a bidentate ligand 
must be lost first to form a 14 electron complex 4.2, which can then undergo 
oxidative addition of the aryl halide to give 4.3. This step goes quite smoothly for 
aryl bromides and iodides, however for aryl chlorides usually a more electron rich 
palladium center is needed. This can be achieved by using more electron rich 
phosphine ligands (such as alkyl phosphines). The aryl halide inserts cis and when 
bidentate ligands are used (as is the case here), there is no transition possible to a 
(more stable) trans complex. Carbon monoxide can then enter the coordination 
sphere, forming a trigonal complex 4.4 which can transition back to a four 
coordinate planar configuration 4.5 by expelling one phosphine of the bidentate 
ligand. The coordination of carbon monoxide to palladium is rapid, as the binding 
is enhanced by favorable back donation. A consequence of this mechanism is that 
excess phosphine ligand will inhibit the transition to the four coordinate complex 
and thus hinders CO insertion. Another factor which can 
slow down or stop CO insertion altogether is steric 
hindrance. Substituents in the ortho position of the halide 
will provide axial shielding of the palladium center from the 
carbon monoxide (figure 4.1). Especially when two ortho 
substituents are present, hindering both axial sites, 
significant slowing of CO insertion is to be expected. Higher 
pressures of CO will enhance this step, however too high pressures can 
paradoxically also have a detrimental effect. Higher pressures could result in 
double addition of CO, forming an α-keto amide.254 At very high pressures, CO 
can also start to coordinate to other active intermediates of the catalytic cycle, 
rendering them inactive.246,255 A careful balance needs to be sought. 
Pd
R
R
P
X
P CO
Figure 4.1: Steric 
hindrance 
to CO approach 
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From either the trigonal 4.4 or planar complex 4.5, an irreversible 1,2 alkyl 
migration is possible of the aryl to carbon monoxide to give an acyl complex 4.6. 
This carbonyl insertion step is enhanced for aryl substrates bearing electron 
withdrawing substituents in the para or ortho position. On the other hand, stronger 
electron donating phosphine ligands will result in stronger binding of carbon 
monoxide (due to increased back bonding), slowing the carbonyl insertion. The 
less electron rich aryl phosphanes are therefore better at mediating this step. 
Product formation can then be achieved via either direct nucleophilic attack of the 
amine on the acyl carbon (4.8) or via amine insertion (4.7) followed by reductive 
elimination. While there is still some discussion, mechanistic studies of both 
monodentate256,257 and bidentate258 systems have shown that direct nucleophilic 
attack is the most likely pathway. Either way, the desired amide product 4.9 is 
released and the active Pd(0) species 4.1 is formed, closing the catalytic cycle. 
4.2  Carbon Monoxide Insertion via Carbon Monoxide 
Precursors 
 
4.2.1 General 
 
While the formation of the amide bond via carbonylation is very versatile,there is 
one rather significant disadvantage:carbon monoxide is a very toxic, colorless and 
odorless gas which should not be used without proper precautions. Modern 
methods allow the usage of this gas at atmospheric pressure in many cases,244,243 
somewhat alleviating the hazard. However the problem of storage and use of 
carbon monoxide gas cylinders remains. A possible solution, at least on a lab scale, 
is to generate the carbon monoxide in situ. This can be done using several 
organic259,260,261,262 and inorganic263,264 precursors, which can release CO under the 
right conditions.265 Since most of the inorganic metal carbonyl precursors are 
(nearly) as toxic as carbon monoxide itself,231 new developments in the use of 
organic precursors based on aromatic formates are more promising.266,267 Their 
general structure is comprised of a formate ester (4.10) with a substituent on the 
carboxyl oxygen which can act as a good leaving group. Deprotonation of the 
hydrogen atom attached to the carbonyl can lead to a decomposition reaction 
whereby an phenolate 4.11 is expelled and CO is released (scheme 4.4).  
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Scheme 4.4: Formate CO precursor decomposition. 
For our purposes,several formate based CO precursors were made (figure 4.2, 
4.12268, 4.14267, 4.15) or bought (4.13). All of them make use of (electron poor) 
aromatic groups to stabilize the negatively charged oxygen, leading to better 
leaving group behavior. However, it is necessary to strike a balance: too reactive 
precursors will not be stable and thus not storable. Too stable precursors on the 
other hand will not easily decompose. Pentafluorophenol formate (4.12) could be 
synthesized and isolated, but degraded over the course of a few days, even when 
stored at -20°C. It was thus deemed unsuitable as a CO precursor. Precursor 4.13 
on the other hand is a commercially available, stable liquid. 4.14 is also quite 
interesting, as it is a bench stable solid. These last two precursors have already 
been described in literature as a source of in situ generated CO.266,267 When 
synthesizing the perhaps odd precursor 4.15, it proved to be highly unstable: when 
it was synthesized by adding formic acid slowly to a mixture of tosyl chloride and 
DIPEA, it immediately decomposed to CO (strong gas evolution), even at 0°C. 
Isolation of this precursor was thus impossible, but the fast decomposition could 
actually be used to our advantage (see chapter 4.2.3). 
 
Figure 4.2: Formate based CO precursors. 
It is clear that precursors such as the described aryl formates 4.13 and 4.14 are 
interesting sources of CO. However for large scale preparations in batch, they are 
not quite satisfactory. Large amounts of CO would be generated in the reaction 
vessel, which again poses a hazard. Flow chemistry can provide solace here: By 
conducting the process in a continuous fashion, the amount of hazardous reagents 
in the reactor at any given time is kept low (chapter 1). Large scale preparations 
can then be performed by simply letting the reactor run for longer periods. 
Our goal was therefore to develop a continuous flow chemistry protocol for 
carbonylation using CO precursors. Two approaches were taken. The first (chapter 
4.12 4.13 4.14 4.15 
4.10 4.11 
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4.2.2) makes use of stable aryl formate CO precursors 4.13 and 4.14.When using 
these CO precursors in first instance, an aryl ester is obtained (4.16, scheme 4.5). 
To form the desired amide 4.17, a follow-up transamidation reaction must take 
place. A flow protocol was developed by our group that is able to performs such 
transamidations, even with the poorly nucleophilic pyrazine monomers.269 By 
linking the carbonylation step with the transamidation step it is possible to create a 
cascaded flow method that provides the desired amide 4.17 in one synthetic 
operation. This route could therefore be a viable alternative to build the 
peptidomimetic multimers by using in situ generated carbon. The second approach 
(chapter 4.2.3) uses the highly unstable CO precursor 4.15 to generate CO which 
can be immediately used to form the amide bond, without passing via an ester 
intermediate. It will provide a direct route to the amide without the need for 
cascading.  
.  
 
Scheme 4.5: Two routes towards Pd-catalyzed amide bond formation via CO precursors  (R = CO 
precursor residue). 
 
 
 
 
 
4.16 4.17 
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4.2.2 CO Insertion with Stable CO Precursors in Flow 
 
This section is based on∗: 
Alonso N., Muñoz J.M, Egle B., Vrijdag J.L., De Borggraeve W.M., de la Hoz A., 
Díaz-Ortiz A., Alcázar J. (2014), First Example of a Continuous-Flow 
Carbonylation Reaction Using Aryl Formates as CO Precursors. Journal of Flow 
Chemistry, in print. 
In this first approach, a flow protocol is to be developed that can use stable CO 
precursors to generate carbon monoxide in the setup and use it for a palladium 
catalyzed carbonylation. As mentioned earlier, the product that will be obtained in 
this case is an aryl ester, not the desired amide. However, once a procedure to 
make the aryl ester is in place, it can be linked to an amide formation flow reaction 
also developed by our research group.269 This would allow the synthesis of the 
(peptidomimetic) amide in a two-step cascade flow protocol. The optimization of 
the carbonylation reaction using stable CO precursors 4.13 or 4.14 must be 
investigated first. 
As in the previous section on flow chemistry methodology (chapter 3.5), first a 
model system needed to be selected. Bromobenzene (4.18) was chosen this time, 
as it is electronically neutral and the reaction product is easily detectable on GC-
MS. 2,4,6-trichlorophenyl formate (4.16) was selected as CO precursor of choice 
for the screening, because it releases CO under milder conditions267 than phenyl 
formate (4.15). In addition, the formed ester 4.19 will be more activated towards 
amide formation due to the presence of three electron withdrawing chloride 
functional groups. 
Initially, the reaction was pre-optimized by our collaborators at Janssen 
Pharmaceutica in Toledo, using microwave heating in batch conditions. This in 
order to assess the formation of precipitation and to obtain starting conditions for 
flow optimization. At first, the solvent and equivalents of reagents were kept the 
same as the in the literature procedure for the batch process described by Ueda et 
al.267 The first reaction, performed at 120°C for 5 minutes resulted in a 
disappointing 29% conversion (table 4.1, entry a). At 140ºC however, the reaction 
                                                     
∗The contribution of the author of this dissertation was in the initial experiments and in the 
adaption to a self constructed flow setup.   
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proceeded with a very high conversion (table 4.1, entry b) and by increasing the 
reaction time to 10 minutes, the reaction was almost complete (table 4.1, entry c). 
When the base was changed to DIPEA, a turbid mixture was obtained (table 4.1, 
entry d). The use of the less reactive phenyl formate as alternative CO precursor 
clearly decreased conversion (table 4.1, entry e), as expected. Other 
catalysts/ligands than those described in the literature were tried either in 
supported or soluble form (table 4.1, entry f-k). However, none of them was 
superior to the reported Pd(OAc)2/Xantphos system. Nevertheless, Pd(PPh3)4 also 
behaved reasonably well in contrast to what is described for phenyl formate 
carbonylations under traditional heating, where the best results are usually 
obtained using bidentate ligands.266 
Table 4.1: Screening of carbonylation reaction using CO precursors in batch. 
 
Entry Precursor [Pd]/ligand Time [s] Conv.a 
a 4.14 Pd(OAc)2/Xantphos 300 29%b 
b 4.14 Pd(OAc)2/Xantphos 300 87% 
c 4.14 Pd(OAc)2/Xantphos 600 98% 
d 4.14 Pd(OAc)2/Xantphos 600 97%c,d 
e 4.13 Pd(OAc)2/Xantphos 600 64% 
f 4.14 Pd(PPh3)4 300 75% 
g 4.14 PdCl2(PPh3)2 300 70% 
h 4.14 PEPPSI-Ipr 300 5% 
i 4.14 PdCl2[P(cy)3]2 300 9% 
j 4.14 Siliacat DPP-Pd 300 10% 
k 4.14 Siliacat DPP-Pd 300 25%e 
Conditions:1 eq. PhBr, 2 eq. precursor, 5 mol% catalyst/ligand, 2 eq. Et3N in DMF (0.24 
M) at 140°C. a: Determined by GC-MS, b: reaction at 120°C, c: 2 eq. DIPEA as base, d: 
turbid mixture obtained, e: ACN as solvent. 
  
The reaction conditions were then translated to a continuous flow process. 
4.18 4.19 
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Figure 4.3: Flow setup diagram. P1, P2: Liquid pumps, TTF: T-tube fitting, SS-CR: Stainless Steel 
Coil Reactor, BPR: Back Pressure Regulator, CV: Collection Vessel. 
As depicted in figure 4.3, the precursor was added via a separate line than the 
other reagents, to avoid premature decomposition. This precursor solution in DMF 
was mixed with another solution containing all other reagents in 1/1 DMF/THF 
using a T-tube fitting (TTF). Due to the high temperatures needed, a stainless steel 
coil reactor (SS-CR) was chosen. A backpressure regulator (BPR) was used to 
keep the carbon monoxide gas in solution. At Janssen Pharmaceutica,the flow 
reactions were performed in a Vapourtec R2+R4 system113 with a backpressure of 
250 psi. After a short screening, the best parameters for flow were determined to 
be 1.3 equivalents of both Et3N and 4.16, 3 mol% Pd(OAc)2, 6 mol% Xantphos, a 
reaction temperature of 150°C and a residence time of 5 minutes. The highlights of 
the reaction scope are depicted in table 4.2. 
 
Table 4.2: Scope of carbonylation using CO precursors in flow. 
 
Entry ArX Yield (%)a 
a PhCl -b 
b PhI 99 
c PhOTf 81 
4.20 4.21 
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d 
 
90 
e 
 
91 
f 
 
91 
g 
 
91c 
h 
 
81d 
Conditions: 0.24 M ArX, 1.3 eq. NEt3, 1.3 eq. precursor, 3 mol% Pd(OAc)2, 6 mol% Xantphos, 5 min 
residence time, 150°C, 17 bar pressure. a: isolated yields, b: No reaction, c: Selectively 
monocarbonylated at the iodine position, d: Reaction temperature 170°C, selective 
monocarbonylated product. 
The protocol is able to convert aryl bromide, iodides and triflates with little 
difficulty (table 4.2, entries b, c). Whereas aryl chlorides did not react (table 4.2, 
entry a). A number of heterocyclic scaffolds proved to be good substrates (table 
4.2, entries d-f) and selective monocarbonylation of dihalide substrates could also 
be achieved (table 4.2, entries g, h). 
The scalability of the process was also assessed by performing the reaction of table 
4.2, entry h on gram scale. During this experiment, it was observed that the 
precursor 4.16 slowly decomposed in stock solutions with DMF, leading to bubble 
formation which caused unstable pumping rates. The exact cause remains 
unknown, although it was postulated that traces of free dimethyl amine in the 
solvent are to blame. This problem was resolved by using pressurized 10 ml 
injection loops of the Vapourtec R2+R4, which can be reloaded with fresh 
solutions without stopping the system.  
The reaction was also attempted using a simpler setup with syringe pumps and 
without the backpressure of 17 bar (which is too high for the syringes to handle). 
The high backpressure proved crucial however, as gas formation was observed in 
the syringes at pressures < 4 bar. This resulted in drastically lowered conversions 
(23-30%) when using the standard conditions and bromobenzene as the substrate 
(which should give a conversion of around 94% when using 17 bar backpressure). 
In addition, the CO gas build-up in the syringes also poses an obvious safety 
hazard. It is therefore not recommended to utilize a low pressure setup for this 
protocol. Since no high pressure flow equipment was available at the time, this 
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flow carbonylation procedure was not further used in Leuven for peptidomimetics 
synthesis. 
4.2.3 CO Insertion via Unstable CO Precursors in Flow 
 
Using Traditional Flow Reactors 
Inspired by the observation that precursor 4.17 decomposed instantaneously, even 
at low temperature, another possible way to produce carbon monoxide in situ was 
explored (figure 4.4). This route would allow formation of the amide in one step, 
without an aryl ester as intermediate (scheme 4.5). 
 
Figure 4.4: Flow setup diagram of carbonylation protocol with an unstable CO precursor. P1, P2, 
P3: syringe pumps, TTF1, TTF2: T-tube fittings, GMC: Glass microchip, T-CR: Teflon coil reactor, 
CV: Collection vessel. 
Two (stable) solutions, one with formic acid (4.23) and the other with tosyl 
chloride (4.22) and DIPEA were mixed and heated in a glass microchip (GMC). 
This should immediately generate carbon monoxide and unreactive tosylate 4.24 
(scheme 4.6). 
 
Scheme 4.6: Production of CO immediately on mixing of the precursor reagents. 
4.22 4.23 
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This reagent stream containing carbon monoxide can then be mixed (TTF2) with 
the catalytic system (Pd(OAc)2/Xantphos) and the substrates (aryl bromide and 
amine nucleophile). The combined reagent streams are then flowed through a coil 
of Teflon tubing (T-CR) at a set temperature to perform the carbonylation step.  
Note that no cascading is necessary in this case, because this method should not 
generate an ester intermediate (the tosylate is a very weak nucleophile) but can 
directly insert the amine nucleophile. This is a distinct advantage compared to CO 
precursors which first produce an ester. In addition, the starting products to 
generate CO (TsCl, HCOOH) are very cheap and easily available. The tosylate 
byproduct is also less toxic231 than the phenol derivatives which are produced 
using previously mentioned aryl formates (figure 4.2). 
Table 4.3: Screening of the carbonylation reaction using an unstable CO precursor in flow. 
 
Run Solvent Temp. GMC (°C) 
Temp. T-CR 
(°C) Conversion
a 
a DMF 60 80 0% 
b DMF 60 100 0% 
c DMF 60 120 3% 
d DMF 60 150 14% 
e Toluene 60 120 0% 
f Toluene 60 150 1% 
g Toluene 100 150 2% 
h THF 60 120 3% 
i THF 60 150 5% 
j THF 100 150 10% 
Conditions: 0.2 M PhBr, 1.5 eq.  PhNH2 , 5 mol% Pd(OAc)2, 10 mol% Xantphos ,3 eq. DIPEA,  1.5 
eq. M  Ts Cl, 1.5 eq. HCOOH, 2  eq. DIPEA, residence time GMC = 20 seconds, residence time T-
CR: 4 minutes 45 seconds. a: Based on GC-MS. 
In the following screening experiments (table 4.3), the reaction solvent and 
temperatures of both the glass microchip (GMC) and the coil reactor (T-CR) were 
varied. Because the decomposition of the CO precursor is very fast, the 
temperature in the GMC was assumed to be non-critical. Using DMF as a solvent, 
4.18 4.25 
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no conversion was observed at 80 and 100°C (table 4.3, entries a, b). Higher 
temperatures (table 4.3, entries c, d) were needed to obtain some conversion, with 
150°C giving a still rather disappointing 14% conversion. It should be noted that 
DMF is by itself also a CO precursor,265 but at temperatures < 150°C it should not 
decompose. The second set of experiments was performed in toluene (table 4.3, 
entries e-g). However this solvent proved to be unsuitable, giving only very low 
conversion even at high temperature. It was also observed in this case that bubble 
formation in the GMC due to CO gas evolution appeared slower. Perhaps the 
reaction of tosyl chloride with formic acid is too slow in this apolar solvent. 
Changing the solvent to THF (table 4.3, entries h-j) gave better results than 
toluene but still no conversions higher than 10% were achieved. Unexpectedly, 
better results were obtained in this case when using a higher GMC temperature for 
the decomposition of the CO precursor (table 4.3, entry j), although it cannot be 
excluded that this is due to experimental variation. To conclude, DMF was found 
to be the best solvent for the carbonylation, however even then the conversions 
were too low for this method to be considered for further development. 
Using a Tube-in-Tube Reactor 
Generating the carbon monoxide in the same line as where the carbonylation 
reaction takes place gave disappointing results. It was therefore decided to utilize 
another reactor design that allows a complete separation of the CO precursor and 
the aminocarbonylation reagent streams. The tube-in-tube reactor (TiTR) is a 
recent innovation that has been used successfully in many cases were gaseous 
(hazardous) reagents  are used in flow, including diazomethane,132 ammonia270 and 
carbon monoxide gas.271 The general principle of this reactor is relatively simple: 
it consists of a thin (inner) tube that is placed inside a larger diameter (outer) tube. 
The inner tube is made of a special polymer (AF-2400) that is permeable to small 
molecules like carbon monoxide gas but not to larger molecules. Gas from the 
inner tube will therefore diffuse into the outer tube (Figure 4.5) where it can 
participate in reactions.  
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Figure 4.5: Principle of the Tube-in-Tube reactor (inner/outer tube cross section).
 
This reactor (figure 4.6) is easily built in 
the lab from 
(see appendix). The flow setup is described 
in scheme 4.6, the (stable) solutions 
necessary to prepare the CO precursor 
(DIPEA /tosyl chloride and formic acid) 
are mixed in TTF1 and pumped through 
the inner tube (IT) of the tube
reactor (TiTR). All reagents necessary for 
the aminocarbonylation reaction are 
pumped through the outer tube (OT) of the 
reactor. The unstable precursor will be formed in the inner tube and immediately 
decompose to carbon monoxide gas. This gas wi
where it can participate in the aminocarbonylation reaction. The outlet of the inner 
tube (containing tosylate and DIPEA salts) is send to the waste. The product will 
be collected from the outlet of the outer tube. 
Figure 4.6: Tube-in-tube reactor. 
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Figure 4.7: Flow setup diagram for tube-in-tube flow carbonylation. P1, P2, P3: syringe pumps, 
TTF: T-Tube Fitting, TiTR: Tube-in-Tube Reactor, CV: Collection Vessel, BPR: Backpressure 
regulator, IT = inner tube, OT = outer tube. 
Some preliminary experiments were performed to obtain a proof of principle. A 
model reaction was chosen using benzyl amine and bromobenzene as substrates. 
The catalytic system was the familiar Pd(OAc)2/Xantphos combination. Due to 
lack of time, only two experiments could be performed, with the temperature 
being the only parameter that was varied. The preliminary results were promising: 
at 100°C, a conversion of 20% was observed (table 4.4, entry a), while at 140°C 
the conversion rose to 30% (table 4.4, entry b). 
Table 4.4: Preliminary results of the carbonylation reaction in the tube-in-tube reactor. 
 
Entry Temperature Conv. 
a 100°C 20% 
b 140°C 30% 
Conditions: Solution A: 0.5 M TsCl, 1 M DIPEA in THF. Solution B: 0.5 M HCOOH in THF. 
Solution C: 0.2 M PhBr, 0.4 M BnNH2, 0.02 M Xantphos, 0.01 M Pd(OAc)2, 0.6 M DIPEA in DMF. 
Residence time IT = 1 min, OT = 10 min. IT backpressure = 40 psi. 
4.18 4.26 
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These results prove that the concept of generating CO in a tube-in-tube reactor is 
feasible and further research into optimizing this setup is ongoing. 
 
4.2.4 Carbonylation: Final Words 
 
In the previous sections, the aminocarbonylation reaction was discussed in detail 
and flow chemistry was used to explore alternative ways to perform these 
reactions in safer manner. Although some interesting results were obtained from 
flow chemistry, they were not (yet) applicable to prepare oligoaryl amide 
peptidomimetics, either due to lack of the proper equipment or not yet optimized 
procedures. So for now we will have to make do with batch aminocarbonylations 
to make the amide bonds of the peptidomimetic scaffolds. Using the proper safety 
precautions (see appendix), working with CO gas can be done in a safe manner.  
In chapter 2, the synthetic routes were developed to make the monomers which 
could be further functionalized using methods from chapter 3. The 
aminocarbonylation to coupling reaction to make amide bonds was explained in 
this chapter. Therefore all the prerequisites are available for the final act: the 
synthesis of the peptidomimetic multimers.    
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4.3 Peptidomimetic Multimer Synthesis 
 
4.3.1 Carbonylation Coupling Methodology 
 
The final mimetic is comprised of several monomers (A, B, C) from chapter 2, 
which are introduced in a modular fashion. To recapitulate: the monomers have a 
halide and protected amine tether in para orientation of a (hetero)cyclic core. Also 
attached to this core is an amino acid side chain. The starting block A (scheme 4.7) 
is first functionalized on the halide moiety, using any of the methods described in 
chapter 3. Then the primary aryl amine functional group is liberated in a 
deprotection step as shown in chapter 4.3.2. The building block can then be 
coupled to the next block (B) via an amide bond using a palladium catalyzed 
carbon monoxide insertion protocol. This gives the peptidomimetic dimerAB, as 
will be demonstrated in chapter 4.3.3. If longer mimetics are required, the 
procedure is simply repeated: deprotecting the terminal amine of AB, followed by 
a coupling reaction with monomer C gives the peptidomimetic trimer ABC 
(chapter 4.3.4). Finally, in chapter 4.3.5, multimers will be made that combine 
aryl-aryl with amide bond linking to result in a hybrid scaffold. 
Scheme 4.7: General coupling methodology 
Using this strategy, the α-helix peptidomimetics can be prepared from the same 
pool of monomers. The different types of multimer scaffolds are shown once more 
in figure 4.8. 
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Figure 4.8: α-helix peptidomimetic archetypes, R subscript refers to residue position on helix.          
Y =  -COOR, -NR2, -Aryl, -Alkyn. Z, Z’, Z”, X, X’, X”: -N, -CH-. Ri = AA sidechain, PG = amine 
protecting group. 
It is left to the compound designer to choose: 
• The functionality attached to the starting block A, choosing from any of 
the methods from chapter 3 or (albeit untested here) another option from 
the large repertoire of reactions possible on aryl halides. This functionality 
could then be another starting point for further attachment of other 
molecular entities. 
• The order and type of amino acid side chains, choosing from those 
described in chapter 2.2. 
• The order and nature of the aromatic core of each monomer (pyridine, 
pyrazine, phenyl), which can influence such factors as solubility, 
conformational stability and so on. 
• The α-helix mimetic pattern (see chapter 1.4.1): i, i+4, i+7 (1.28, 1.31) or 
i, i+4 (1.29) or i, i+2, i+5 (1.30). 
• Although not explored further, in principle the terminal amine of a 
mimetic could also be a tether for further functionalization. 
 
 
 
 
 
 
 
 
 
 
1.28 1.29 1.30 1.31 
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4.3.2 Free the Amine: the Deprotection Step 
 
 
Scheme 4.8: General deprotection step of monomer 
After functionalizing the initial monomer, the amine group needs to be liberated 
(scheme 4.8). Depending on the monomer used, this means either reducing a nitro 
functional group or removing a Boc protecting function (see chapter 2).  
While nitro functionalities are usually removed using metal-acid combination,204 
these are not suitable here because of the acid labile protecting scheme of the side 
chains. The use of Pd on carbon with hydrogen gas was also not an option due to 
the possibility of reductive cleavage of the benzylic side chains.272 Other methods 
needed to be sought which are both neutral or basic and selective, leaving benzylic 
ethers untouched. A first possibility used hydrazinium monoformate with zinc 
powder in methanol,273 which was reported to be very mild and selective. However 
no conversion was observed using these conditions (scheme 4.2). Another method 
made use of Fe(acac)3 as a catalyst and hydrazine hydrate as the reductant in 
methanol under microwave irradiation.274 This procedure seemed particularly 
interesting as it was also available as a flow chemistry protocol. Unfortunately, 
this method resulted in low conversion and a complex reaction mixture with 
several unidentifiable side products. 
 
Scheme 4.9: Failed nitro reduction attempts. 
It was perhaps by providence that a paper by Lipshutz et al. was published in 2014, 
reporting the selective reduction of nitro groups using Zn metal and ammonium 
2.51c 4.27 
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chloride in water with small amounts of an advanced surfactant.275 This extremely 
fast and convenient protocol (scheme 4.10) delivered the amines in quantative 
conversion (TLC) with no detectable side products in a short time (about 2 hours). 
The initial enthusiasm was somewhat damped by the discovery that the free 
amines of the pyridine monomer are not stable. Probably their highly electron rich 
nature makes them susceptible for oxidation by air. The decomposition is slow 
enough however to permit a following reaction if the amine is used immediately 
after work-up and kept under an atmosphere of argon as much as possible. 
Attempts were made to make the hydrochloride salt of the amines in order to 
improve stability. Unfortunately these salts were extremely hygroscopic and 
resulted in difficult to handle viscous oils. This can probably be attributed to the 
presence of several protonation sites. Salts made with polyprotic acids could give 
better results but this was not explored. 
 
Scheme 4.10: Reduction deprotection step,  product not isolated. 
Removing the Boc protecting group is quite straightforward in those cases where 
the amino acid side chains of the mimetic are not protected (by acid labile 
protecting groups). A simple treatment with an acid such as TFA in DCM as 
solvent276 delivered the desired amine 4.29a in excellent yield (scheme 4.11). 
However when using protected side chains another, neutral, protocol is needed. 
One such method makes use of suspending the substrate in boiling water to 
remove the Boc group in good yields189 (compound 4.29b). 
 
Scheme 4.11: Deprotection of Boc protected monomers a: TFA/DM, b: H2O at 100°C.  
 
2.51 
4.27a 
4.28 
4.29a 
4.27b 
4.29b 
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4.3.3 Dimerisation using Carbonylation 
 
The carbonylation reaction was used to make the amide bond connecting two 
monomers, forming a peptidomimetic dimer. Such a dimer will be able to mimic 
two amino acid residues from the i and i+4 position of an α-helix.Or, if a 
Marimganti monomer (2.78) is used, the i, i+2, i+5 positions.  
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Scheme 4.12: Synthesis of peptidomimetic dimers using carbonylation coupling. Intramolecular 
hydrogen bonding shown with dashed lines. Isolated Yields. 
4.30 4.31 4.32 
4.33 4.34 4.35 
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Several examples of such dimers are presented in scheme 4.12. Both homo- (4.30, 
4.32, twice the same monomer type) or heterodimers (4.31, 4.33, 4.34-38 two 
different monomer types) could be made. In cases where a pyrazine (4.30, 4.32, 
4.35) or disubstituted monomer (4.36, 4.38) was used as the second (B) monomer, 
two intramolecuar hydrogen bonds are possible. This results in a highly planar 
conformation. However, as mentioned in chapter 1.4.3, sometimes it is useful to 
allow for some conformational flexibility. This can be done by using a phenyl 
monomer as the second (B) monomer, which cannot form a second, conformation 
stabilizing intramolecular hydrogen bond (4.31, 4.33-34, 4.37). 
Evidently absent from these dimers are those with a pyridine scaffold as the 
second (B) monomer. Performing the carbonylation coupling on these scaffolds 
was problematic as shown in table 4.5. 
Table 4.5: Carbonylation attempts on the pyridine monomer. 
 
Entry -Y -OR -X [Pd]/L Base Result 
a -COOMe -OiBu -Cl Pd(OAc)2 Xantposa Na2CO3 II 
b -COOMe -(4-F-Ph) -Br Pd(OAc)2 Xantposa Na2CO3 II 
c -(2-OMe-Ph) -OiPr -Cl Pd(OAc)2 Xantposa Na2CO3 II 
d -(2-OMe-Ph) -OiPr -Cl Pd(OAc)2 Xantposa Et3N II 
e -(2-OMe-Ph) -OiPr -Cl Pd(OAc)2 Xantposa Cs2CO3 II 
f -(2-OMe-Ph) -OiPr -Cl Pd(OAc)2 Xantposa Ag2CO3 II 
g -(2-OMe-Ph) -OiPr -Cl Noneb Na2CO3 -c 
h -COOMe -OiBu -Cl Pd(PPh3)2Cl2d Et3Ne -f 
General conditions: 1 eq. ArX, 1 eq. Ar’NH2, 10 eq. base in Toluene (0.075M) at 80°C. a: 5 mol% 
Pd(OAc)2 + 5 mol% Xantphos, b: No palladium added and no CO used. c: No reaction, starting 
products fully recovered. d: 10 mol%catalyst, e: used as solvent, f: Complex reaction mixture, no 
trace of product (ESI-MS, GC-MS, CI-MS) 
4.40I 4.40II 4.39 
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Using the normal procedure with the Pd(OAc)2/Xantphos catalyst system, no 
carbon monoxide insertion was observed, only direct coupling of the aniline (table 
4.5, entry a). Replacing the chlorine functional group with a bromide had no effect 
(table 4.5, entry b). A number of alternative bases were also tried (table 4.5, entry 
d-f), but again the desired compound could not be obtained. Using the same 
catalyst system that was successful in making esters via carbonylation on the 
monomer stage (chapter 3.3) only resulted in a complex reaction mixture where no 
trace of the product could be found (table 4.4, entry h). It was hypothesized that 
either a competing Buchwald-Hartwig amination215 or a SNAr reaction (chapter 3.2) 
could be the culprit. Given the very low nucleophilicity of the pyrazine coupling 
partner (4.39), the former hypothesis seems more likely. To verify this a control 
experiment using the same conditions, but without the palladium catalyst, was 
performed (table 4.5, entry g). Only starting products were found, confirming that 
a palladium catalyzed amination reaction was indeed the cause. 
An alternative could be to couple this monomer via a 2 step procedure by first 
making the ester 4.41 using carbonylation (see chapter 3.3) and then performing a 
transamidation with an A monomer (scheme 4.13). The latter transformation is a 
flow protocol that is currently in the last stages of development in our lab.277 
However due to lack of time this alternative pathway could not be explored. 
 
Scheme 4.13: Alternative amide bond formation using a 2 step pathway 
Another alternative could be to use the Boc protected pyridine monomers 2.49 
(chapter 2). However their synthesis is more involved: a 3 step pathway with 
chromatographic separations is needed compared to a one step synthesis without 
chromatography for the nitro protected monomers 2.51. However, proof of 
principle for the preparation of multimers with this monomer is given in chapter 
4.1.3 (compound 4.49). 
Since the pyrazine monomer 2.31 can also form the same intramolecular hydrogen 
bond as the pyridine, it is not crucial to have the pyridine as a B monomer. 
Therefore it was decided to use them only as A blocks. 
2.51 4.41 4.42 
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4.3.4 Trimerisation using Carbonylation 
 
With the dimers in hand, adding another monomer to the peptidomimetic requires 
only to deprotect the dimer and performing another carbonylation reaction 
(scheme 4.14). 
 
 
Scheme 4.14: Trimer formation using consecutive deprotection-carbonylation steps. 
In this way pyrazine trimers 4.44 and 4.46 could be obtained, a class of 
peptidomimetics not yet reported in literature. When using alanine side chains, the 
deprotected dimer 4.43 that was obtained proved to be practically insoluble in 
every conventional solvent tried (acetone, heptanes, water, toluene, EtOAc, 
DMSO, DMF, NMP, dioxane, DCM, ACN, DMI, CS2). It could only be brought 
into solution in either large amounts of boiling pyridine or the ionic liquid N,N’-
butyl-methyl-imidazolium acetate. It was assumed that the cause was the small 
alanine side chain substituents, which could allow strong intermolecular hydrogen 
4.30 4.43 4.44 
4.32 4.45 4.46 
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bonding and π-stacking of the scaffold to take place by not interfering sterically. 
When a larger, out-of-plane leucine side chain was used, the deprotected dimer 
4.45 was easily soluble in DCM and other organic solvents. This observation 
seems to confirm the hypothesis that out-of-plane substituents are needed to hinder 
the strong intermolecular interactions of these multimers. 
 
4.3.5 Hybrid Multimers 
 
By using the same Suzuki coupling protocol from chapter 3.6 to functionalize the 
monomer, aromatic groups can be introduced that also bear an amino acid side 
chain. This will give rise to hybrid peptidomimetics, combining aryl-aryl with 
oligoaryl amide type mimetics (see chapter 1.4.3). Because of the modular design 
of the monomers, the same carbonylation reaction can be used to couple another 
(C)  monomer to the aryl-aryl dimer AB via an amide bond (scheme 4.15). 
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Scheme 4.15: Hybrid peptidomimetic trimer formation. 
Three examples (4.47, 4.48, 4.49) were made to demonstrate this principle, using 
combinations of pyridine, pyrazine and phenyl scaffolds.  
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4.4 Conclusions 
 
• The mechanistically complex palladium catalyzed carbonylation reaction 
enables modular design of the peptidomimetic multimers. 
• CO precursors are interesting and in most cases safer alternatives to 
storing carbon monoxide gas. A flow protocol was developed using 2,4,6-
trichloro-formate as a CO source. It required high backpressures however 
which were not attainable with our equipment at the time. 
• A highly unstable CO precursor made from reacting tosyl chloride with 
formic acid was found. Using a traditional flow reactor where all reagents 
are in the same reaction stream resulted in disappointingly low 
conversions. A  more advanced tube-in-tube reactor design was used to 
separate the CO generating stream from the other reagents. The 
preliminary results were encouraging both more research is needed. 
• Several α-helix dimer, trimer and hybrid peptidomimetics with patterns i, 
i+4, i+7 or i, i+4 or i, i+2, i+5 were made in a modular fashion using 
combinations of pyridine, pyrazine, phenyl and Marimganti monomers. 
The pyridine monomer had to be used as the starting (A) monomer when a 
nitro functionality was used as a protecting group. 
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5.1  General Conclusions and Overview 
 
We have attempted to contribute to the arsenal of methods to modulate protein-
protein interactions, targets that are increasingly important for pharmaceutical 
applications. As synthetic chemists, we chose the rational design approach and 
prepared minimalistα-helix peptidomimetics. A modular synthesis strategy was 
developed to assemble monomers via palladium catalyzed aminocarbonylation 
into peptidomimetic multimers. We also introduced flow chemistry to expand our 
repertoire of synthetic tools and several flow protocols were developed with a 
much wider applicability than just our target molecules. The end result was the 
successful preparation of a variety of oligoaryl amide α-helix mimetics displaying 
diverse amino acid side chains.  
To summarize: 
• A wide range of amino acid side chains were prepared or available with an 
alcohol moiety to allow attachment to the monomers. Chapter 2.2. 
 
Figure 5.1: Amino acid side chains with alcohol moiety.PG = -Boc or –Trt. 
• In an at times strenuous exercise in heterocyclic and aromatic chemistry, 
various monomers were developed with pyrazine, phenyl, pyridine and 
difunctionalized cores. Amino acid side chains could be attached to them 
in a mild fashion. The thiazole monomer proved elusive however. 
Chapter 2.3-2.7. 
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Figure 5.2: Monomers.R =amino acid side chain. 
• The monomers could be further functionalized using the versatility of the 
halide moiety. Chapter 3. 
 
Figure 5.3: Some functionalization possibilities of the monomers (X= Br, Cl). 
• A flow protocol with broad scope was developed in collaboration with 
Janssen Pharmaceutica to perform Negishi sp2-sp3 coupling reactions. 
Chapter 3.5. 
 
Scheme 5.1: Negishi coupling in flow. X = Br, I, Cl (activated) 
• Carbonylation was investigated as a coupling method to make amide 
bonds. Safer alternatives were sought and found in the form of stable and 
unstable carbon monoxide precursors. A flow protocol was made in 
collaboration with Janssen Pharamceutica to utilize stable CO precursors 
in continuous synthesis. Chapter 4.2.2 
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• A novel unstable CO precursor (tosyl formate) was also utilized in flow 
and when using a special tube-in-tube reactor design, interesting results 
were obtained that call for further elaboration. None of the flow methods 
could be used for peptidomimetic synthesis for the time being due to 
equipment and time constraints. Chapter 4.2.3. 
 
Scheme 5.2: Carbonylation using CO precursors in flow. 
• The monomers were coupled via amide bonds made with palladium 
catalyzed aminocarbonylation in batch. Several types of α-helix 
minimalist peptidomimetics were made in a modular fashion using this 
strategy, including novel pyrazine oligoaryl amide scaffolds. Chapter 4.3. 
 
 
Scheme 5.3: Modular synthesis of minimalist mimetics.R subscript refers to residue 
position on helix.          Y =  -COOR, -NR2, -Aryl, -Alkyn. Z, Z’, Z”, X, X’, X”: -N, -CH-. 
Ri = AA sidechain, PG = amine protecting group. 
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5.2  Future Outlook 
 
Proof of principle was given for the synthesis of (novel) minimalist 
peptidomimtics in a modular fashion, one which allows extensive freedom in 
molecular architecture and post-modification. The tools developed here could now 
be used in a rational design approach to find modulators of PPI where α-helices 
are a part of the interaction surface. PPI inhibitors are no longer a class were only 
macromolecules (such as peptides) can be a part of. Small molecules, which are 
cheaper and can have better pharmacokinetics, have been shown to be viable 
alternatives (see chapter 1.4). While no minimalist mimetic has made it into 
clinical trials yet, it should be kept in mind that the field is still in a stage of 
relative infancy. Minimalist mimetics do have proven activity in vitro (for 
examples see chapter 1.4.3). In any case, this class of peptidomimetics can be 
excellent molecular probes to investigate PPI.278,279 The scaffolds shown here have 
a well controllable structure, they can be post-modified to attach other molecular 
entities. As such they can be a useful tool in PPI research and this fact should be 
exploited further. 
The modular synthetic strategy and functionalization methods allow for much 
structural diversity and therefore the monomers are ideal building blocks for 
foldameric structures with a wide range of applications.280 The intermolecular 
aromatic interactions of the rigid planar multimers could also be exploited, 
especially in the case of the pyrazine multimers. In essence, the oligoaryl amide 
scaffolds are a conformationally stable backbone on which functionalities can be 
attached for applications were good control of spatial arrangement is needed. 
Examples include gelators,281 liquid crystals282 and a host of macromolecular 
constructs for molecular recognition283 or chromophore separation.284 
The purely synthetic aspects of the work presented here can also be a fertile 
ground from which other research directions may grow. Carbonylation remains a 
very interesting transformation, even aside from its use in the synthesis of 
peptidomimetics. However the safety aspect of carbon monoxide and the 
reluctance to use it at higher pressures or large scale somewhat limit the wide 
spread use of this highly useful C1 building block in the laboratory. While the aryl 
formate precursors described in chapter 4.2.2 can be useful if safety is the main 
concern, their atom economy is rather poor (e.g. per mol of CO from precursor 
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4.16, almost 200 grams of toxic chlorinated phenol waste is generated, an effective 
mass yield of only about 14%). The storage safety of the more active stable 
precursors could also be a concern when large amounts are required (see 
appendix). Using the unstable precursor 4.17 on the other hand has the same atom 
economy concerns, but the waste is at least more benign and the starting products 
are cheaper, more easily available and safer than the stable precursors. Especially 
the combination with the tube-in-tube flow reactor deserves further attention, since 
this also separates the precursor waste stream from the product stream, which can 
make purification easier and avoid side reactions. Flow chemistry could also be 
utilized to prepare CO using much harsher conditions from even simpler, cheaper 
starting reagents (e.g. DMF or methyl formate). Again separation of the CO 
generating line from the product line using membrane techniques will be useful 
here.285 
The lessons learned from the application of flow chemistry to synthetic problems 
have made our research group more proficient in the use of this powerful tool, 
which will continue to prove its use in the future. 
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6.1  Construction of Tube-in-Tube Reactor 
 
The construction of the Tube-in-Tube reactor is relatively facile and requires only 
a few components. The reactor used in this work has an inner tube volume of 704 
µL, an outer tube volume of 2815 µL and thus a reactor volume (actual volume in 
the outer tube where reaction takes place) of 2111 µL. To build this reactor, the 
following items are needed: 
BOM: 
Amount Item 
140 cm PTFE tubing, (for outer tube), OD = 3.20 mm, ID = 1.60 mm 
160 cm AF-2400 semi-permeable tubing (for inner tube), OD = 1 mm, ID = 
0.8 mm, (supplier: Biogeneral Inc.) 
2 SS Swagelok Tube Fitting, Union Tee, 1/8 in. Tube OD, Swagelok 
Part No. SS-200-3 
4 SS Swagelok Tube Fitting, Reducer, 1/16 in. x 1/8 in. Tube OD, 
Swagelok part No. SS-100-R-2 
* PTFE tubing, OD = 1.6 mm, ID = 1 mm 
 
Straps 
*: As long as is needed to connect to other parts of the flow system. 
Obviously if a larger or smaller reactor is desired, one only has to change the 
length of the inner and outer tubing to achieve the desired volume. 
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Figure 6.1: Assembled Tube-in-Tube reactor. a: Union Tee. b:Reducer, c: Straps.
Step 1: push the inner AF
whole length of PTFE outer tubing (ID 1.6 mm). 
Leave about 10 cm of AF
out at each end of the tube.
Step 2: push the ends of AF
the Union Tee’s and connect the outer tube via 
nut/ferrules to the bottom of the union Tees 
(figure 6.1). The inner tubing (AF
now stick out from the top of each Union Tee.
Step 3: attach the top Reducer pieces to the 
Union Tees, push the PTFE tubing (OD =1.6 mm) 
over the AF-2400 inner tubing and connect them 
to the Reducer pieces (see figure 6.2).
Step 4: Attach PTFE tubing (1.6 mm OD) to the 
side of the Union Tees via Reducers. Attach all 
inlets and outlets to other flow system 
components. Tie the Union Tees together with 
the straps. 
Figure 6.2: Step 3. 
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6.2  G6/VWF Modulators synthesis 
 
This section is based on∗ 
Broos, K.; Trekels, M.; Jose, R. A.; Demeulemeester, J.; Vandenbulcke, A.; 
Vandeputte, N.; Venken, T.; Egle, B.; De Borggraeve, W. M.; Deckmyn, H.; De 
Maeyer, M., Identification of a Small Molecule That Modulates Platelet 
Glycoprotein Ib-von Willebrand Factor Interaction. J. Biol. Chem. 2012, 287 (12), 
9461-9472. 
and 
Jose, R. A.; Voet, A.; Broos, K.; Jakobi, A. J.; Bruylants, G.; Egle, B.; Zhang, K. 
Y. J.; De Maeyer, M.; Deckmyn, H.; De Borggraeve, W. M., An integrated 
fragment based screening approach for the discovery of small molecule 
modulators of the VWF-GPIb alpha interaction. Chem. Commun. 2012, 48 (92), 
11349-11351. 
In a multidisciplinary collaboration involving research groups of biochemistry 
(Laboratory for Thrombosis research, H. Deckmyn), computational biochemistry 
(Laboratory for molecular modeling, M. de Maeyer) and synthetic chemistry 
(MolDesignS, W. De Borggraeve) modulators were sought for the GPIbα/VWF 
protein protein interaction. This protein complex is of interest in the therapeutic 
area of anti-thrombotics.286,287 Two approaches were taken, the first by 
computational screening of the interaction surface.35 From this screening, 24 
molecules emerged as potential hits and were tested in vitro. None of these 
showed any activity except one molecule, named G6, which stimulated the 
GPIbα/VWF interaction. The synthesis of this molecule was performed in our lab 
(scheme 6.1). Based on this scaffold, a number of analogues were tested. Several 
of those proved to also be able to stimulate the PPI and based on the them a 
pharmacophore model was developed. To further elaborate the binding mechanism, 
STD NMR studies288 were performed, however initially the poor water solubility 
of G6 presented a roadblock. This could be solved by preparing the methylated 
iodide salt of G6 (scheme 6.1), which was water soluble and showed very similar 
                                                     
∗
  The author of this dissertation contributed to the synthetic part of these publications. 
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biological activity. Based on the STD NMR measurements, the binding epitope 
could be determined (figure 6.3). 
 
Scheme 6.1: Synthesis of G6 and its salt. 
 
Figure 6.3: STD NMR results of G6 salt. Colors indicate the intensity of the STD effect.Reprinted 
with permission from reference 35. 
A second approach used fragment based screening to select low-affinity binders of 
the GPIbα/VWF interaction.29 A small library of 80 fragments were screened for 
activity, using STD-NMR (an example of such a fragment and its synthesis is 
given in scheme 6.2). Several active fragments were found that stimulated the 
binding of VWF to GPIbα. No further optimization of the fragments was 
performed. 
 
G6 
G6 salt 
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Scheme 6.2: Synthesis of a fragment for STD-NMR screening. 
 
6.3  Failed Amide Coupling of Pyrazine 
 
Several methods were attempted to couple aminopyrazine to an aromatic 
carboxylic acid using conventional procedures based on activated ester (table 6.1). 
None of them was successful, underlining the low nucleophilicity of the 
aminopyrazine core. 
 
Entry Activating reagent Result 
a EDC/HOBt - 
b HATU - 
c PyBOP - 
d DCC/pyridine.HF - 
e Ph3PCl2 - 
Table 6.1: Attempts for traditional amide coupling of the aminopyarazine core. 
 
6.4  Chemical Safety  
 
An important skill of the synthetic chemist is to be able to work with hazardous 
chemical reagents in a safe manner. To this end, the safety profile of some high-
risk chemicals or procedures that were used in this work will be discussed. 
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Liquid ammonia (NH3(l)), acolorless liquid with a strong odor (noticeable> 10-50 
ppm). This useful solvent was utilized in the preparation of the phenyl monomer, 
on gram scale. Liquid ammonia has a boiling point of -33°C, with a density of 0.7 
kg/l. The gas is lighter than air (0.597 kg/m³). Fortunately, the liquid has a high 
heat of evaporation, causing it to evaporate rather slowly (even at room 
temperature). 
• It is very irritating to eyes, skin and lungs (irritation at concentration 
higher than 200 ppm, permanent damage possible > 700 ppm) 
• Possibility of frostbite when liquid ammonia comes into contact with skin 
• Flammable gas, UEL-LEL = 16-25%, self ignition temperature =  651°C, 
but high ignition energy required (making it difficult to ignite) 
• LC50 (mouse) = 4200 ppm/hour, acute possible lethal dosis = 5000 ppm 
• Very toxic for aquatic organisms 
• Reacts vigorously (possibly explosive) with halogens (bromine, chlorine, 
Iodine,…) and sulphur 
• Incompatible with: Strong acids and oxidants,sodium/potassium nitrate; 
Chlorites; Chlorates; AgCl; HgCl; AuCl3; aldehydes and epoxides with 
low molecular weight; K3Fe(CN)6;  
• Can form explosive nitrides with (oxides of) silver, gold and mercury 
• Corrodes copper, aluminum, zinc and their alloys 
 
Safety precautions  
 
• Wear gloves, lab coat and safety goggles 
• Work inside the fume hood 
• Used glassware should be left in the fume hood after the experiment and 
cleaned with copious amounts of water. 
• Avoid any kind of pressure build-up in the reaction setup 
• A full-face respirator with a type K filter (green) should be within reach in 
case of emergency 
• Do not pour water directly on puddles of spilled ammonia (splash hazard) 
• If ammonia smell is perceived outside the fume hood, immediately close 
the main gas valve and evacuate  
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Nitration: was used often in the preparations of the Marimganti monomers 
(chapter 2.7), also on larger (multigram) scale. Nitration in general entails some 
common risks, some concerning the inherent reactivity of the reagents used, but 
also some arising due to the combination of specific chemicals: 
• Nitration is often carried out using mixed acid, pure fuming nitric acid or 
nitrate salt/strong sulphuric acid or other combinations of acids. Therefore, 
all the risks associated with the use of corrosive/oxidizing acids apply. 
• When using mixed acids or fuming nitric acid (and some other, more 
uncommon reagents), one should be wary to avoid the so-called ‘runaway’. 
A runaway is a term used to describe (in this case a nitration) reaction 
which has run out of control due to rapid increase of heat and oxidation of 
the organic substrate. This is accompanied by the formation of copious 
amounts of toxic nitric oxides gas and vigorous splashing of the corrosive 
acids. If the pressure is allowed to build up, or if the nitrated product is 
explosive, an explosion could result. In small scale reactions the explosion 
hazard is very small, but on large scale (>300 mL of acids) this is a risk 
which should be taken into account. Telltale signs of an impending 
runaway are the rapid rise of reaction mixture temperature and evolution 
of brown-red nitric oxide gases. In such cases, the reaction mixture must 
be immediately dumped into a large volume (at least 10x that of the acids) 
of ice water. Therefore, when performing a nitration, the ice water must 
be available in close proximity to the reaction. It is also advisable to 
check the internal temperature of the reaction mixture continuously during 
the nitration process, especially on large scale operations. It is also not 
advisable to perform nitration in closed systems. 
• It should also be kept in mind that low molecular weight nitro compounds 
(or with a high oxygen-to-carbon ratio, e.g. polynitro compounds) are 
potential explosives and that their sensitivity is increased when (traces) of 
acid are present. This is especially true for nitrate esters (-ONO2) of 
simple alcohols (e.g. ethanol, methanol, isopropanol), an added danger is 
that nitrates are usually water insoluble. It is therefore advisable to keep 
alcoholic solvents removed from nitration mixtures. 
• Acetic anhydride mixed with fuming nitric acid (used in chapter 2, table 
2.7) will form tetranitromethane if allowed to stand for prolonged periods 
of time (> 1 day). Tetranitromethane is very toxic and forms sensitive and 
very powerful explosive mixtures with organic solvents. It is therefore 
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advisable to not leave such nitration mixtures for prolonged periods of 
time without work-up. 
• Fuming nitric acid can combust or explode when mixed with combustible 
substances (such as acetone, dioxane, amines, etc.), especially if heat can 
build up. Care must be taken to avoid uncontrolled mixing of these 
chemicals. Keep in mind that paper and cotton can also be nitrated, so do 
not clean up spilled nitration mixture with paper tissue or cotton cloth, 
when they dry out they can become extremely flammable (due to 
nitrocellulose formation, this is in fact how it was accidently discovered). 
If paper or cloth does get into contact with the acid, rinse it with copious 
amounts of water. 
• Fuming nitric acid slowly turns yellow (and eventually red-orange) during 
storage; this is due to nitric oxide gas formation. These nitric oxides are 
quite oxidizing and could degrade reaction yields and/or make the reaction 
mixture more prone to a runaway reaction. To remove them it is possible 
to bubble dry air through the acid until it is colorless again, take care as 
the vapors that are released are very corrosive.  
• It is inadvisable to leave a nitration unattended due to the risk of a delayed 
runaway. If the specific reaction conditions require it however, a safety 
screen should be put in place. Large scale nitrations (>200 mL acid) 
should not be left unattended. 
• When performing N-nitrations or nitrations in the presence of free amine 
moieties (esp. aromatics) keep in mind that in all likelihood, N-nitroso 
side products are to be expected. N-nitroso compounds are known 
carcinogens; therefore suitable precautions should be taken (fumehood, 
gloves, proper waste disposal…) to prevent exposure. 
 
LiAlH4: used in the preparation of the AA side chain alcohols. Care should be 
taken as reductions involving LiAlH4can generate hydrogen gas, which is 
extremely flammable. The dry reagent itself also reacts vigorously with water and 
should be kept away from it at all times. Addition of this reagent to a reaction 
should always be done with good cooling and under an inert atmosphere. 
BBr3: was used on multigram scale preparations of the Marimganti monomer 
(chapter 2.7).It is a corrosive and highly toxic liquid that reacts violently with 
water and alcohols. It should be handled with acid resistant gloves and in a fume 
hood at all times. 
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CO-precursors: While working with these compounds (whose safety profile has 
not yet been well investigated) it was noticed that some aryl formates with electron 
withdrawing groups on the aromatic ring can decompose very easily (e.g. 4.14, 
4.16). While this feature may be desirable for carbonylation reactions, care must 
be taken when using and storing them. Vessels containing CO precursors should 
be stored in a well ventilated storage and away from bases and heat (which can 
cause their decomposition to CO). Special care should be given to remove all 
traces of acid/base when preparing these or new aryl formate CO precursors. 
Traces of impurities could cause (slow) decomposition. It is therefore also not 
recommended to store them in tightly closed glass vessels, which could explode in 
case of pressure build-up. Solutions of the precursors should not be stored but used 
immediately. Any reactions with CO precursors (including flow reactions) should 
be performed in a fume hood. On some occasions, we have observed syringe 
rupturing due to CO build-up when using them for flow chemistry reactions if 
DMF was used as a solvent. When using these reagents in batch (especially on 
large scale), care should be taken when adding base to the reaction mixture, as this 
will cause (desired) decomposition, which could rapidly evolve CO gas. Lastly, 
the phenol derivatives also formed after decomposition can be toxic and can cause 
allergic reactions or skin irritation. One can easily calculate how much CO will be 
released when a certain batch of CO precursor would completely decompose: for 
example, 1 g (4.4 mmol) of precursor 4.16 could liberate up to 4.4 mmol (12 mg) 
of CO gas which corresponds to a concentration of approx. 11 ppm (12 mg/m³ = 
12 ×
.
	
 ppm ≈ 11 ppm) in a volume of 1 m³ at 25°C and 1 atm. 
Carbon monoxide gas:Carbon monoxide was used frequently for the amide bond 
formation between the monomers and is the main transformation performed in this 
dissertation. For a gas known as “the silent killer”, it should be no surprise that 
stringent safety precautions are needed for its use and this will be presented in 
more detail here. 
Physical Properties 
Odorless and colorless, about as heavy as air (d = 0.97, air = 1).  
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Flammability 
Highly flammable, with wide explosion limits: LEL-UEL: 12.5 – 74%. Burns with 
a blue flame, auto-ignition temperature = 609°C and has a low minimum ignition 
energy (MIE) < 0.3 mJ. 
Incompatibilities 
As a reducing agent, it can react violently with strong oxidizers. It can also react 
with metals, forming highly toxic and volatile metal carbonyl compounds, 
especially nickel and zinc are sensitive. In fact these metals are purified 
industrially in this way. For this reason alloys containing nickel or zinc should 
never be used for connections with CO gas as they will corrode over time and 
cause leaking.  
Toxicity 
Carbon monoxide is very toxic and this is its main safety concern.289CO can bind 
to haemoglobin with an affinity 200 times that of oxygen, forming 
carboxyhaemoglobin (HbCO). In addition, after binding one molecule of CO the 
HbCO binds oxygen more tightly on its other subunits (it has four) resulting in 
decreased release of oxygen in distant tissues. The result is oxygen deprivation, 
which is particularly damaging for organs that have a high demand for oxygen 
such as the heart and brain. It should come as no surprise then that carbon 
monoxide poisoning can induce permanent damage to these tissues.  
Conc. Sypmtoms 
35 ppm Headache and dizziness within six to eight hours of constant exposure 
100 ppm Slight headache in two to three hours 
200 ppm Slight headache within two to three hours; loss of judgment 
400 ppm Frontal headache within one to two hours 
800 ppm Dizziness, nausea, and convulsions within 45 min; insensible within 2 hours 
1600 ppm Headache, tachycardia, dizziness, and nausea within 20 min, death in less than 2 hours 
3200 ppm Headache, dizziness and nausea in five to ten minutes. Death within 30 minutes. 
6400 ppm Headache and dizziness in one to two minutes. Convulsions, 
respiratory arrest, and death in less than 20 minutes. 
12800 ppm Unconsciousness after 2–3 breaths. Death in less than three minutes. 
Table 6.2: Symptoms of carbon  monoxide poisoning.290,291 
For the small scale batch synthesis used in this dissertation, carbon monoxide was 
introduced by means of balloons (containing approx. 1 L of CO). While this is 
-Chapter 6- Appendix 
 
 
-129- 
 
only a small amount of CO, it should be kept in mind that 1 L of CO in 2 m³ of air 
(approx. the volume of a fume hood) gives rise (assuming perfect mixing) to a 
concentration of about 0.05 % or 500 ppm, already 5 times higher than the 
concentration dangerous to human health (100 ppm).292 It is therefore imperative 
that proper functioning of the fume hood is always checked before an experiment. 
Likewise, a major hazard is the gas cylinder containing CO gas. It should always 
be placed in a fume hood. It is very important that proper regulators are used and 
the cylinder does not leak or is able to fall and damage the regulator. A quick 
calculation, assuming a leakage rate of ±1.4 L/s (the rate if the regulator is opened 
all the way with an outlet pressure of <2 bar), will show that it takes less than 10 
seconds to reach levels above 100 ppm in a room of about 60 m³. Or about 10 min 
to reach concentrations of 12800 ppm. Again this demonstrates the need to 
monitor both CO levels and room ventilation functioning. 
General Precautions 
• Always check the proper functioning of the fume hood before starting the 
experiment. All operations must be conducted in a fume hood. 
• Always properly label balloons used for CO gas.Never reuse them and be 
careful with organic solvents around CO balloons as they can cause the 
plastic to weaken and the balloon to burst. Test them by filling with inert 
gas first. 
• CO reactions should be done in a separate lab, with access control and 
which is equipped with sensors for CO gas and alarms in case of 
ventilation failure. 
• A normal gas mask does not protect against CO, a special filter (specific) 
for CO needs to be used. 
• A second person, trained in the use of CO, gas masks and emergency 
administration of oxygen must be present outside the room to observe. A 
gas mask with CO filter must be present outside the room. 
• When pumping CO from a reaction mixture (e.g. to bubble through a 
solution, be mindful that it will exit at the pump, which therefore must be 
placed inside a fume hood. Venting of CO gas must be done in a 
controlled manner, inside a closed fume hood. 
• When any symptoms of CO intoxication are apparent (table 6.2), 
immediately evacuate and seek medical attention. 
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Emergency Procedures 
If a person is intoxicated with carbon monoxide: 
• Always consider your own safety first, wear a CO gas mask before 
entering. Always call the emergency number and explain the situation, 
alert another person as well. 
• If the victim is conscious, assist him/her in evacuating the lab and move 
victim to fresh air. Administer oxygen and seek medical attention 
immediately.  
• If the victim is unconscious, evacuate the victim from the lab if this can 
be done in a safe way. Administer oxygen and wait for medical assistance 
to arrive.  
In case of a large carbon monoxide leak (i.e. damaged gas cylinder): 
• Wear CO gas mask. 
• Press the evacuation alarm. 
• Immediately call the emergency number and explain the situation. 
• Evacuate. 
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7.1  General Experimental Conditions 
 
NMR spectra were measured on a Bruker Avance 300 (working at 300 MHz for 
1H-NMR spectra, operating at 75MHz for 13C-NMR). 2D NMR experiments were 
recorded on a Bruker Avance 400 instrument. Chemical shifts are reported in parts 
per million (ppm) and are referenced to the internal standard tetramethylsilane. For 
13C spectra, residual solvent signals are used as the internal standard (CDCl3: 
77.16 ppm, DMSO-d6: 39.52 ppm). All the NMR peak assignments are putative, 
based on computational prediction (ACDLabs, HNMR/CNMR-DB, version 
6.0, 2002), unless otherwise noted. 
Mass spectra were obtained using a HP5989A apparatus (CI or EI, 70 eV 
ionization energy) with an Apollo 300 data system. Alternatively, a Thermo 
Finnigan LCQ advantage apparatus was used (ACPI/ESI) with an Agilent 1100 
pump and injection system coupled to an Xcalibur data analyzing software using 
MeOH as eluent. Exact mass measurements were obtained on a Kratos MS50TC 
instrument at 150-200°C in EI mode with a resolution of 10000. 
MPLC flash chromatography was performed using a Büchi SepacoreTM flash 
apparatus, consisting of a C-660 Büchi fraction collector, C-615 Pump manager, 
C-635 UV-Photometer, two C-605 pump modules and a Linseis D120S plotter. 
Cartridges were self packed with 40-63 mesh silica gel (Davisil® type LC60A). 
TLC was performed using Machery-Nagel SIL G-25 UV254 pre-coated glass silica 
plates. 
IR spectra were recorded using a Bruker Alpha-P with universal sampling module 
coupled to Opus software. 
Chemicals were bought from commercial vendors (Sigma-Aldrich, Acros, TCI, 
Strem, Fluka, Iris Biotech) and were used without prior purification unless 
otherwise specified in the specific procedure. Reaction solvents were obtained 
from commercial sources as well. Dried solvents were bought, except Et2O, 
toluene and THF, which were dried using an Mbraun SPS 800 drying setup. 
Melting points were obtained using a Reichert-Jung Thermovar, Electrothermal 
9200 instrument ( the obtained values were not corrected). 
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Flow reactions were performed in a Vapourtec R2+R4 module. Alternatively, 
when home built setups were used, reagents were pumped using a Chemyx Fusion 
200 syringe pump. Reactor chips were obtained from Chemtrix and heated in a 
Chemtrix Start Unit, with temperature control provided by a Laird Technologies 
MTTC1410 unit. 
Palladium leaching was determined by Inductively Coupled Plasma Emission 
Spectroscopy in a multitype ICP emission spectrometer (Shimadzu's ICPE-9000). 
GC-MS was recorded using a Thermoscientific TraceGC oven with manual split 
injection (split flow: 20 ml/min, split ratio: 17, injector temperature: 250°C) and 
He carrier gas (flow: 1.2 ml/min). A Restek Rxi-5ms column (20 m) was used and 
a temperature profile of 40°C (hold for 1 min) to 300°C (rate: 20°C/min, hold 5 
min). Mass spectra were recorded using a Thermoscientific ITQ900 (source 
temperature: 250°C). 
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7.2  Building Block Synthesis 
7.2.1 Synthesis of Amino Acid Side Chains 
 
N-(tert-butyl)-2-hydroxyacetamide (2.10) 
 
 
Ethyl glycolate (2 g, 22.2 mml) and tert-butylamine (5.1 mL, 48.8 mmol) were 
mixed in a dry flask equipped with a stirring bar, reflux condenser and a CaCl2 
drying trap to protect the reaction from moisture. The reaction mixture was heated 
at reflux temperature for 21 hours. The mixture was cooled to RT and evaporated 
under reduced pressure. The residue was dissolved in 50 mL of boiling CHCl3 and 
heptanes (25 mL) was slowly added. The hot mixture was left to cool slowly to RT 
and then left in a fridge to crystallize. After filtration, washing with heptanes and 
drying, the product was obtained as white crystals (310 mg, 11% yield). 
Molecular Formula: C6H13NO2 
MW: 131.17 g/mol 
All analytical data were found to be in accordance with the literature.176 
tert-Butyl hydroxyacetate (2.12) 
 
 
Formic acid (2 mL, 52.4 mmol) was dissolved in 50 mL of EtOAc, NEt3 (7.8 mL, 
55.9 mmol) was added and the mixture was stirred for 5 minutes under an argon 
atmosphere. tert-Butyl-2-chloroacetate (5 mL, 35 mmol) was added and the 
reaction was stirred at RT for 18 hours. The obtained beige suspension was filtered 
and the precipitate was washed with Et2O. The filtrate was washed with water, 
dried over MgSO4, filtered and evaporated in vacuo. The yellow oil that was 
obtained (4.1 g) was suspended in a solution of NaHCO3 in 80 mL of water. The 
suspension was then stirred for 3 days at RT and subsequently extracted three 
times with Et2O. The combined organic phases were dried over MgSO4, filtered 
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and evaporated in vacuo. The product were obtained as a light yellow oil (2.9 g, 
63% yield). 
Molecular Formula: C6H13NO2 
MW: 131.17 g/mol 
All analytical data was found to be in accordance with the literature.177 
di-tert-Butyl ((Z)-[(3-hydroxypropyl)amino]methylylidene)biscarbamate (2.14) 
 
 
 
Methyl carbamimidothioate hemisulfate (1 g, 3.59 mmol) was dissolved in 10 mL 
of dioxane and 10 mL of water. sodium hydroxide (7.18 ml, 7.18 mmol) was then 
added, followed by Boc2O (4.34 ml, 18.68 mmol). The mixture was then stirred at 
RT for 20 hours. Afterwards, the precipitate was filtered of and washed with water. 
The filtrate was then concentrated to about half volume and filtered and washed 
again. The combined precipitates were suspended in water at 50°C, stirred for 10 
min and then filtered. The precipitate was then dried over P2O5 overnight to give 
N,N'-bis(tert-butoxycarbonyl)-S-methylisothiourea as a white solid (2.2 g). 
400 mg of this precursor was added to a solution of 3-aminopropanol (104 µL, 
1.38 mmol) in 1.5 mL of dry DMF under an argon atmosphere. The mixture was 
stirred for 16 hours at RT, subsequently diluted with DCM and washed three times 
with water. The organic phase was dried over Na2SO4, filtered and evaporated in 
vacuo. The product was obtained as a white solid (200 mg, 46% yield). 
 
Molecular Formula: C14H27N3O5 
MW: 317.38 g/mol 
All analytical data was found to be in accordance with the literature.178 
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tert-Butyl 3-(hydroxymethyl)-1H-indole-1-carboxylate (2.16) 
 
 
Indole-3-carboxaldehyde (1 g, 6.89 mmol), Na2CO3 (1.62 g, 15.29 mmol) and 
DMAP (34 mg, 0.276 mmol) was suspended in a mixture of 15 mL ACN with 5 
mL of water. Boc2O (1.8 g, 8.27 mmol) was then added slowly and the reaction 
mixture was stirred at RT for 18 hours. The light yellow suspension was then 
diluted with water and extracted with EtOAc. The combined organic phases were 
dried over MgSO4, filtered  and evaporated in vacuo. N-Boc-indole-3-
carboxaldehyde was obtained as a white solid (1.55 g).  
This N-boc-indole-3-carboxaldehyde was dissolved in 9 mL of dry MeOH under 
an argon atmosphere. NaBH4 (480 mg, 12.65 mmol) was then slowly added over 
20 minutes while keeping the temperature at 0°C. The reaction mixture was then 
left to stir for 18 hours at RT. Afterwards 1M NaOH in water was added to quench 
the reaction. The mixture was then extracted three times with Et2O, the combined 
organic phases were dried over MgSO4, filtered and evaporated in vacuo. A 
yellow oil was obtained that slowly crystallizes on standing. The crude product 
was recrystallized from water:acetone to give the pure product as white needle 
crystals (740  mg, 50% yield). 
Molecular Formula: C14H17NO3 
MW: 247.29 g/mol 
All analytical data were found to be in accordance with the literature.179 
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tert-Butyl 4-(hydroxymethyl)-1H-imidazole-1-carboxylate (2.18) 
 
 
 
4-(hydroxymethyl)-imidazole (500 mg, 5.1 mmol) and NEt3 (1 mL, 7.65 mmol) 
was dissolved in 2 mL of dry DMF under an argon atmosphere. The solution was 
cooled to 0°C and Boc2O (1.11 g, 5.1 mmol) was slowly added, keeping the 
temperature at 0°C. The reaction mixture was then allowed to warm to RT and 
stirred for 17 hours. The solvent was evaporated under reduced pressure and the 
residue was suspended in a mixture of water and EtOAc. The organic phase was 
separated and the aqueous phase was extracted two times with fresh EtOAc. The 
combined organic phases were dried over MgSO4, filtered and evaporated in 
vacuo. The product was obtained as a colorless oil (900  mg, 89% yield). 
Molecular Formula: C9H14N2O3 
MW: 198.22 g/mol 
All analytical data were found to be in accordance with the literature.180 
(1-Trityl-1H-imidazol-4-yl)methanol (2.20) 
 
 
 
4-(hydroxymethyl)-imidazole (2 g, 20.4 mmol) and NEt3 (5.68 mL, 40.8 mmol) 
was dissolved in 20 mL of dry DMF under an argon atmosphere. The solution was 
cooled to 0°C and trityl chloride (6.26 g, 22.4 mmol) was slowly added, keeping 
the temperature at 0°C. The reaction mixture was then allowed to warm to RT and 
stirred for 22 hours. The reaction mixture was then poured into 240 mL of ice 
water. Copious amounts of a white precipitate were formed, this was filtered of 
and washed with water and dioxane. The precipitate was dried in an dessicator 
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over P2O5 for 4 days.  The product was thus obtained as a white solid (6.2 g, 89% 
yield). 
Molecular Formula: C23H20N2O 
MW: 340.42 g/mol 
1H-NMR (300MHz, d6-DMSO, ppm):δ 4.33 (d, J = 5.58 Hz, 2H, H6), 4.88 (t, J = 
5.57 Hz, 1H, -OH), 6.72 (s, 1H, H2), 7.08-7.10 (bm, 6H, H12,14,17,19,22,24), 7.29 (s, 
1H, H4), 7.37-7.45 (bm, 9H, H11,13,15,15,13,25,16,18,20). 
 
4-(Tritylamino)butan-1-ol (2.22) 
 
 
 
4-aminobutanol (1.03 mL, 11.24 mmol) was dissolved in 7 mL of dry THF under 
an argon atmosphere. The solution was cooled to 0°C and trityl chloride (1.31 g, 
4.68 mmol), dissolved in 7 mL dry THF, was slowly added at 0°C. The reaction 
mixture was then allowed to warm to RT and stirred for 20 hours. The solvent was 
evaporated and the residue was redissolved in DCM (50 mL). The organic phase 
was washed three times with water, dried over MgSO4, filtered and evaporated in 
vacuo. The product was obtained as colorless, very viscous oil (1.52 g, 98% yield). 
Molecular Formula: C23H25NO 
MW: 331.45 g/mol 
All analytical data were found to be in accordance with the literature.181 
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Ethyl (1-trityl-1H-tetrazol-5-yl)acetate (2.24) 
 
 
Ethyl-1H-tetrazole-5-acetate (1 g, 6.4 mmol) en NEt3 (1.15 mL, 8.3 mmol) was 
dissolved in 5 mL of dry DCM. The solution was cooled to 0°C and trityl chloride 
(1.9 g, 6.7 mmol) was slowly added, keeping the temperature at 0°C. The reaction 
mixture was then allowed to warm to RT and stirred for 20 hours. The white 
suspension was subsequently filtered and the filtrate was evaporated under 
reduced pressure. The crude product was redissolved in EtOAc and the organic 
phase was washed with water, brine, dried over MgSO4, filtered and evaporated in 
vacuo. The product was obtained as a white solid (2.4 g, quantitative yield) 
Molecular Formula: C24H22N4O2 
MW: 398.46 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ1.23 (t, J = 7.2 Hz, 3H, H4), 4.00 (s, 2H, H2), 
4.17 (q, J = 7.19 Hz, 2H, H5), 7.08-7.13 (bm, 6H, H11,13,16,18,21,23), 7.31-7.37 (bm, 
9H, H10,12,14,15,17,19,20,22,24). 
13C-NMR (75MHz, CDCl3, ppm): δ14.09 (C4), 32.12 (C2), 61.50 (C5), 83.12 (C6), 
127.82 (C11,13,13,18,21,23), 128.38 (C12,17,22), 141.23 (C10,14,15,19,20,24), 159.27 (C1), 
168.30 (C3). 
HR-MS: Calculated mass: 398.1743,  Found mass: 398.1773 
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5-Methyl-1-trityl-1H-tetrazole (2.26) 
 
 
5-Methyltetrazole (3 g, 36 mmol), TBAB (116 mg, 0.36 mmol) and trityl chloride 
(10 g, 36 mmol) were suspended in 50 mL DCM and 37.5 mL of an aqueous1M 
NaOH solution. The biphasic mixture was vigorously stirred for 18 hours at RT. 
Afterwards, 50 mL of water was added and the organic layer was separated. The 
water layer was extracted twice with fresh DCM. The combined organic layers 
were washed with water, 5% NaHCO3 in water and brine. Then it was dried over 
MgSO4, filtered and evaporated in vacuo. The crude product was recrystallized 
from EtOAc to give the product as a white solid (10.8 g, 92% yield). 
Molecular Formula: C21H18N4 
MW: 326.39 g/mol 
All analytical data were found to be in accordance with the literature.183 
2-(1-Trityl-1H-tetrazol-5-yl)ethanol (2.27) 
 
 
 
Ethyl (1-trityl-1H-tetrazol-5-yl)acetate (2.24) (1 g, 2.81 mmol) was dissolved in 10 
mL of dry THF under an argon atmosphere. The solution was cooled to 0°C and 
LiAlH4 (2.11 mL of a 2 M solution in THF, 4.22 mmol) was slowly added while 
keeping the temperature at 0°C. The reaction mixture was then allowed to warm to 
RT and stirred for 24 hours. The suspension was cooled to 0°C again and 0.2 mL 
of water, 0.2 mL of 15% NaOH in water and 0.8 mL of water was added in this 
order. The suspension was again stirred for 30 min while allowing it to warm to 
RT. The mixture was then diluted with EtOAc, filtered over Celite and washed 
with EtOAc. The filtrate was dried over MgSO4, filtered and evaporated in vacuo. 
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The crude product (a light yellow oil) was purified using MPLC (1/1 
EtOAc/heptanes) to give the pure product as a colorless oil (600 mg, 60% yield). 
Molecular Formula: C22H20N4O 
MW: 356.42 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 3.17 (t, J = 5.87, 2H, H2), 4.03 (t, J = 5.87 Hz, 
2H, H3), 7.07-7.12 (bm, 6H, H9,11,14,16,19,21), 7.28-7.38 (bm, 9H, H8,10,12,13,15,17,18,20,22).  
Tm: oil 
 
7.2.2 Synthesis of Pyrazine Monomers 
 
3,5-Dibromo-2-aminopyrazine (2.29) 
 
Pyrazin-2-amine (5 g, 52.6 mmol) was dissolved in a mixture of DMSO (Ratio: 10, 
Volume: 100 ml) and water (Ratio: 0.25, Volume: 2.500 ml). The solution was 
subsequently cooled to  < 15°C. NBS (20.00 g, 112 mmol) was added slowly over 
a period of approx. 50 min. Afterwards the reaction was stirred at R.T. for 6 hours. 
The reaction mixture was then poured into 300 ml of icewater. The aqueous phase 
was extracted with EtOAc. The organic fraction was washed with sat. NaHCO3 
solution, water and afterwards dried over MgSO4. The solvent was evaporated in 
vacuo to obtain a brown coloured solid. The crude product was purified by 
sublimation to give 3,5-dibromopyrazin-2-amine (11.5 g, 45.5 mmol, 72 % yield) 
as white-yellow crystals. 
Molecular Formula: C4H3Br2N3 
MW: 252.89 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 5.12 (bs, 2H, -NH2), 8.04 (s, 1H, H6). 
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13C-NMR (75MHz, CDCl3, ppm): δ 123.64(C5), 123.95(C3),143.11(C6), 
151.88(C2). 
FT-IR (cm-1): 3338, 2953 cm-1 
Tm: 87°C 
General Procedures for SNAr with alcohols on 3,5-dibromo-2-aminopyrazine: 
Procedure A: with NaH: The alcohol (1.5 eq) was dissolved in dry THF (0.25 M) 
under an argon atmosphere. This solution was then cooled to 0°C and NaH (1.5 eq) 
was slowly added (Caution: evolution of hydrogen gas!), keeping the temperature 
at 0°C. The suspension was then allowed to stir at 0°C for 30 min. 3,5-dibromo-2-
aminopyrazine (2.29) (1 eq.), dissolved in dry THF (0.4 M),  was then slowly 
added while keeping the temperature at 0°C. After addition, the reaction mixture is 
allowed to heat to RT and then heated at 50°C for 18 hours. The reaction mixture 
was subsequently cooled to RT and diluted with EtOAc. The organic phase was 
then washed with water and brine before being dried over MgSO4 and evaporated 
in vacuo. The crude product was then purified using MPLC.  
Procedure B: with NaHMDS: The alcohol (1.5 eq) was dissolved in dry THF 
(0.15 M) under an argon atmosphere. This solution was then cooled to 0°C and 
NaHMDS (1.5 eq, 1 M solution in THF) was slowly added, keeping the 
temperature at 0°C. The suspension was then allowed to stir at RT for 30 min. 3,5-
Dibromo-2-aminopyrazine (2.29) (1 eq.), dissolved in dry THF (0.4 M),  was then 
slowly added while keeping the temperature at 0°C. After addition, the reaction 
mixture is allowed to heat to RT and then heated at 50°C for 18 hours. The 
reaction mixture was subsequently cooled to RT and diluted with EtOAc. The 
organic phase was then washed with water and brine before being dried over 
MgSO4 and evaporated in vacuo. The crude product was then purified using 
MPLC. 
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5-Bromo-3-methoxypyrazin-2-amine (2.30a) 
 
 
 
A solution of 3,5-dibromopyrazin-2-amine (2.29) (1 g, 3.95 mmol) in 3 mL of dry 
methanol was prepared and cooled to 0°C. NaOMe (1 mL of a 25% solution in 
MeOH) was then added drop wise while vigorous stirring the mixture. After 
addition, the reaction mixture was refluxed for 16 hours. Afterwards the solution 
was allowed to cool to room temperature and left standing overnight. The resulting 
precipitate was filtered, washed with ice-cold methanol and air-dried to give 5-
bromo-3-methoxypyrazin-2-amine (670 mg, 83 % yield) as a white solid. 
Molecular Formula: C5H6BrN3O 
MW: 204.02 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 4.01 (s, 3H, H7), 4.78 (s, 2H, -NH2),7.64 (s, 
1H, H6). 
13C-NMR (75MHz, CDCl3, ppm): δ 54.4 (C7), 121.0 (C5), 134.4 (C6), 144.2 (C2), 
147.7 (C3). 
FT-IR (cm-1): 3484 (s, -NH2) 
Tm: 137.2-139.0°C 
3-(Benzyloxy)-5-bromopyrazin-2-amine (2.30b) 
 
 
 
Using general procedure A, purified using MPLC (7/3 heptanes/EtOAc), obtained 
as yellow crystals in 81% yield. 
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Molecular Formula: C11H10BrN3O 
MW: 280.12 g/mol 
All analytical data were found to be in accordance with the literature.293 
5-Bromo-3-[(4-fluorobenzyl)oxy]pyrazin-2-amine (2.30c) 
 
 
 
Using procedure B, purified using MPLC (70/30 heptanes/EtOAc), obtained as a 
yellow solid in 64% yield. 
 
Molecular Formula: C11H9BrFN3O 
MW: 298.11 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 4.79 (bs, 2H, -NH2), 5.37 (s, 2H, H7), 7.10 (t, J 
= 8.8 Hz, 2H, H9,13), 7.45 (dd, J = 8.8 Hz, 11 Hz , 2H, H10,12), 7.69 (s, 1H, H6). 
13C-NMR (75MHz, CDCl3, ppm): δ 68.33 (C7), 115.6 (d, J = 21.4 Hz, C9,13), 
120.82 (C5), 127.84 (C8), 130.70 (d, J = 7 Hz, C10,12), 134.70 (C6), 144.07 (C2), 
146.86 (C3), 147.71 (d, J = 548.5, C11). 
HR-MS: Calculated mass: 296.9913,  Found mass: 296.9918 
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5-Bromo-3-[(1-trityl-1H-imidazol-4-yl)methoxy]pyrazin-2-amine (2.30d) 
 
 
 
Using procedure A, purified using MPLC (6/4 EtOAc/heptanes), obtained as a 
white solid in 35% yield. 
 
Molecular Formula: C27H22BrN5O 
MW: 512.40 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 4.88 (bs, 2H, -NH2), 5.32 (s, 2H, H7), 7.00 (s, 
1H, H9), 7.10-7.14 (bm, 6H, H14,16,20,22,26,28), 7.32-7.36 (bm, 9H, 
H13,15,17,19,21,23,25,27,29), 7.48 (s, 1H, H10), 7.61 (s, 1H, H6).  
13C-NMR (75MHz, CDCl3, ppm): δ 62.85 (C7), 75.59 (C11), 122.55 (C9), 128.15 
(C13,17,19,23,25,29), 128.18 (C15,21,27), 129.73 (C14,16,20,22,26,28), 134.34 (C6), 135.37, 
139.18 (C10), 142.18 (C12,18,24), 143.49 (C5), 144.37 (C2), 146.86 (C3). 
HR-MS: Calculated mass: 165.0651,  Found mass: 165.0646 (M – C21H15Br) 
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5-Bromo-3-[2-(1-trityl-1H-tetrazol-5-yl)ethoxy]pyrazin-2-amine (2.30e) 
 
 
 
Using procedure B, purified using MPLC (1/1 heptanes/EtOAc), obtained as a 
yellow solid in 54% yield. 
 
Molecular Formula: C26H22BrN7O 
MW: 528.40 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 3.43 (t, J = 6.19 Hz, 2H, H8), 4.56 (bs, 2H, -
NH2), 4.72 (t, J = 6.19 Hz), 2H, H7), 7.06-7.09 (bm, 6H, H13,15,19,21,25,27), 7.28-7.36 
(bm, 9H, H12,14,18,20,22,24,26,28), 7.62 (s, 1H, H6). 
HR-MS: Calculated mass: 286.1416,  Found mass: 286.1442 (M – Trt) 
5-bromo-3-[4-(tritylamino)butoxy]pyrazin-2-amine (2.30f) 
 
 
Using procedure B,purified using MPLC (1/9 EtOH/heptanes), obtained as a light 
yellow solid in 10% yield. 
 
Molecular Formula: C27H27BrN4O 
MW: 503.43g/mol 
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1H-NMR (300MHz, CDCl3, ppm):δ 1.62 (m, 2H, H9), 1.84 (m, 2H, H8), 2.20 (t, J 
= 7.4 Hz, 2H, H10), 4.33 (t, J = 6.80 Hz, 2H, H7), 4.73 (bs, 2H, -NH2), 7.18 (m, 3H, 
H15,21,27), 7.27 (m, 6H, H13,17,19,23,25,29), 7.47 (m, 6H, H14,16,20,22,26,28), 7.61 (s, 1H, H6). 
13C-NMR (75MHz, CDCl3, ppm): δ 26.59 (C8), 27.42 (C9), 43.31 (C10), 67.40 (C7), 
70.91 (C11), 121.12 (C5), 126.26 (C15,21,27), 127.82 (C14,16,26,28), 128.61 
(C13,17,19,23,25,29), 134.22 (C6), 144.09 (C2), 146.16 (C12,18,24), 147.32 (C3). 
HR-MS: Calculated mass: 260.1201,  Found mass: 260.1222 
5-Bromo-3-isobutoxypyrazin-2-amine (2.30g) 
 
 
 
Using procedure B, purified by filtering over silica and eluting with 9/1 
heptanes/EtOAc, obtained as a red oil in 88% yield. 
 
Molecular Formula:C8H12BrN3O 
MW: 246.10 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.03 (d, J = 6.8 Hz, 6H, H9,10),  2.12 (m, 1H, 
H8), 4.14 (d, J = 6.8 Hz, 2H, H7), 4.81 (bs, 2H, -NH2), 7.62 (s, 1H, H6) 
13C-NMR (75MHz, CDCl3, ppm): δ 19.52 (C9,10), 24.32 (C8), 70.84 (C7), 120.94. 
(C5), 134.49 (C6), 144.27 (C2),147.56 (C3). 
Procedure C: For diBoc protection of pyrazine building blocks (2.31): 
The amine 2.30 (1 eq.) and DMAP (0.1 eq.) were dissolved in dry DCM (0.2 M) 
under an argon atmosphere. Boc2O (2.5 eq.) was then slowly added at RT, while 
stirring vigorously. Afterwards the reaction was heated to reflux for 16 hours. The 
mixture was then cooled to RT and the solvent was evaporated in vacuo. The 
residue was suspended in EtOAc and washed with water brine. The organic phase 
was then dried over MgSO4, filtered and evaporated in vacuo. 
-Chapter 7- Experimental 
 
-149- 
 
di-tert-Butyl (5-bromo-3-methoxypyrazin-2-yl)imidodicarbonate (2.31a) 
 
 
5-Bromo-3-methoxypyrazin-2-amine (1 g, 4.90 mmol) was dissolved in THF 
(Volume: 20 ml) and cooled to < 5°C in an icebath. Boc2O (2.84 ml, 12.25 mmol) 
was slowly added and the mixture was stirred for 1 hour in the icebath. afterwards 
the soltion was allowed to warm to R.T. and left stirring overnight. Water was 
added (20 ml) and the aqueous phase was extracted with EtOAc. The combined 
EtOAc fractions were washed with sat. NaHCO3 , water and subsequently dried 
over MgSO4. The solvent was evaporated in vacuo to give the crude product. 
Purification was carried out by MPLC (9/1 heptanes/EtOAc) to give the product as 
white crystals (1.8 g, 91 % yield). 
Molecular Formula:  C15H22BrN3O5 
MW: 404 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.42 (s, 18H, H11,12,13,15,16,17), 4.02 (s, 3H, H7), 
8.12 (s, 1H, H6). 
13C-NMR (75MHz, CDCl3, ppm): δ 27.8 (C11,12,13), 30.99 (C15,16,17), 54.9 (C7), 77.2 
(C10), 83.6 (C14), 132.3 (C2), 145.0 (C6), 148.7 (C8), 149.9 (C9), 159.2 (C5), 163.7 
(C3). 
HR-MS:Calculated mass: 403.0768, Found mass: 403.0743 
FT-IR (cm-1): 1797 (s, carbamate) 
Tm: 73.5-76.0°C 
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di-tert-Butyl (5-bromo-3-[2-(1-trityl-1H-tetrazol-5-yl)ethoxy]pyrazin-2-
yl)imidodicarbonate (2.31e) 
 
 
Prepared using the general procedure C, purified using MPLC (7/3 
heptanes/EtOAc), the product was obtained as a colorless oil in 25% yield. 
Molecular Formula: C36H38BrN7O5 
MW: 728.63g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.38 (s, 18H, H9,10,11,33,34,35), 3.42 (t, J = 7.40 
Hz, 2H, H6), 4.81 (t, J = 7.71, 2H, H5), 7.06-7.11 (bm, 6H, H18,20,28,30,23,25), 7.31-
7.37 (bm, 9H, H17,19,21,22,24,26,27,29,31), 8.13 (s, 1H, H1). 
13C-NMR (75MHz, CDCl3, ppm): δ 27.86 (C9,10,11,33,34,35), 25.60 (C6), 65.21 (C5), 
83.10 (C13), 83.67 (C8,32), 127.27 (C4), 127. 83 (C18,20,23,25,28,30), 127.93(C1), 128.38 
(C19,24,29), 130.23 (C17,21,22,26,27,31), 136.72 (C3), 141.25 (C14,15,16), 149.83 (C12,36), 
154.57 (C2), 161.63 (C7). 
Tm: oil 
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di-tert-Butyl (5-bromo-3-isobutoxypyrazin-2-yl)imidodicarbonate (2.31g) 
 
 
 
Prepared using the general procedure C, purified using MPLC (8/2 
heptanes/EtOAc), the product was obtained as a yellow oil in 79% yield. 
Molecular Formula: C18H28BrN3O5 
MW: 446.34 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.00 (d, J = 6.5 Hz, 6H, H7,8), 1.41 (s, 9H, 
H9,10,11,15,16,17), 2.08 (m, 1H, H6), 4.16 (d, J = 6.5Hz, 2H, H5), 8.09 (s, 1H, H1) 
13C-NMR (75MHz, CDCl3, ppm): δ 19.06 (C8,7), 27.42 (C6), 27.88 (C9,10,11,15,16,17), 
74.03 (C5), 83.55 (C12,14), 135.05 (C3), 136.00 (C1), 136.81 (C4), 149.91 (C12,13), 
155.37 (C2) 
HR-MS: Calculated mass: 445.1212, Found mass: 445.1246 
Tm: oil 
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7.2.3 Synthesis of Phenyl Monomers 
 
5-Bromo-2-nitrophenol (2.33) 
 
KOtBu (5.54g, 49.4 mmol) was added to 20 mL of NH3(l) under an argon 
atmosphere while stirring. A solution of cumene hydroperoxide (1.56 mL, 
10.86mmol) and 1-bromo-4-nitrobenzene (2g, 9.90 mmol)  in 7 mL of dry THF 
wasthen added dropwise. The reaction mixture was refluxed at -33°C for 30 
minutes, after which the reaction was quenched by first slowly adding solid NH4Cl, 
followed by sat. aqueous NH4Cl. Aqueous HCl (1M) was then added until an acid 
pH was observed on a pH indicator strip. The mixture was subsequently extracted 
with EtOAc (3x50 mL), dried and evaporated in vacuo. Purification was 
performed using MPLC (9/1 heptanes/EtOAc) to give  the product as bright 
yellow crystals (1.23 g, 57% yield). 
Molecular Formula: C6H4BrNO3 
MW: 218 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 7.14 (dd, J = 2.9Hz, 1H, H4), 7.38 (d, J = 2Hz, 
1H, H6), 7.98 (d, J = 9Hz, 1H, H3),10.63 (s, 1H, H1). 
13C-NMR (75MHz, CDCl3, ppm): δ 123.0 (C6), 123.9 (C4), 126.1 (C3), 132.3 (C5), 
132.7 (C2), 155.3 (C1). 
FT-IR (cm-1): 1521, 1310 (s, -NO2). 
Tm: 27.9-29.1°C 
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2-(5-Bromo-2-nitrophenoxy)-N-(tert-butyl)acetamide (2.34a) 
 
 
 
5-Bromo-2-nitrophenol (2.33) (358 mg, 1.64 mmol), N-(tert-butyl)-2-
hydroxyacetamide (2.10) (236 mg, 1.80 mmol) and PPh3 (644 mg, 2.46 mmol) 
were dissolved in 4 mL of dry THF under an argon atmosphere. The solution was 
then cooled to 0°C and DIAD (497 mg, 2.46 mmol) was slowly added while 
keeping the temperature at 0°C. Afterwards the reaction mixture was allowed to 
warm to RT and stirred for an additional 18 hours. Then the solvent was 
evaporated and the residue redissolved in EtOAc and filtered over Silica gel. The 
filtrate was once again evaporated in vacuo to deliver the crude product. 
Purification was performed using MPLC (8/2 heptanes/EtOAc) to give the product 
as a yellow solid (440 mg, 85%). 
Molecular Formula: C12H15BrN2O4 
MW: 331.16 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.45 (s, 9H, H10,11,12), 4.49 (s, 2H, H7), 7.09 
(bs, 1H, -NH), 7.22 (d, J = 1.94 Hz, 1H, H6), 7.28 (dd, J = 8.9 Hz, 1.9 Hz, 1H, H4), 
7.95 (d, J = 8.7 Hz, 1H, H3). 
13C-NMR (75MHz, CDCl3, ppm): δ 28.67 (C10,11,12), 51.55 (C9), 68.11 (C7), 118.22 
(C6), 124.95 (C4), 127.80 (C3), 129.90 (C2), 151.46 (C1), 164.97 (C5). 
HR-MS: Calculated mass: 284.0286,  Found mass: 284.0277 (M – NO2) 
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7.2.4 Synthesis of Thiazole Monomers 
 
5-Nitro-1,3-thiazol-2-amine (2.38) 
 
 
 
2-Amino-thiazole (2.37)  (200 mg, 2 mmol) was dissolved in  0.62 mL of pre-
chilled (0°C) 98% H2SO4, making sure that the temperature during dissolution 
never rose above 10°C. The mixture was cooled in an ice bath and 95% HNO3 
(126 mg, 2 mmol) was slowly added while keeping the temperature below 12°C at 
all times. The reaction mixture was then stirred for 3 hours at 0°C, allowed to 
warm to RT and stirred for an additional 16 hours at RT. Afterwards, the mixture 
was poured over 30 mL of ice water, resulting in a green suspension. The 
suspension was then extracted using EtOAc (3 x 30 mL). The brown organic phase 
was washed with water and brine, dried over MgSO4 and filtered. Active charcoal 
was then added and the mixture was stirred at boiling temperature for 5 min before 
filtering of the charcoal. The obtained yellow filtrate was evaporated in vacuo to 
give the product as a yellow-brown solid (70 mg, 24% yield). 
Molecular Formula: C3H3N3O2S 
MW: 145.14 g/mol 
All analytical data were found to be in accordance with the literature. 
2-Bromo-5-nitro-1,3-thiazole (2.39) 
 
 
 
CuBr2 (455 mg, 2.04 mmol) was dissolved in 2 mL of dry ACN under an 
atmosphere of argon in the dark. tBuONO (120 µL, 0.9 mmol) was then slowly 
added over 20 min to this suspension. Subsequently it was stirred at 60°C for 30 
min. 5-Nitro-1,3-thiazol-2-amine (2.38) (100 mg, 0.68 mmol), suspended in 1 mL 
of dry ACN, was then added slowly at 60°C and the reaction mixture was stirred at 
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this temperature for an additional 22 hours. The brown-red suspension was then 
poured into sat. aqueous NaHCO3 and the water phase was extracted three times 
with EtOAc. The combined organic phases were dried over MgSO4, filtered and 
evaporated in vacuo. The product was obtained as a brown-red solid (120 mg, 72% 
yield). 
Molecular Formula: C3HBrN3O2S 
MW: 207.89 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 8.34 (s, 1H, H4). 
HR-MS: Calculated mass: 207.8942,  Found mass: 207.8928 
2,4-Dichloro-5-nitro-1,3-thiazole (2.44) 
 
 
 
3 mL of 95% HNO3 , made free of dissolved NOX by bubbling dry air through it 
for 30 min, was cooled to 0°C using an ice bath. 2,4-dichloro-thiazole (500 mg, 
3.27 mmol) was then added slowly over 10 min, making sure the reaction 
temperature stayed  between 15 and 20°C. The mixture was then stirred for 5 min 
at 0°C and subsequently 35 min at RT. Afterwards the reaction mixture was 
poured over 100 mL of ice water, forming a white precipitate. The water phase 
was extracted three times using EtOAc and the organic layers were washed with 
water, sat. aq. NaHCO3, water, brine and then dried over MgSO4. After filtration 
and evaporation of the filtrate, the product was obtained as yellow crystals (505 
mg, 78% yield). The product was found to be sensitive to moisture and should be 
stored in a dessicator. 
Molecular Formula: C3Cl2N2O2S 
MW: 199.02 g/mol 
All analytical data were found to be in accordance with the literature.199 
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7.2.5 Synthesis of Pyridine Monomers 
 
2,6-Dibromopyridin-3-amine (2.47) 
 
 
3-Aminopyridine (2 g, 21.25 mmol) was dissolved in a mixture of 40 mL DMSO 
and 1 mL Water and cooled to 0°C. To this solution, NBS (7.56 g, 42.5 mmol) 
was added slowly over a period of 30 minutes. The deep red mixture was then 
stirred at RT for 1 hour and subsequently poured into 400 ml of icewater. The 
water was extracted with EtOAc and the organic phase was washed with sat. 
NaHCO3, water and brine. After drying the organic phase over MgSO4 and 
evaporating in vacuo, the crude product was obtained as brown-red crystals. It was 
purified by crystallization from heptanes to give the pure product as orange 
crystals (4.87 g , 91% yield). 
Molecular Formula: C5H4Br2N2 
MW: 251.91 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 4.15 (s, H7), 6.90 (d, J = 8Hz, H4), 7.21 (d, J = 
8Hz, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 124.8 (C4), 126.4 (C2), 127.3 (C6), 127.6 (C5), 
141.0 (C3). 
HR-MS:Calculated mass: 249.8733, Found mass: 249.8741 
FT-IR (cm-1): 3441, 3331 (s, -NH2) 
Tm: 144.3-145.8°C 
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6-Bromo-2-methoxypyridin-3-amine (2.48) 
 
 
 
2,6-Dibromopyridin-3-amine (2.47) (1 g, 3.97 mmol) was dissolved in 10 mL 
dioxane, under an argon atmosphere. To this solution was added NaOMe (1.287 g, 
23.82 mmol) and the mixture was refluxed for 24 hours. The mixture was then 
cooled to RT, diluted with sat. NH4Cl solution and extracted with Et2O. The 
organic phase was then washed with water and brine, dried over MgSO4 and 
evaporated in vacuo to give 6-bromo-2-methoxypyridin-3-amine (700 mg, 87 % 
yield) as a red oil which crystallizes over time. 
Molecular Formula: C6H7BrN2O 
MW: 203.04 g/mol 
All analytical data were found to be in accordance with the literature.294 
tert-Butyl (6-bromo-2-methoxypyridin-3-yl)carbamate (2.49) 
 
 
6-Bromo-2-methoxypyridin-3-amine (100 mg, 0.493 mmol) was dissolved in 4 
mL of dry THF, under an argon atmosphere and cooled in an ice bath. NaHMDS 
(0.985 mL of 1M solution in THF, 0.985 mmol) was then added slowly via a 
septum. Immediate discoloration to deep red was observed. The reaction mixture 
was stirred at RT for 4 hours. The solvent was subsequently evaporated and the 
residue suspended in EtOAc. The organic phase was washed with water and brine, 
dried over MgSO4 and evaporated. The crude product was then purified using 
MPLC (80/20 heptanes/EtOAc) to give the product as a light yellow oil (100 mg, 
67% yield). 
Experimental -Chapter 7- 
  
-158- 
 
Molecular Formula: C11H15BrN2O3 
MW: 303.15 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.52 (s, 9H, H10,11,12), 4.00 (s, 3H, H7), 7.03 (d, 
J = 8 Hz, 1H, H5), 8.18 (d, J = 8 Hz, 1H, H4). 
13C-NMR (75MHz, CDCl3, ppm): δ 28.2 (C10,11,12), 54.4 (C7), 81.2 (C9), 120.5 (C5), 
122.5 (C3), 126.8 (C4), 128.8 (C2), 152.1 (C6), 152.4 (C8). 
HR-MS: Calculated mass: 302.0251, Found mass: 302.0266 
FT-IR (cm-1): 1727 (s, carbamate) 
Tm: oil 
Procedure D: For SNAr reactions with alcohols on 2,6-dichloro-5-nitropyridine:  
2,6-dichloro-3-nitropyridine (2.50) and the alcohol(1.2 eq.) were dissolved in dry 
toluene (0.86 M) under an argon atmosphere. The solution was cooled to 0°C and 
NaH (1.4 eq.) was then added slowly. Stirring at 0°C was continued for another 15 
min after addition. The mixture was stirred at RT for 24 hours and then quenched 
by adding water. The mixture was then extracted with Et2O, dried over MgSO4, 
filtered and evaporated in vacuo. In most cases, the product did not require further 
purification. 
 
6-Chloro-2-methoxy-3-nitropyridine (2.51a) 
 
 
Using the general procedure D, the product was obtained as white crystals in 72% 
yield. 
 
Molecular Formula: C6H5ClN2O3 
MW: 188.57 g/mol 
All analytical data were found to be in accordance with the literature.201 
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6-Chloro-2-[(4-fluorobenzyl)oxy]-3-nitropyridine (2.51c) 
 
 
Using the general procedure D, the product was obtained as yellow crystals in 
95% purity (710 mg, 97 % yield). 
Molecular Formula: C12H8ClFN2O3 
MW: 282.65 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 5.54 (s, 2H, H7), 7.03-7.11 (bm, 3H, H5,10,12), 
7.47-7.53 (bm, 2H, H9,13), 8.29 (d, J = 8.3 Hz, 1H). 
tert-Butyl 3-[(6-chloro-3-nitropyridin-2-yl)oxy]propanoate (2.51d) 
 
 
 
Using the general procedure D, the product was obtained as light yellow crystals 
(94 % yield). 
Molecular Formula: C12H15ClN2O5 
MW: 302.71 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.47 (s, 9H, H11,12,13), 2.77 (t, J = 6.16 Hz, 2H, 
H8), 4.74 (t, J = 6.35 Hz, 2H, H7), 7.04 (d, J = 8.3 Hz, 1H, H5), 8.26 (d, J = 8.3 Hz, 
1H, H4). 
13C-NMR (75MHz, CDCl3, ppm): δ28.04 (C11,12,13), 34.95 (C8), 64.43 (C7), 81.38 
(C10), 116.80 (C5), 137.52 (C4), 152.94 (C3), 155.73 (C6), 169.75 (C2). 
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6-Chloro-2-isopropoxy-3-nitropyridine (2.51e) 
 
 
Using the general procedure D, the product was obtained as yellow crystals in 
95% purity (97 % yield). 
Molecular Formula: C8H9ClN2O3 
MW: 216.62 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.44 (m, 6H, H8,9), 5.50 (m, 1H, H7), 6.98 (d, J 
= 8Hz, 1H, H5), 8.22 (d, J = 8Hz, 1H, H4). 
13C-NMR (75MHz, CDCl3, ppm): δ 21.7 (C8,9), 72,5 (C7), 115.9 (C5), 132.7 (C3), 
137.3 (C4), 152.7 (C6), 155.7 (C2). 
HR-MS: Calculated mass: 216.0339, Found mass: 216.0302 
FT-IR (cm-1):1516,1338 (s, -NO2) 
Tm: 62.3-63.9°C 
2-(Benzyloxy)-6-chloro-3-nitropyridine (2.51f) 
 
Using the general procedure D, the product was obtained as yellow crystals in 
95% purity (quantitative yield). 
Molecular Formula:C12H9ClN2O3 
MW: 264.66 g/mol 
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1H-NMR (300MHz, CDCl3, ppm):δ 5.58 (s, 2H, H7), 7.04 (d, J = 8.8 Hz, 1H, H5), 
7.35-7.42 (bm, 3H, H9,11,13), 7.52 (dd, J = 7.86 Hz, 1.7 Hz, 2H, H10,12), 8.28 (d, J = 
8 Hz, 1H, H4). 
13C-NMR (75MHz, CDCl3, ppm): δ 69.90 (C7), 116.85 (C5), 127.00 (C8), 128.01 
(C9,13), 128.37 (C11), 128.61 (C10,12), 135.20 (C3), 137.63 (C4), 152.90 (C6), 155.73 
(C2). 
HR-MS: Calculated mass: 264.0302,  Found mass: 264.0307 
3-[(6-Chloro-3-nitropyridin-2-yl)oxy]-N-tritylpropan-1-amine (2.51g) 
 
 
 
Using the general procedure D, the product was obtained as yellow crystals in 
95% purity (54% yield). 
Molecular Formula: C27H24ClN3O3 
MW: 473.95 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 2.00 (m, 2H, H8), 2.33 (t, J = 6.61 Hz, 2H, H9), 
4.64 (t, J = 6.2 Hz, 2H, H7), 7.00 (d, J = 8.2 Hz, 1H, H5), 7.20-7.28 (bm, 9H, 
H14,16,18, 19,21,23,24,26,28), 7.43-7.48 (bm, 6H, H14,18,19,23,25,27), 8.25 (d, J = 8.5 Hz, 1H, 
H4). 
13C-NMR (75MHz, CDCl3, ppm): δ 29.74 (C8), 40.17 (C9), 67.14 (C7), 70.93 (C10), 
116.41 (C5), 126.22 (C16,21,26), 127.76 (C15,17,20,22,25,27), 128.60 (C14,18,19,23,24,28), 
136.54 (C4), 146.03 (C11,12,13), 152.94 (C3), 153.49 (C6), 156.11 (C2). 
HR-MS: Calculated mass: 473.1506, Found mass: 473.1520 
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2,6-Dibromo-3-nitropyridine (2.52) 
 
 
 
2,6-Dichloro-3-nitropyridine (1 g, 4.77 mmol) was dissolved in 12 mL of HBr (33 
w%) in AcOH and stirred at 80°C for 20 hours. The reaction mixture was then 
allowed to cool to RT and the solvent was evaporated in vacuo. The residue (a 
yellow oil that crystallizes on standing) was redissolved in EtOAc and the organic 
phase was washed with water, sat. aq. NaHCO3, water and brine. It was then dried 
over MgSO4, filtered and the solvent evaporated in vacuo to give the product as a 
yellow solid (1.25 g, 93% yield). 
 
Molecular Formula: C5H2Br2N2O2 
MW: 281.89 g/mol 
All analytical data were found to be in accordance with the literature.202 
6-Bromo-2-[(4-fluorobenzyl)oxy]-3-nitropyridine (2.53) 
 
 
Using the general procedure D, the product was obtained as a yellow solid (69% 
yield). 
Molecular Formula:C12H8BrFN2O3 
MW: 327.11 g/mol 
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7.2.6 Synthesis of Marimganti Type Monomers 
 
4-Methoxyphenyl acetate (2.55) 
 
 
4-Methoxyphenol (5 g, 40.3 mmol), acetyl chloride (5.75 ml, 81 mmol) and 
Alumina oxide (6.16 g, 60.4 mmol) were suspended in 100 mL of EtOAc. This 
mixture was stirred under an argon atmosphere at RT for 24 hours. After this 
period, the mixture was diluted with an extra 50 mL of EtOAc and washed three 
times with sat. NaHCO3 and once with brine. The organic phase was dried over 
MgSO4, filtered and evaporated under reduced pressure. The product  was 
obtained as a colorless oil (6.636 g, 99 % yield). 
Molecular Formula: C9H10O3 
MW: 166.17 g/mol 
All analytical data were found to be in accordance with the literature.203 
3-Bromo-4-methoxyphenyl acetate (2.56) 
 
 
4-Methoxyphenyl acetate (2.55) (5 g, 30.1 mmol) was dissolved in 40 mL of DCM 
and cooled in an icebath. A solution of dibromine (1.546 ml, 30.1 mmol) in 20 mL 
of DCM was prepared separately and added dropwise (over a period of 50 min) to 
the first solution under stirring. The reaction was kept under an atmosphere of 
argon. After the addition of Br2 was complete, the mixture was allowed to warm to 
RT and stirred for another 6 hours. The mixture was subsequently poured into 100 
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mL of 10% Na2S2O3 solution. The DCM phase was then separated and further 
washed with 10% Na2S2O3, sat. NaHCO3 twice and brine. The organic phase was 
then dried over MgSO4, filtered and evaporated under reduced pressure to afford 
the crude product as a light yellow oil. Further purification was carried out using 
MPLC (CHCl3) to give the product as a yellow oil. (6.2 g, 84 % yield). 
Molecular Formula: C9H9BrO3 
MW: 245.07 g/mol 
All analytical data were found to be in accordance with the literature.295 
3-Bromo-4-methoxyphenol (2.57) 
 
 
 
3-Bromo-4-methoxyphenyl acetate (2.56) (16.24 g, 66.3 mmol) was dissolved in 
150 mL of methanol. A solution of KOH (4.08 g, 72.9 mmol) in 20 mL of water 
was added and the mixture was stirred at RT for 35 min. The methanol  was 
removed from the reaction mixture by evaporated in vacuo  and the residual liquid 
was further diluted with 200 mL of water. The water phase was then made acidic 
by addition of aq. 1M HCl and the mixture was extracted three times with DCM 
(500 mL in total). The brown organic phase was treated with active charcoal, 
filtered and dried over MgSO4. After filtering again, the filtrate was evaporated in 
vacuo to give the product as a yellow oil (16.6 g, quantitative yield). 
 
Molecular Formula: C7H7BrO2 
MW: 203.03 g/mol 
All analytical data were found to be in accordance with the literature.296 
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5-Bromo-4-methoxy-2-nitrophenyl acetate (2.60) 
 
 
3-Bromo-4-methoxyphenyl acetate (2.56) (500 mg, 2.04 mmol) was dissolved in 1 
mL of acetic anhydride and cooled in to 0°C in an ice bath. To this solution was 
slowly added nitric acid (0.126 ml, 3.06 mmol), dissolved in 1 mL of acetic 
anhydride, while stirring vigorously. After this addition, the reaction mixture was 
allowed to warm to R.T. and stirred for 3 hours and 30 min. Subsequently, the 
mixture was poured into 30 mL of icewater under stirring. An orange oil separated, 
which transforms into a yellow precipitate on stirring in the water after 10 minutes. 
This precipitate was filtered of, washed with water and sat. NaHCO3 solution and 
finally dried in air to give the product as a yellow crystals (350 mg, 59% yield).  
Molecular Formula: C9H8BrNO5 
MW: 290.07 g/mol 
All analytical data were found to be in accordance with the literature. 
2-Bromo-1,4-phenylene diacetate (2.63) 
 
 
 
Anhydrous ZnBr2 (10.4 g, 46.2 mmol) was suspended in 10.4 mL of acetic 
anhydride. Benzoquinone (4 g, 37.1 mmol) was then added and the mixture was 
stirred at 100°C for 3 hours. The reaction mixture was then poured in ice water (28 
mL) and left stirring for 30 min. A brown precipitate formed which was filtered? 
The precipitate was crystallized from hot a EtOH-Water mixture (1/2 EtOH/water) 
to give the product as off-white crystals (7.1 g, 70% yield). 
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Molecular Formula:C10H9BrO4 
MW: 273.08 g/mol 
All analytical data were found to be in accordance with the literature.206 
4-Bromo-2-nitrophenol (2.67) 
 
 
 
4-Bromophenol (500 mg, 2.89 mmol) was dissolved in 3mL of acetic acid and 
cooled in an ice bath while stirring. Nitric acid (0.119 ml, 2.89 mmol) was then 
added very slowly, while keeping the temperature around 0°C. After the addition, 
the yellow reaction mixture was stirred for 20 minutes at RT. During this time, a 
bright yellow precipitate was formed. The suspension was then poured into 50 mL 
of ice water while stirring vigorously. The voluminous yellow precipitate was 
filtered of, washed with water and allowed to dry in air. The product  was obtained 
this way as yellow crystals (480  mg, 76 % yield). 
 
Molecular Formula: C6H4BrNO3 
MW: 218.00 g/mol 
All analytical data were found to be in accordance with the literature.297 
 
4-Bromo-2-nitrophenyl acetate (2.68) 
 
 
4-Bromo-2-nitrophenol (2.67) (100 mg, 0.59 mmol) was dissolved in 3 mL of dry 
Et2O under an argon atmosphere. NEt3 (164 µL, 1.18 mmol) and DMAP (7.2 mg, 
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0.059 mmol) were added and the mixture was cooled to 0°C. Acetyl chloride (84 
µL, 1.18 mmol) was slowly added while keeping the temperature at 0°C. 
Afterwards the reaction was allowed to warm to RT and stirred for an additional 
20 hours. The mixture was completely solidified and it was diluted with Et2O. The 
organic phase was washed with water, sat. aq. NaHCO3, water and brine. After 
drying over MgSO4 , filtering and evaporating the solvent in vacuo, the product 
was obtained as a yellow oil (116 mg, 93% yield). 
Molecular Formula: C8H6BrNO4 
MW: 260.04 g/mol 
All analytical data were found to be in accordance with the literature.298 
2-Bromo-4-fluoro-1-methoxybenzene (2.72) 
 
p-Fluoranisole (9 mL, 79 mmol) was dissolved in DCM (50 mL). Br2 (4.49 mL, 87 
mmol), dissolved in DCM (20 mL), was then slowly added at 0°C. The solution 
was subsequently stirred at room temperature for 24 hours. This was diluted with 
DCM, washed with Na2S2O3-solution, H2O and brine. Afterwards, the mixture was 
dried and evaporated in vacuo to give the product as a colorless oil (14.44 g, 89% 
yield). 
Molecular Formula:C7H6BrFO  
MW: 205.02 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ 3.87 (s, 3H, H7), 6.84 (dd, J = 5 Hz, 9Hz, 1H, 
H6), 6.98 (m, 1H, H5), 7.30 (dd, J = 3 Hz, 8Hz, 1H, H3). 
13C-NMR (75MHz, CDCl3, ppm): δ 111.6 (d, 3JCF = 9Hz, C2), 112.2 (d, 3JCF =  8 
Hz, C5), 114.6 (d, 2JCF = 22 Hz, C4), 120.5 (d, 2JCF =  26 Hz, C3), 152.5 (d, 4JCF = 3 
Hz, C1), 156.6 (d, 1JCF = 243 Hz, C4
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HR-MS:Calculated mass: 203.9586, Found mass: 203.9594 
FT-IR (cm-1):N/A 
Tm: oil 
2-Bromo-4-fluorophenol (2.73) 
 
2-Bromo-4-fluoro-1-methoxybenzene (2.72) (900 mg,4.39 mmol) was dissolved in 
20 mL dry DCM, under an argon atmosphere. The solution was cooled to -78°C 
and BBr3 (2 mL, 21.95 mmol), dissolved in 10 mL of dry DCM, was slowly added. 
Afterwards, the solution was stirred for 24 hours at RT. The mixture was poured 
on ice water, and then the aquatic phase was extracted with DCM. The organic 
phase was washed with brine, dried and evaporated in vacuo. Purification was 
performed using MPLC (heptanes/EtOAc 9/1) to give the product as a white solid 
(680 mg, 81% yield). 
Molecular Formula: C6H4BrFO 
MW: 191.00 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ 6.97 (d, J = 7Hz, 2H, H5,6), 7.22 (d, J = 7Hz, 
1H, H3). 
13C-NMR (75MHz, CDCl3, ppm): δ 109.5 (d, 3JCF = 10 Hz, C2), 116.0 (d, 2JCF =  
26 Hz, C5), 116.3 (d, 3JCF = 8Hz, C6), 118.7 (d, 2JCF =  26Hz, C3), 148.8 (d, 4JCF = 3 
Hz, C1), 156.4 (d, 1JCF = 242 Hz, C4). 
HR-MS:Calculated mass: 189.94295, Found mass: 189.94276 
FT-IR (cm-1): 3355 (s, OH) 
Tm: 40-41°C 
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2-Bromo-4-fluorophenyl methyl carbonate (2.74) 
 
2-Bromo-fluorophenol (2.73) (100 mg, 0.524 mmol) and NaOH (25 mg, 0.624 
mmol) were dissolved in 1 mL of H2O while stirring. Methylchloroformate (65 
µL, 0.681 mmol) was slowly added at 0°C. The solution was stirred for 1hour at 
RT. The reaction mixture was then extracted with DCM (3x50 mL), washed with 
NaHCO3 and brine, dried and evaporated in vacuo to give the product as a white 
solid (130 mg, 99% yield). 
Molecular Formula: C9H8BrFO3 
MW: 248 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 7.06 (m, H6), 7.20 (m, H5), 7.36 (d, J = 8Hz, 
H3). 
13C-NMR (75MHz, CDCl3, ppm): δ 56 (C8), 115.5 (d, 2JCF = 24 Hz, C5), 116.4 (d, 
3JCF = 10 Hz, C2), 120.5 (d, 2JCF = 26 Hz, C3), 124.0 (d, 3JCF = 9 Hz, C6), 144.7 
(d,4JCF = 4 Hz, C1), 153.3 (C7), 160.0 (d, 1JCF = 250 Hz, C4). 
HR-MS:Calculated mass: 247.9484, Found mass: 247.9525 
FT-IR (cm-1): 1753 (s, carbonate) 
Tm: 67.8-70.1°C 
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2-Bromo-4-fluoro-5-nitrophenyl methyl carbonate (2.75) 
 
2-Bromo-4-fluorophenyl methyl carbonate (2.74) (6.2 g, 24.9 mmol) was 
dissolved in H2SO4 (98%) (39.3 mL, 737 mmol) while stirring at 0°C.KNO3 (2.77 
g, 12 mmol) was slowly added. Afterwards, the solution was stirred for 1 hour at 
RT. The mixture was then poured over ice water, extracted with DCM, washed 
with H2O and brine, dried and evaporated in vacuo.The product was obtained as a 
light yellow solid (6.55 g, 89%). 
Molecular Formula: C8H5BrFNO5 
MW: 294.03 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 3.99 (s, 3H, H8), 7.63 (d, J = 10 Hz, 1H, H3), 
8.04 (d, J = 7Hz, 1H, H6). 
13C-NMR (75MHz, CDCl3, ppm): δ 54.3 (C8), 120.5 (d, 3JCF = 2 Hz,  C6), 123.3 (d, 
2JCF = 25 Hz, C3), 123.9 (d, 3JCF = 9 Hz, C2), 136.2 (d, 2JCF = 11 Hz, C5), 144.5 (d, 
4JCF= 4 Hz,C1), 151.9 (C7), 152.7 (d, 1JCF = 268 Hz, C4). 
HR-MS:Calculated mass: 234.92421, Found mass: 234.92170 (M - CO2Me) 
FT-IR (cm-1): 1751 (d, carbonate), 1530, 1370 (s, NO2);  
Tm: 70.1-72.0°C 
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2-Bromo-4-fluoro-5-nitrophenol (2.76) 
 
2-Bromo-4-fluoro-5-nitrophenyl methyl carbonate (2.75) (6.55 g, 22.28 mmol) 
was dissolved in 94 mL of MeOH. While stirring at 0°C, KOH (3.12 g, 55.7 mmol) 
was added to the solution. The reaction mixture was subsequently stirred for 20 
hours at RT. HCl (1M) was then added until the water phase tested acidic on a pH 
indicator strip and most of the solvent was evaporated. H2O was added and the 
mixture was extracted with EtOAc (3x150 mL), dried and evaporated in vacuo. 
The product was obtained as a yellow solid (5.18 g, 98% yield). The product was 
stored in the freezer at -20°C to avoid decomposition. 
Molecular Formula: C6H3BrFNO3 
MW: 236.00 g/mol 
1H-NMR (300MHz, DMSO-d6, ppm):δ 7.38 (d, J = 7Hz, 1H, H3), 7.73 (d, J = 
11Hz, 1H, H6). 
13C-NMR, HR-MS, FT-IR and Tm: Due to instability of the molecule at room 
temperature these measurements were not performed. 
 
Procedure E:For Mitsunobu coupling of amino acid side chains to 2.76: 
2-Bromo-4-fluoro-5-nitrophenol (2.76) (1 eq.), the amino acid side chain alcohol 
(1.1 eq) and PPh3 (1.5 eq.) were dissolved in dry THF (0.5 M) under an 
atmosphere of argon.The solution was then cooled to 0°C and DIAD (1.5 eq) was 
slowly added while keeping the temperature at 0°C. Afterwards the reaction 
mixture was allowed to warm to RT and stirred for an additional 18 hours. Then 
the solvent was evaporated and the residue redissolved in EtOAc and filtered over 
silica gel. The filtrate was once again evaporated in vacuo to deliver the crude 
product. Further purification was performed using MPLC. 
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Procedure F: For SNAr reaction to introduce a second amino acid side chain on 
the Marimganti monomer: 
The monosubstituted monomer (2.77) (1 eq.) and the amino acid side chain 
alcohol (1.2 eq.) were dissolved in dry THF (0.2 M) under an atmosphere of argon. 
The reaction mixture was cooled to 0°C and NaHMDS (1 M in THF, 1.2 eq.) was 
slowly added while keeping the temperature at 0°C. Afterwards the reaction 
mixture was allowed to warm to RT and stirred for an additional 20 hours. The 
solvent was evaporated in vacuo and the residue was redissolved in EtOAc. The 
organic phase was then washed with water, brine and dried over MgSO4. After 
filtration and evaporation of the filtrate in vacuo, the crude product was obtained. 
Further purification was performed by MPLC. 
1-(Benzyloxy)-2-bromo-4-fluoro-5-nitrobenzene (2.77a) 
 
 
 
Using procedure E, after purification using MPLC (1/1 heptanes/EtOAc) the 
product was obtained as a yellow solid (78% yield). 
 
Molecular Formula:C13H9BrFNO3 
MW: 326.12 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ 7.36-7.5 (m, 5H, H9,10,11,12,13), 7.56 (d, J = 10 
Hz, 1H, H2), 7.63 (d, J = 6 Hz, 1H, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 71.9 (C7), 109.4 (C5), 120.2 (d, 3JCF = 9Hz, 
C3),; 123.2 (d, 2JCF = 25Hz, C2), 127.3 (C10,12), 128.6 (C11), 128.8 (C9,13), 134.9 
(C8), 136,0 (d, 2JCF = 8Hz, C6), 149.5 (d, 1JCF = 262Hz, C1),151.5 (C4). 
HR-MS:Calculated mass: 324.9750, Found mass: 324.9749 
FT-IR (cm-1): 1512, 1322 (s, NO2), 1240 (s, C-O-C stretch) 
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Tm: 126.3-129.1°C 
1-Bromo-5-fluoro-2-methoxy-4-nitrobenzene (2.77b) 
 
 
Using procedure E, after purification using MPLC (1/1 heptanes/EtOAc) the 
product was obtained as a yellow solid (94% yield). 
 
Molecular Formula:C7H5BrFNO3 
MW: 250.02 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 3.97 (s, 3H, H7), 7.55 (d, J = 3.3 Hz, 1 H, H2), 
7.57 (s, 1H, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 57.18 (C7), 107.47 (d, J = 2.7 Hz, C5) ,  119.35 
(d, J = 7.6 Hz, C3), 123.19 (d, J = 26 Hz, C2), 149.48 (d, J = 262 Hz, C1), 152.54 (d, 
J = 3 Hz, C4). 
HR-MS: Calculated mass: 248.9439,  Found mass: 248.9438 
4-[(2-Bromo-4-fluoro-5-nitrophenoxy)methyl]-1-trityl-1H-imidazole (2.77c) 
 
 
 
Using procedure E, after purification using MPLC (8/2 heptanes/EtOAc) the 
product was obtained as a yellow solid (44% yield). 
Molecular Formula: C29H21BrFN3O3 
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MW: 558.40 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 5.15 (s, 2H, H7), 6.94 (s, 1H, H9), 7.1-7.13 
(bm, 6H, H18,20,23,25,28,30), 7.31-7.36 (bm, 9H, H17,19,21,22,24,26,27,29,31), 7.48-7.50 (m, 
H5,11), 7.79 (d, J = 8 Hz, H2). 
13C-NMR (75MHz, CDCl3, ppm): δ 66.77 (C7), 75.71 (C13), 110.52 (d, J = 3 Hz, 
C5), 120.37 (d, J = 8.6 Hz, C3), 121.51 (C9), 123.00 (d, J = 25 Hz, C2), 128.19 
(C17,21,22,26,27,31), 128.27 (C19,24,29), 129.69 (C18,20,23,25,28,30), 135.23 (C8), 139.37 (C11), 
142.01 (C14,15,16),  149.47 (d, J = 261 Hz, C1), 151.52 (d, J = 2.7 Hz, C4). 
5-[2-(2-Bromo-4-fluoro-5-nitrophenoxy)ethyl]-1-trityl-1H-tetrazole (2.77d) 
 
 
 
Using procedure E, after purification using MPLC (8/2 heptanes/EtOAc) the 
product was obtained as a white solid (46% yield). 
Molecular Formula: C28H21BrFN5O3 
MW: 574.40 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 3.52 (t, J = 6.6 Hz, 2H, H8), 4.52 (t, J = 6.6 Hz, 
2H, H7), 7.07-7.11 (bm, 6H, H15,17,20,22,25,27), 7.28-7.36 (bm, 9H, 
H14,16,18,19,21,23,24,26,28), 7.49 (d, J = 9.7 Hz, 1H, H5), 7.55 (d, J = 6 Hz, H2). 
13C-NMR (75MHz, CDCl3, ppm): δ 26.00 (C8), 67.77 (C7), 83.08 (C10), 108.91 (d, 
J = 3.4 Hz, C5), 119.95 (d, J = 8.9 Hz, C3), 123.00 (d, J = 24.8 Hz, C2), 127.77 
(C14,18,19,23,28,24), 128.38 (C16,21,26), 130.22 (C15,17,20,22,25,27), 141.23 (C11,12,13), 149.63 
(d, J = 262 Hz, C1), 151.47 (d, J = 2.97 Hz, C4), 161.99 (C9). 
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1-Bromo-5-fluoro-2-(2-methoxyethoxy)-4-nitrobenzene (2.77f) 
 
 
 
Using procedure E, after purification using MPLC (9/1 heptanes/EtOAc) the 
product was obtained as a white solid (76% yield). 
Molecular Formula: C9H9BrFNO4 
MW: 294.07 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 3.48 (s, 3H, H9), 3.83 (t, J = 4.6 Hz, H8), 4.24 
(t, J = 4.6 Hz, H7), 7.55 (d, J = 9.9 Hz, H5), 7.63 (d, J = 6 Hz, H2). 
13C-NMR (75MHz, CDCl3, ppm): δ 59.49 (C9), 70.14 (C8), 70.59 (C7), 109.18 (d, J 
= 2.6 Hz, C5), 120.00 (d, J = 8.5 Hz, C3), 123.09 (d, j = 25 Hz, C2), 149.59 (d, J = 
252 Hz, C1), 151.93 (d, J = 3.6 Hz, C4) 
HR-MS: Calculated mass: 292.9700,  Found mass: 292.9721 
tert-Butyl 4-[(2-bromo-4-fluoro-5-nitrophenoxy)methyl]-1H-imidazole-1-
carboxylate (2.77g) 
 
 
 
Using procedure E, after purification using MPLC (7/3 heptanes/EtOAc) the 
product was obtained as a white solid (46% yield). 
 
Molecular Formula:C15H15BrFN3O5 
MW: 416.20 g/mol 
HR-MS: Calculated mass: 341.9526,  Found mass: 341.9523 (M –OtBu) 
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tert-Butyl (2-bromo-4-fluoro-5-nitrophenoxy)acetate (2.77h) 
 
 
 
Using procedure E, after purification using MPLC (8/2 heptanes/EtOAc) the 
product was obtained as a orange solid (31% yield). 
 
Molecular Formula: C12H13BrFNO5 
MW: 350.41 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.44 (s, 9H, H13,14,15), 4.46 (s, 2H, H10), 7.57 
(d, J = 6.6 Hz, 1H, H5), 7.61 (d, J = 9.6 Hz, 1H, H2). 
13C-NMR (75MHz, CDCl3, ppm): δ 28.03 (C13,14,15), 66.95 (C10), 83.59 (C12), 
109.09 (d, J = 2.6 Hz, C5), 120.05 (d, J = 8.5 Hz, C3), 123.46 (d, j = 25 Hz, C2), 
149.85 (d, J = 251 Hz, C1), 150.80 (d, J = 3.6 Hz, C4), 166.21 (C11). 
HR-MS: Calculated mass: 348.9961,  Found mass: 348.9545 
 
1-(Benzyloxy)-2-bromo-4-methoxy-5-nitrobenzene (2.78aa) 
 
 
 
Using procedure F, after purification using MPLC (7/3 heptanes/EtOAc) the 
product was obtained as yellow crystals (47% yield). 
 
Molecular Formula: C14H12BrNO4 
MW: 338.15 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ 3.94 (s, 3H, H14),5.15 (s, 3H, H7), 7.32-7.50 
(m, 6H, H2,9,10,11,12,13),7.53 (s, 1H, H5). 
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13C-NMR (75MHz, CDCl3, ppm): δ 57.3 (C14), 71.8 (C7), 110.7 (C5), 119.2 (C2), 
119.6 (C3), 127.3 (C10,12), 128.4 (C11), 128.7 (C9,13), 135.4 (C8), 138.0 (C6), 147.9 
(C4), 148.6 (C1). 
HR-MS:Calculated mass: 336.9957, Found mass: 336.9950 
FT-IR (cm-1):1513, 1334 (s, NO2), 1221 (m, C-O-C stretch) 
Tm: 146.4-150. 2°C 
1-Bromo-2-isobutoxy-5-methoxy-4-nitrobenzene (2.78ab) 
 
 
 
Using procedure F, after purification using MPLC (9/1 heptanes/EtOAc) the 
product was obtained as a yellow solid (52% yield). 
Molecular Formula: C17H18BrNO4 
MW: 380.23 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.04 (d, J = 6 Hz, 6H, H16,17), 2.14 (m, 1H, 
H15), 3.82 (d, J  = 6.8 Hz, 2H, H14), 5.14 (s, 2H, H7), 7.32 (s, 1H, H2), 7.35-7.48 
(bm, 5H, H9,10,11,12,13), 7.51 (s, 1H, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 19.05 (C16,17), 28.31 (C15), 71.87 (C14), 76.68 
(C7), 110.65 (C5), 119.36 (C2), 120.02 (C3), 127.30 (C10,12), 128.36 (C9,13), 128.73 
(C9,13), 135.53 (C8), 138.1 (C6), 147.54 (C4), 148.33 (C1). 
HR-MS: Calculated mass: 379.0419,  Found mass: 379.0390 
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4-[(5-Bromo-4-methoxy-2-nitrophenoxy)methyl]-1-trityl-1H-imidazole (2.78ba) 
 
 
Using procedure F, after purification using MPLC (1/1 heptanes/EtOAc) the 
product was obtained as a yellow solid (51% yield). 
Molecular Formula: C30H24BrN3O4 
MW: 570.43 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 3.90 (s, 3H, H7), 5.14 (s, 2H, H8), 6.92 (s, 1H, 
H16), 7.09-7.14 (bm, 6H, H18,20,23,25,28,30), 7.32-7.34 (bm, 9H, H16,19,21,22,24,26,27,29,31), 
7.40 (s, 1H, H2), 7.44 (d, J = 1.5 Hz, 1H, H11), 7.56 (s, 1H, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 56.96 (C7), 67.76 (C8), 75.58 (C12), 108.18 
(C5), 118.15 (C2), 121.29 (C3), 122.82(C16), 128.13 (C16,19,21,22,24,26,27,29,31), 129.78 
(C18,20,23,25,28,30), 135.84 (C11), 139.16 (C9), 142.16 (C13,14,15), 146.58 (C4), 149.98 
(C1). 
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tert-Butyl 3-[(5-bromo-4-methoxy-2-nitrophenoxy)methyl]-1H-indole-1-
carboxylate (2.78bb) 
 
 
 
Using procedure F, after purification using MPLC (9/1 heptanes/EtOAc) the 
product was obtained as a yellow solid (37% yield). 
Molecular Formula:C21H21BrN2O6 
MW: 477.31 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.68 (s, 9H, H19,20,21), 3.90 (s, 3H, H7), 5.32 (s, 
2H, H8), 7.25-7.38 (m, 2H, H14,15), 7.43 (s, 1H, H2), 7.48 (s, 1H, H5), 7.67 (d, J = 
7.1 Hz, H16), 7.71 (s, 1H, H10), 8.14 (d, J = 8.1 Hz, H13). 
HR-MS: Calculated mass: 476.0583,  Found mass: 476.0611 
4-[(2-Bromo-4-isobutoxy-5-nitrophenoxy)methyl]-1-trityl-1H-imidazole (2.78ca) 
 
 
 
Using procedure F, after purification using MPLC (1/1 heptanes/EtOAc) the 
product was obtained as a yellow viscous oil (49% yield). 
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Molecular Formula: C33H30BrN3O4 
MW: 612.54 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.05 (d, J = 5.3 Hz, 6H, H36,37), 2.14 (m, 1H, 
H35), 3.80 (d, J = 6 Hz, 2H, H34), 5.09 (s, 2H, H7), 6.89 (s, 1H, H9), 7.09-7.13 (bm, 
6H, H16,18,21,23,26,28), 7.25 (s, 1H, H2), 7.3-7.34 (bm, 9H, H15,17,19,20,22,24,25,27,29), 7.45 
(d, J = 1.6 Hz, 1H, H10), 7.62 (s, 1H, H5). 
HR-MS: Calculated mass: 323.1548, Found mass: 323.1555 (M – Trt) 
5-(2-[2-Bromo-4-(2-methoxyethoxy)-5-nitrophenoxy]ethyl)-1-trityl-1H-tetrazole 
(2.78da) 
 
 
 
Using procedure F, after purification using MPLC (8/2 heptanes/EtOAc) the 
product was obtained as a yellow viscous oil (91% yield). 
 
Molecular Formula: C31H28BrN5O5 
MW: 630.49 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 3.45 (s, 3H, H9), 3.58 (t, J = 6.9 Hz, H11), 3.48 
(t, J = 4.5 Hz, 2H, H8), 4.20 (t, J = 4.5 Hz, H7), 4.46 (t, J = 6.5 Hz, H10), 7.07-7.11 
(bm, 6H, H18,20,23,25,28,30), 7.28-7.35 (bm, 9H, H2,17,19,21,22,24,26,27,29,31), 7.43 (s, 1H, 
H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 26.08 (C11), 59.46 (C9), 67.72 (C10), 70.73 
(C7), 70.86 (C8), 83.00 (C13), 110.11 (C5), 119.08 (C2), 121.43 (C3), 127.80 
(C15,19,20,24,25,29), 128.36 (C17,22,27), 130.23 (C16,18,21,23,26,28), 138.81 (C6), 141.26 
(C14,15,16), 147.17 (C4), 149.05 (C1), 162.19 (C12). 
h HR-MS: Calculated mass: 387.0154, Found mass: 387.0151 (M - Trt) 
-Chapter 7- Experimental 
 
-181- 
 
7.3  Functionalization of Monomers 
 
7.3.1 Nucleophilic Substitution Reactions 
 
Procedure G: Nucleophilic substitution of secondary amines on pyridine 
monomer (2.51): 
Nitropyridine 2.51 (1 eq.), morpholine (1.5 eq.) and NEt3 (1.5 eq.) were dissolved 
in dry THF (0.4 M) under an argon atmosphere. The reaction mixture was then 
stirred at 80°C for 18 hours. Afterwards the mixture was allowed to cool to RT 
and diluted with water. The aqueous phase was extracted with EtOAc, washed 
with water two times, washed with brine once and dried over MgSO4. The organic 
phase was then evaporated in vacuo to give the product, which did not require 
further purification. 
4-(6-Isopropoxy-5-nitropyridin-2-yl)morpholine (3.1a) 
 
 
 
Using procedure G, the product was obtained as a yellow solid (93% yield). 
 
Molecular Formula: C12H17N3O4 
MW: 267.28 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.42 (d, J = 6.5 Hz, 6H, H12,13), 3.67 (m, 4H, 
H7,8), 3.81 (m, 4H, H9,10), 5.38 (m, 1H, H11), 6.13 (d, J = 9.1 Hz, 1H, H5), 8.27 (d, J 
= 9.1 Hz, 1H, H4). 
13C-NMR (75MHz, CDCl3, ppm): δ 21.92 (C12,13), 44.97 (C7,8), 66.45 (C9,10), 70.30 
(C11), 97.35 (C5), 123.36 (C3), 138.16 (C4), 157.07 (C6), 158.84 (C2). 
HR-MS: Calculated mass: 225.0750,  Found mass: 225.0712 
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tert-Butyl 3-[(6-morpholin-4-yl-3-nitropyridin-2-yl)oxy]propanoate (3.1b) 
 
 
 
Using procedure G but performed at RT instead of 80°C, after MPLC (1/1 
heptanes/EtOAc)purification, the product was obtained as yellow crystals (72% 
yield). 
Molecular Formula: C16H23N3O6 
MW: 353.37 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.47 (s, 9H, H15,16,17), 2.77 (t, J = 6.4 Hz, 
2H, H12), 3.68 (m, 4H, H7,8), 3.80 (m, 4H, H9,10), 4.65 (t, J =  6.1 Hz, 2H, H11), 
6.16 (d, J =9.1 Hz, 1H, H5), 8.28 (d, J = 9.1 Hz, 1H, H4). 
13C-NMR (75MHz, CDCl3, ppm): δ 28.07 (C15,16,17), 35.10 (C12), 45.00 (C7,8), 
62.75 (C11), 66.42 (C9,10), 81.21 (C14), 97.86 (C5), 123.01 (C3), 138.13 (C4), 157.01 
(C6), 158.74 (C2), 170.33 (C13). 
HR-MS: Calculated mass: 353.1587,  Found mass: 353.1602 
4-[6-(Benzyloxy)-5-nitropyridin-2-yl]morpholine (3.1c) 
 
 
 
Using procedure G, the product was obtained as a yellow solid (78% yield). 
 
Molecular Formula: C16H17N3O4 
MW: 315.32 g/mol 
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1H-NMR (300MHz, CDCl3, ppm):δ 3.66 (m, 4H, H7,8), 3.88 (m, 4H, H9,10), 5.50 (s, 
2H, H11), 6.15 (d, J =9.1 Hz, 1H, H5), 7.27-7.38 (bm, 3H, H13,15,17), 7.48 (d, J = 7 
Hz, 2H, H14,16), 8.27 (d, J = 9.1 Hz, 1H, H4).  
13C-NMR (75MHz, CDCl3, ppm): δ 45.06 (C7,8), 66.39 (C9,10), 68.22 (C11), 98.07 
(C5), 123.01 (C3), 126.97 (C13,17), 127.77 (C15), 128.48 (C14,16), 136.64 (C12), 
138.13 (C4), 156.95 (C6), 158.68 (C2). 
HR-MS: Calculated mass: 315.1219,  Found mass: 315.1247 
4-(6-[(4-Fluorobenzyl)oxy]-5-nitropyridin-2-yl)morpholine (3.1d) 
 
 
 
Using procedure G, the product was obtained as aa yellow solid (91% yield). 
Molecular Formula: C16H16FN3O4 
MW: 333.31 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 3.68 (m, 4H, H7,8), 3.80 (m, 4H, H9,10), 5.46 (s, 
2H, H11), 6.17 (d, J =9.1 Hz, 1H, H5), 7.06 (m, 2H, H14,18), 7.46 (m, 2H, H15,17), 
8.29 (d, J = 9.1 Hz, 1H, H4). 
13C-NMR (75MHz, CDCl3, ppm): δ 45.00 (C7,8), 66.37 (C9,10), 67.56 (C11), 98.13 
(C5), 115.39 (d, H = 21.5 Hz, C14,16), 123.13 (C3), 128.84 (d, J = 8 Hz, C13,17), 
132.32 (d, J = 3Hz, C12), 138.18 (C4), 156.84 (C6), 158.69 (C2), 162.39 (d, J = 246 
Hz, C15). 
HR-MS: Calculated mass: 333.1125,  Found mass: 333.1163 
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7.3.2 Ester Synthesis via Carbonylation 
 
Procedure H: Alkoxycarbonylation of monomers. 
All solid reagents (Pd(OAc)2 (5 mol%), the monomer (1 eq.) and Xantphos (10 
mol%)) were brought into an oven-dried 2-necked flask with a septum, under an 
atmosphere of argon. The flask was evacuated and backfilled with argon, this was 
repeated 2 times. Methanol (10 eq.) and triethylamine (0.2 M) were added with a 
syringe via the septum. The resulting mixture was purged with carbon monoxide 
for 2 minutes (Caution! Carbon monoxide is a highly toxic and flammable gas). 
The reaction was then placed under a carbon monoxide atmosphere by means of a 
balloon and heated to 70°C in an oil bath for 24 hours. After this time, the mixture 
was cooled, diluted with EtOAc and filtered over kiezelguhr. The resulting filtrate 
was evaporated in vacuo to obtain the crude product. Purification was carried out 
by MPLC.  
Methyl 5-[bis(tert-butoxycarbonyl)amino]-6-methoxypyrazine-2-carboxylate (3.5) 
 
 
Using Procedure H, after purification by MPLC (8/2 heptanes/EtOAc), the 
product was obtained as white crystals (88% yield). 
Molecular Formula: C17H25N3O7 
MW: 383.40 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ  1.40 (s, 18H, H14,15,16,17,18,19), 4.05 (s, 3H, 
H11), 4.10 (s, 3H, H10), 8.55 (s, 1H, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 52.9 (C11), 54.5 (C10), 75.5 (C14,15,16,17,18,19) 
83.7 (C12,13), 136.6 (C5), 139.0 (C3), 141.4 (C8,9), 149.6 (C2), 155.4 (C6), 164.2 (C7). 
HR-MS:Calculated mass: 283.1180, Found mass: 283.1182 (M – Boc) 
-Chapter 7- Experimental 
 
-185- 
 
FT-IR (cm-1): 1742, 1705 (carbamate) 
Tm: 99.7-102.1°C 
Methyl 5-[bis(tert-butoxycarbonyl)amino]-6-isobutoxypyrazine-2-carboxylate (3.6) 
 
 
 
Using Procedure H, after purification by MPLC (8/2 heptanes/EtOAc), the 
product was obtained as a colorless oil (79% yield). 
Molecular Formula: C20H31N3O7 
MW: 425.48 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.01 (d, J = 6.8 Hz, 6H, H12,13), 1.39 (s, 18H, 
H16-21), 2.10 (m, 1H, H11), 4.00 (s, 3H, H22), 4.26 (d, J = 6 Hz, 2H, H10), 8.71 (s, 
1H, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 19.14 (C12,13), 27.84 (C16-21), 27.92 (C11), 
52.92 (C22), 73.55 (C10), 83.66 (C14,15), 136.34 (C5), 139.11 (C3), 141.32 (C8,9), 
149.63 (C2), 155.58 (C6), 164.22 (C7). 
HR-MS: Calculated mass: 425.2162, Found mass: 425.2125 
Tm: oil 
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Methyl 5-methoxy-4-nitro-2-(2-phenylethoxy)benzoate (3.7) 
 
 
 
Using Procedure H, after purification by MPLC (8/2 heptanes/EtOAc), the 
product was obtained as a yellow oil (39% yield). 
 
Molecular Formula: C17H17NO6 
MW: 331.32 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 3.13 (t, J = 7 Hz, 2H, H10), 3.90 (s, 3H, H8), 
3.93 (s, 3H, H17), 4.23 (t, J = 6.8 Hz, H9), 7.24-7.32 (bm, 5H, H12-16), 7.39 (s, 1H, 
H2), 7.48 (s, 1H, H5). 
Tm: Oil. 
Ethyl 6-isopropoxy-5-nitropyridine-2-carboxylate (3.8) 
 
 
 
6-Chloro-2-isopropoxy-3-nitropyridine (2.51e) (100 mg, 0.46 mmol) and 
Pd(PPh3)2Cl2 (16 mg, 0.023 mmol) were brought into an oven-dried 2-necked 
flask with a septum, under an atmosphere of argon. The flask was evacuated and 
backfilled with argon, this was repeated 2 times. 2 mL of dry ethanol and 1 mL of 
dry triethylamine were added with a syringe via the septum. The resulting mixture 
was purged with carbon monoxide for 2 minutes (Caution! Carbon monoxide is a 
highly toxic and flammable gas). The reaction was then placed under a carbon 
monoxide atmosphere by means of a balloon and heated to 80°C in an oil bath for 
24 hours. After this time, the mixture was cooled, diluted with EtOAc and filtered 
over kiezelguhr. The resulting filtrate was evaporated in vacuo to obtain the crude 
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product. Purification was carried out by MPLC (7/3 heptanes/EtOAc) to give the 
product as a yellow oil (70 mg, 60% yield). 
 
Molecular Formula: C10H12N2O5 
MW: 240.21 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.44 (d, J = 6 Hz, 6H, H8,9), 4.44 (q, 2H, H10), 
5.63 (m, 1H, H7), 7.73 (d, J = 8 Hz, 1H, H5), 8.25 (d, J = 8.2 Hz, 1H, H4). 
13C-NMR (75MHz, CDCl3, ppm): δ 14.19 (C11), 22.74 (C8,9), 62.26 (C10), 71.82 
(C7), 117.10 (C5), 135.36 (C4), 148.91 (C6), 155.40 (C2), 163.41 (C12). 
HR-MS: Calculated mass: 254.0903,  Found mass: 254.0919 
Ethyl 6-(benzyloxy)-5-nitropyridine-2-carboxylate (3.9) 
 
 
 
2-(Benzyloxy)-6-chloro-3-nitropyridine (2.51f) (500 mg, 1.89 mmol) and 
Pd(PPh3)2Cl2 (66 mg, 0.095 mmol) were brought into an oven-dried 2-necked 
flask with a septum, under an atmosphere of argon. The flask was evacuated and 
backfilled with argon, this was repeated 2 times. 8 mL of dry ethanol and 4 mL of 
dry triethylamine were added with a syringe via the septum. The resulting mixture 
was purged with carbon monoxide for 2 minutes (Caution! Carbon monoxide is a 
highly toxic and flammable gas). The reaction was then placed under a carbon 
monoxide atmosphere by means of a balloon and heated to 80°C in an oil bath for 
24 hours. After this time, the mixture was cooled, diluted with EtOAc and filtered 
over kiezelguhr. The resulting filtrate was evaporated in vacuo to obtain the crude 
product. Purification was carried out by MPLC (8/2 heptanes/EtOAc) to give the 
product as a brown oil (381 mg, 70% yield). 
 
Molecular Formula: C14H12N2O5 
MW: 288.26 g/mol 
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1H-NMR (300MHz, CDCl3, ppm):δ 1.47 (t, J = 7.5 Hz, 3H, H11), 4.47 (q, 2H, H10), 
5.66 (s, 2H, H7), 7.33-7.40 (bm, 3H, H12,14,16), 7.58 (d, J = 6.6 Hz, 2H, H13,15), 7.80 
(d, J = 7.6 Hz, 1H, H5), 8.32 (d, J = 8.54 Hz, 1H, H4). 
13C-NMR (75MHz, CDCl3, ppm): δ 14.23 (C11), 62.39 (C10), 69.44 (C7), 98.08, 
118.00 (C5), 128.30 (C14), 128.48 (C12,16), 128.51 (C13,15), 135.57 (C8), 135.80 (C4), 
148.89 (C6), 155.39 (C2), 163.22 (C9). 
HR-MS: Calculated mass: 211.0871,  Found mass: 211.0875 (M – Bn) 
 
7.3.3 Alkyne Attachment via Sonogashira Coupling 
 
2-Isopropoxy-3-nitro-6-[(trimethylsilyl)ethynyl]pyridine (3.10) 
 
 
 
6-Chloro-2-isopropoxy-3-nitropyridine (2.51e) (100 mg, 0.46 mmol), 
Pd(PPh3)2Cl2 (16  mg, 0.023 mmol), CuI (4 mg, 0.023 mmol) were brought into an 
oven-dried 2-necked flask with a septum, under an atmosphere of argon. The flask 
was evacuated and backfilled with argon, this was repeated 2 times. 4 mL of 
degassed, dry Toluene, NEt3 (190 µL, 1.38 mmol) and trimethylsilylacetylene (85 
µL, 0.60 mmol) were then added via a septum. The reaction mixture was stirred at 
RT for 23 hours. It was then quenched with a aq. sat. NH4Cl solution and extracted 
three times with EtOAc. The combined organic layers were dried over MgSO4, 
filtered and evaporated in vacuo. The residue was purified using MPLC (95/5 
heptanes/EtOAc) to give the product as a yellow oil (120  mg, 94% yield). 
 
Molecular Formula: C13H18N2O3Si 
MW: 278.38 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 0.10 (s, 9H, H12,13,14), 1.22 (d, J = 6.2 Hz, 6H, 
H8,9), 5.39 (m, 1H, H7), 6.90 (d, J = 8.3 Hz, 1H, H5), 7.96 (d, J = 7.95 Hz, 1H, H4). 
-Chapter 7- Experimental 
 
-189- 
 
13C-NMR (75MHz, CDCl3, ppm): δ 0.00 (C12,13,14), 22.24 (C8,9), 71.62 (C7), 99.36 
(C11), 102.85 (C10), 107.57 (C3), 120.22 (C5), 135.43 (C4), 144.93 (C6), 156.09 (C2). 
HR-MS: Calculated mass: 278.1087,  Found mass: 278.1082 
Tm: oil 
 
3-Methoxy-5-[(trimethylsilyl)ethynyl]pyrazin-2-amine (3.11) 
 
 
 
5-Bromo-3-methoxypyrazin-2-amine (2.30a)  (70 mg, 0.343 mmol), Pd(PPh3)2Cl2 
(24  mg, 0.034 mmol), CuI (6.5 mg, 0.034 mmol) were brought into an oven-dried 
2-necked flask with a septum, under an atmosphere of argon. The flask was 
evacuated and backfilled with argon, this was repeated 2 times. 2 mL of degassed, 
dry THF, 0.5 mL of NEt3 and trimethylsilylacetylene (121 µL, 0.86 mmol) were 
then added via a septum. The reaction mixture was stirred at RT for 26 hoursAfter 
this time, the mixture was cooled, diluted with EtOAc and filtered over kiezelguhr. 
The resulting filtrate was evaporated in vacuo to obtain the crude product. 
Purification was carried out by MPLC (8/2 heptanes/EtOAc) to give the product as 
a white solid (67 mg, 88% yield). 
 
Molecular Formula: C10H15N3OSi 
MW: 221.33 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 0.26 (s, 9H, H10,11,12), 4.01 (s, 3H, H7), 4.97 
(bs, 2H, -NH2), 7.76 (s, 1H, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 0.00 (C10,11,12), 53.98 (C7), 94.35 (C9), 102.16 
(C8), 123.61 (C6), 138.50 (C5), 144.87 (C3), 147.52 (C2). 
HR-MS: Calculated mass: 221.0984,  Found mass: 221.0978 
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7.3.4 Alkylation via Negishi Coupling in Flow 
 
Calculations of residence time using violet crystal as tracer.  
Two solution of violet crystal in water and THF (0.2 M) were pumped at 0.2 
mL/min (each one) using R2+R4 system. The mixed solution was driven to a 
column containing the catalyst supported (1 g), giving a residence time of 4min 
and 56 sec. The estimated residence time based on flow rate was 5 min. 
General procedure for Negishi reactions run in flow  
Two solutions were prepared: one with the aryl halide (1 eq.) in dry THF (with 
concentration specified in table 3.3) and one with dimethyl zinc in dry toluene (1.3 
eq., dilution of the commercial 2 M toluene solution). These solutions were then 
pumped using the R2+R4 Vapourtec system. The mixed solution was driven 
through a preheated glass column containing the supported catalyst (SiliaCat DPP-
Pd, 1 g), which was packed manually. The conversion of the starting product was 
checked at the reactor outlet using GC-MS. To isolate the product, the outlet 
solution was evaporated in vacuo. The residue was then redissolved in ethyl 
acetate or diethyl ether and washed with water and brine. The organic layer was 
separated, dried (MgSO4), filtered and the solvents evaporated in vacuo to obtain 
the desired product, which usually did not require further purification.  
Example experimental procedure for batch reactions in microwave  
4-nitrobromobenzene (101 mg, 0.5 mmol) and Siliacat-DPP-Pd (8 mg) were 
placed in a 5 mL microwave vial with stirring bar. The vial was flushed with 
nitrogen and sealed using a crimp cap with a Teflon septum. 0.5 mL of THF and 
0.125 mL of toluene were then added via the septum, followed by slow addition of 
the 2 M dimethylzinc solution in toluene (0.375 mL, 0.75 mmol). The vessel was 
then placed in a microwave oven and heated to 60°C for 5 minutes. After this time, 
the mixture was allowed to cool to RT and a sample was taken for GC-MS 
analysis. 
Scale up runs  
The same procedure as for the small scale runs was used (0.25 M feed 
concentration of aryl bromide, 60°C, Rt = 3 min), except the reaction was run for a 
-Chapter 7- Experimental 
 
-191- 
 
longer period. The end products were purified in this case using flash 
chromatography. 
Measurement of Pd leaching 
The sample (between 50 and 120 mg) was dissolved in 10ml of HNO3 (0.1%) and 
was stirred for 15 minutes at 100 ºC. Then, this mixture was filtered (0.45 microns, 
NYL) and dilutedtenfold cith 0.1% HNO3. This dilution was introduced into the 
ICP emission spectrometer and the Palladium content was measured. 
Compounds from Table 3.4: 
4-Methylnitrobenzene (3.15a). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, ppm): δ2.47 (s, 3H), 7.32 (d, J = 8.8 Hz, 2H), 8.12 (d, 
J = 8.8 Hz, 2H).  
13C-NMR (CDCl3, 100 MHz, ppm): δ21.6, 123.5, 129.8, 145.9.  
m/z calc. 137.05. Found (EI): 137.05.  
1,2,3,5-Tetramethylbenzene (3.15b). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, ppm): δ2.26 (s, 3H), 3.37 (s, 6H), 2.40 (s, 3H), 6.96 
(s, 2H).  
13C-NMR (CDCl3, 100 MHz, ppm): δ14.7, 20.4, 21.2, 128.2, 131.9, 134.7, 136.0.  
m/z calc. 134.11. Found (EI): 134.11. S8  
3-Methoxy-2-methylpyridine (3.15c). Colorless oil.  
1H-NMR (DMSO, 400 MHz, δ ppm): 2.35 (s, 3H), 3.80 (s, 3H), 7.19 (dd, J = 8.3, 
4.6 Hz, 1H), 7.31(dd, J = 8.3, 1.2 Hz, 1H), 7.99 (dd, J = 4.6, 1.2 Hz, 1H).  
13C-NMR (DMSO, 100 MHz, δ ppm): 19.2, 55.3, 116.9, 122.1, 139.8, 147.4, 
153.4.  
m/z calc. 123.07. Found (EI): 123.06.  
4-Methylanisole (3.15d). Colorless oil.  
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1H-NMR (CDCl3, 400 MHz, δ ppm): 2.44 (s, 3H), 3.86 (s, 3H), 6.97 (d, J = 8.8 Hz, 
2H), 7.49 (d, J = 8.8 Hz, 2H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 30.3, 55.3, 114.1, 127.7, 133.5, 158.7.  
m/z calc. 122.07. Found (EI): 122.08.  
1-Ethyl-4-methylbenzene (3.15e). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, ppm): δ1.21 (t, J = 7.4 Hz, 3H), 2.31 (s, 3H), 2.60 (q, 
J = 7.6 Hz, 2H), 7.09 (s, 4H).  
13C-NMR (CDCl3, 100 MHz, ppm): δ15.7, 20.9, 28.4, 127.7, 128.9, 134.9, 141.2.  
m/z calc. 120.09. Found (EI): 120.09.  
4-Methylacetophenone (3.15f). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 2.41 (s, 3H), 2.57 (s, 3H), 7.25 (d, J = 8.1 Hz, 
2H), 7.86 (d, J = 8.3 Hz, 2H).  
m/z calc. 134.07. Found (EI): 137.07.  
p-Tolualdehyde (3.15g). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 2.46 (s, 3H), 7.35 (d, J = 8.1 Hz, 2H), 7.80 (d, 
J = 8.3 Hz, 2H), 9.97 (s, 1H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 22.0, 129.7, 130.0, 134.07, 145.7, 192.3.  
m/z calc. 120.06. Found (EI): 120.06.  
2-Methylbenzonitrile (3.16h). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 2.57 (s, 3H), 7.25-7.36 (m,2H), 7.52 (t, J = 
7.6 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 20.5, 118.1, 126.2, 130.3, 132.6, 132.8, 
142.5.  
m/z calc. 117.05. Found (EI): 117.06.  
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1-tert-Butyl-4-methylbenzene (3.15i). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, ppm): δ1.36 (s, 9H), 1.43 (s, 3H), 7.45 (dt, J = 8.5, 
2.1 Hz, 2H), 7.53 (dt, J = 8.5, 2.1 Hz, 2H).  
13C-NMR (CDCl3, 100 MHz, ppm): δ14.1, 31.8, 34.5, 125.6, 126.6, 138.2, 149.9.  
m/z calc. 148.12. Found (EI): 148.12.  
4-Methylanisole (3.15j). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 2.44 (s, 3H), 3.86 (s, 3H), 6.97 (d, J = 8.8 Hz, 
2H), 7.49 (d, J = 8.8 Hz, 2H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 30.3, 55.3, 114.1, 127.7, 133.5, 158.7.  
m/z calc. 122.07. Found (EI): 122.08. 
Ethyl 4-methylbenzoate (3.15k). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 1.39 (t, J = 7.2 Hz, 3H), 2.40 (s, 3H), 4.36 (q, 
J = 7.2 Hz, 2H), 7.23 (d, J = 7.9 Hz, 2H), 7.97 (t, J = 8.1 Hz, 2H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 14.2, 21.5, 60.6, 127.7, 128.9, 129.4, 143.3, 
166.6.  
m/z  calc. 164.08. Found (EI): 164.08. S9  
2-Methoxy-6-methylpyridine (3.15l). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, ppm): δ 2.44 (s, 3H), 3.9 (s, 3 H), 6.52 (d, J = 8.3 Hz, 
1H), 6.7 (d, J = 7.2 Hz, 1H), 7.44 (dd, J = 8.3, 7.2 Hz, 1H).  
13C-NMR (CDCl3, 100 MHz, ppm): δ 24.1, 53.1, 107.0, 115.6, 138.6, 156.2, 163.6. 
 m/z calc. 123.07. Found (EI): 123.06.  
3-Methoxy-2-methylpyridine (3.15m). Colorless oil.  
1H-NMR (DMSO, 400 MHz, δ ppm): 2.35 (s, 3H), 3.80 (s, 3H), 7.19 (dd, J = 8.3, 
4.6 Hz, 1H), 7.31(dd, J = 8.3, 1.2 Hz, 1H), 7.99 (dd, J = 4.6, 1.2 Hz, 1H).  
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13C-NMR (DMSO, 100 MHz, δ ppm): 19.2, 55.3, 116.9, 122.1, 139.8, 147.4, 
153.4.  
m/z calc. 123.07. Found (EI): 123.06.  
2,6-Dimethylpyridine (3.15n). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 2.50 (s, 6H), 7.92 (d, J = 7.6 Hz, 2H), 7.43 (t, 
J = 7.6 Hz, 1H).  
13C-NMR (CDCl3, 100 MHz, δ ppm):24.4, 120.0, 136.4, 157.6.  
m/z calc. 107.07. Found (EI): 107.07.  
1-Chloro-4-methylbenzene (3.15p). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 2.32 (s, 3H), 7.06 (d, J = 8.1 Hz, 2H), 7.38 
(d, J = 8.3 Hz, 2H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 20.9, 119.0, 130.8, 131.2, 136.7.  
m/z calc. 126.02. Found (EI): 126.02.  
Compounds from table 3.5: 
1-Ethyl-4-nitrobenzene (3.16a). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 1.29 (t, J = 7.6 Hz, 3H), 2.77 (q, J = 7.6 Hz, 
2H), 7.35 (d, J = 8.8 Hz, 2H), 8.15 (d, J = 8.8 Hz, 2H). 
13C-NMR (CDCl3, 100 MHz, δ ppm): 15.0, 30.3, 123.6, 128.6, 135.7, 152.0.  
m/z calc. 151.06. Found (EI): 151.06.  
2-(4-Nitrophenyl)pyridine (3.16b). White solid. m.p.: 130-131 ºC (lit:130-131 ºC) 
1H-NMR (CDCl3, 400 MHz, δ ppm): 7.34-7.38 (m, 1H), 7.81-7.87 (m, 2H), 8.19 
(dt, J = 9, 2.1 Hz, 2H), 8.35 (dt, J = 9, 2.1 Hz, 2H), 8.76-8.78 (m, 1H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 121.2, 123.5, 124.0, 127.7, 137.1, 145.2, 
150.1, 154.8.  
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m/z calc. 200.06. Found (EI): 200.05.  
1-Cyclopropyl-4-nitrobenzene (3.16c). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 0.81-1.19 (m, 4H), 1.96-2.04 (m, 1H), 7.17 
(d, J = 8.6 Hz, 2H), 7.70 (d, J = 8.9 Hz, 2H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 11.0, 15.8, 123.6, 125.9, 129.9, 152.6.  
m/z calc. 163.06. Found (EI): 163.05. S10  
1-Cyclopropyl-4-ethylbenzene (3.16d). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 0.67-0.71 (m, 2H), 0.93-0.97 (m, 2H), 1.25 (t, 
J = 7.6 Hz, 3H), 1.86-1.93 (m, 1H), 2.63 (q, J = 7.6 Hz, 2H), 7.03 (d, J = 8.1 Hz, 
2H), 7.12 (d, J = 8.3 Hz, 2H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 8.9, 14.9, 15.7, 28.4, 125.6, 127.7, 141.1, 
141.3. 
 m/z calc. 146.11. Found (EI): 146.11.  
2-(4-Ethylphenyl)pyridine (3.16e). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm):1.22 (t, J = 7.7 Hz, 3H), 2.67 (q, J = 7.6 Hz, 
2H), 7.25-7.28 (m, 1H), 7.44-7.54 (m, 4H), 8.12 (d, J = 9 Hz, 2H), 8.6 (d, J = 9 Hz, 
1H), 8.76-8.78 (m, 1H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 15.8, 28.1, 121.4, 121.8, 127.4, 128.1, 135.9, 
136.7, 143.1, 149.6, 158.1.  
m/z calc. 183.10. Found (EI): 183.10.  
1-Ethyl-4-(phenylmethyl)benzene (3.16f). Colorless oil. 
1H-NMR (CDCl3, 400 MHz, δ ppm): 1.21 (t, J = 7.5 Hz, 3H), 2.61 (q, J = 7.5 Hz, 
2H), 3.94 (s, 2H), 7.09-7.12 (m, 4H), 7.18-7.19 (m, 3H), 7.25-7.28 (m, 2H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 16.1, 28.9, 42.0, 126.3, 126.4, 128.4, 128.7, 
128.8, 128.9, 129.0, 129.3, 129.4.  
m/z calc. 196.29. Found (EI): 196.02.  
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5-(4-Ethylphenyl)-pentanenitrile (3.16g). Colorless oil. 
1H-NMR (CDCl3, 400 MHz, δ ppm): 1.22 (t, J = 7.6 Hz, 3H), 1.64-1.71 (m, 2H), 
1.73-1.81 (m, 2H), 2.34 (t, J = 6.9 Hz, 2H), 2.59-2.65 (m, 4H), 7.07-7.14 (m, 4H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 16.1, 17.5, 25.3, 28.9, 30.8, 35.0, 120.1, 
128.3, 128.7, 138.8, 142.4.  
m/z calc. 187.28. Found (EI): 187.28.  
2-[2-(4-Ethylphenyl)-ethyl]-1,3-dioxolane (3.16h). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 1.22 (t, J = 7.6 Hz, 3H), 1.95-1.99 (m, 2H), 
2.61 (q, J = 7.6 Hz, 2H), 2.72 (dt, J = 8.1, 2.0 Hz, 2H), 4.89 (t, J = 4.6 Hz, 1H), 
7.11-7.14 (m, 4H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 16.1, 28.9, 30.2, 36.0, 65.4, 104.3, 128.3, 
128.7, 139.2, 142.2.  
m/z calc. 206.28. Found (EI): 206.28.  
Ethyl-3-(4-ethylphenyl)propanoate (3.16i). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 1.20-1.25 (m, 6H), 2.59-2.64 (m, 4H), 2.92 (t, 
J = 7.9 Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 7.11-7.13 (m, 4H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 14.6, 16.1, 28.9, 31.0, 36.5, 60.8, 128.4, 
128.7, 138.2, 142.6, 173.5.  
m/z calc. 206.28. Found (EI): 206.18.  
4-[2-(1,3-Dioxolan-2-yl)ethyl]benzaldehyde (3.16j). Colorless oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 1.99-2.03 (m, 2H), 2.84 (dt, J = 8.1, 2.2 Hz, 
2H), 3.85-3.92 (m, 2H), 3.97-4.03 (m, 2H), 4.91 (t, J = 4.6 Hz, 1H), 7.38 (d, J = 
7.8 Hz, 2H), 7.81 (d, J = 8.0 Hz, 2H), 9.97 (s, 1H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 30.7, 35.4, 65.4, 103.9, 128.4, 129.5, 130.4, 
130.8, 135.0, 149.6, 192,4.  
m/z calc. 206.24. Found (EI): 206.24.  
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Ethyl-3-(2-nitrophenyl)propanoate (3.16k). Yellow oil.  
1H-NMR (CDCl3, 400 MHz, δ ppm): 1.23 (t, J = 7.1 Hz, 3H), 2.72 (t, J = 7.5 Hz, 
2H), 3.23 (t, J = 7.5 Hz, 2H), 4.13 (q, J = 7.2 Hz, 2H), 7.36-7.42 (m, 2H), 7.52-
7.55 (m, 1H), 7.94-7.95 (m, 1H).  
13C-NMR (CDCl3, 100 MHz, δ ppm): 14.6, 16.1, 28.8, 35.3, 65.1, 125.3, 128.0, 
132.6, 133.6, 136.1, 149.8, 172.8.  
m/z calc. 223.23. Found (EI): 223.20.  
Functionalized Building Blocks 
di-tert-Butyl (5-ethyl-3-methoxypyrazin-2-yl)imidodicarbonate (3.20).Yellow solid. 
 
1H-NMR (CDCl3, 400 MHz, δ ppm): 1.25 (t, J = 7.6 Hz, 3H), 1.35 (s, 18H), 2.76 
(q, 2H), 3.34 (s, 3H), 8.00 (s, 1H). 
 
13C-NMR (CDCl3, 100 MHz, δ ppm): 13.15, 27.32, 55.66, 82.70, 132.74, 149.92, 
154.40, 155.18. 
6-Ethyl-2-[(4-fluorobenzyl)oxy]-3-nitropyridine (3.21). Yellow oil. 
 
1H-NMR (CDCl3, 400 MHz, δ ppm): 1.28 (t, J = 7.5 Hz, 3H), 2.80 (q, 2H), 5.54 (s, 
2H), 6.68 (d, J = 7.9 Hz, 1H), 7.02-7.11 (bm, 2H), 7.44 (m, 2H), 8.23 (d, J = 7.8 
Hz, 1H). 
 
1-(benzyloxy)-2-Ethyl-4-methoxy-5-nitrobenzene (3.22). Brown solid. 
 
1H-NMR (CDCl3, 400 MHz, δ ppm):1.24 (t, J = 7.8 Hz, 3H), 2.74 (q, 1H), 3.93 (s, 
3H), 3.94 (s, 2H), 7.26 (s, 1H), 7.34-7.5 (bm, 5H), 7.53 (s, 1H). 
 
 
 
 
 
 
 
 
 
 
 
Experimental -Chapter 7- 
  
-198- 
 
7.3.5 Suzuki Aryl-Aryl Coupling 
 
tert-Butyl (2-iodophenoxy)acetate (3.24) 
 
 
 
The same Mitsunobu method as in protocol E was used to deliver the product, 
after purification using MPLC (6/4 heptanes/EtOAc), in 64% yield. 
 
Molecular Formula: C12H15IO3 
MW: 334.15 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ1.48 (s, 9H, H10-12), 4.58 (s, 2H, H7), 6.72 (m, 
2H, H2,6), 7.27 (t, J = 8 Hz, 1H, H1), 7.79 (d, J = 7.5 Hz, 1H, H3). 
13C-NMR (75MHz, CDCl3, ppm): δ28.05 (C10-12), 66.64 (C7), 82.54 (C9), 86.38 
(C4), 112.11 (C6), 123.32 (C2), 129.34 (C1), 139.77 (C3), 156.72 (C5), 167.33 (C8). 
HR-MS: Calculated mass: 334.0066,  Found mass: 334.0059 
tert-Butyl [2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]acetate (3.25) 
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tert-Butyl (2-iodophenoxy)acetate (3.24) (100 mg, 0.299 mmol), bis(pinacolato-
diborane (114 mg, 0.45 mmol), KOAc (293 mg, 2.99 mmol) and Pd(dppf)Cl2 (12 
mg, 0.015 mmol)were brought in a dry two-necked flask with a cooler and a 
septum, under an atmosphere of argon. The flask was evacuated and subsequently 
purged with argon. This was repeated 2 times. 5 mL of dry and degassed DMSO 
was added via a syringe. The mixture was stirred at 80°C, for 48 hours. 
Afterwards, the reaction was cooled to RT, diluted with waterextracted with 
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EtOAc. The organic phase was dried over MgSO4, filtered and evaporated to give 
the crude product. After purification using MPLC (EtOAc), the pure product was 
obtained as colorless crystals (100 mg, quant. yield). It was stored in a freezer at -
20°C. 
 
Molecular Formula: C18H27BO5 
MW: 334.21 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ 1.26 (s, 6H, H15,18), 1.36 (s, 6H, H16,17), 1.47 
(s, 9H, H10-12), 4.54 (s, 2H, H7), 6.78 (d, J = 8.8 Hz, 1H, H6), 6.99 (t, J = 7 Hz, 1H, 
H2), 7.36 (t, J = 7.7 Hz, 1H, H1), 7.68 (d, J = 7.7 Hz, 1H, H3). 
Due to the instability of the product at RT over time, no further analysis was 
performed. 
General Procedure for Suzuki coupling to the Pyrazine Monomer: 
The pyrazine monomer 2.30 (1 eq.), the aryl boronic ester or acid 3.26 (1.2 eq.), 
SPhos (4 mol%), Pd(OAc)2 (2 mol%) and K2CO3 (3 eq.) were brought in a dry 
two-necked flask with a cooler and a septum, under an atmosphere of argon. The 
flask was evacuated and subsequently purged with argon. This was repeated 2 
times. A degassed mixture of ACN/water (3/2, 0.2 M) was added via a syringe. 
The mixture was stirred at 100°C, for 24 hours. Afterwards, the reaction was 
cooled to RT, diluted with EtOAc and filtered over a plug of Celite. The filtrate 
was dried over MgSO4, filtered and evaporated to give the crude product which 
was purified by MPLC. 
tert-Butyl [2-(5-amino-6-methoxypyrazin-2-yl)phenoxy]acetate (3.27a) 
 
 
 
Using the general procedure for Suzuki couplings on pyrazine monomers, after 
purification using MPLC (7/3 heptanes/EtOAc), the product was obtained as a 
colorless oil (68% yield). 
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Molecular Formula: C17H21N3O4 
MW: 331.37 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ1.49 (s, 9H, H10-12), 4.05 (s, 3H, H19), 4.58 (s, 
2H, H7), 4.89 (bs, 2H, -NH2), 6.85 (d, J = 8 Hz, 1H, H6), 7.09 (t, J = 8 Hz, 1H, H2), 
7.26 (t, J =  8 Hz, 1H, H1), 7.95 (d, J = 8 Hz, 1H, H3), 8.51 (s, 1H, H18). 
13C-NMR (75MHz, CDCl3, ppm): δ 28.06 (C10-12), 53.28 (C19), 66.30 (C7), 82.38 
(C9), 112.34 (C6), 121.80 (C2), 126.81 (C4), 128.52 (C1), 130.19 (C3), 134.92 (C18), 
135.55 (C16), 143.71 (C13), 147.60 (C5), 155.10 (C15), 167.81 (C8). 
HR-MS: Calculated mass: 331.1532,  Found mass: 331.1541 
tert-Butyl (2-[5-amino-6-(benzyloxy)pyrazin-2-yl]phenoxy)acetate (3.27b) 
 
 
 
Using the general procedure for Suzuki couplings on pyrazine monomers, after 
purification using MPLC (7/3 heptanes/EtOAc), the product was obtained as a 
white solid (55% yield). 
 
Molecular Formula: C23H25N3O4 
MW: 407.46 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ1.49 (s, 9H, H10-12), 4.59 (s, 2H, H7), 4.83 (bs, 
2H, -NH2), 5.50 (s, 2H, H19), 6.85 (d, J = 8 Hz, 1H, H6), 7.09 (t, J = 8 Hz, 1H, H2), 
7.26 (t, J =  8 Hz, 1H, H1), 7.7.35-7.42 (bm, 3H, H21,23,25), 7.49 (dd, J = 8 Hz, 2 Hz, 
2H, H22,24), 7.92(d, J = 8 Hz, 1H, H3), 8.53 (s, 1H, H18). 
HR-MS: Calculated mass: 407.1845,  Found mass: 407.1831 
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3-Methoxy-5-(2-methoxyphenyl)pyrazin-2-amine (3.27c) 
 
 
 
Using the general procedure for Suzuki couplings on pyrazine monomers, after 
purification using MPLC (6/4 heptanes/EtOAc), the product was obtained as a 
white solid (70% yield). 
 
Molecular Formula: C12H13N3O2 
MW: 231.25 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ3.98 (s, 3H, H7), 4.06 (s, 3H, H14), 4.85 (s, 2H, 
-NH2), 6.99 (d, J = 8Hz, 1H, H6), 7.06 (t, J = 8Hz, 1H, H2), 7.30 (t, J = 8Hz, 1H, 
H1), 7.91 (dd, J = 2, 8Hz, 1H, H3), 8.30 (s, 1H, H13).  
13C-NMR (75MHz, CDCl3, ppm): δ 53.3 (C7), 55.5 (C15), 111.5 (C6), 120.9 (C2), 
126.3 (C4), 128.8 (C3), 130.0 (C1), 134.6 (C13), 136.0 (C10), 143.5 (C8), 147.7 (C11), 
156.8 (C5). 
HR-MS: Calculated mass: 231.1003, Found  mass: 231.1008 
FT-IR (cm-1): 3465 (s, NH2) 
Tm: 139.2-140.9°C 
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3-Methoxy-5-(4-methoxyphenyl)pyrazin-2-amine (3.27d) 
 
 
 
Using the general procedure for Suzuki couplings on pyrazine monomers, after 
purification using MPLC (6/4 heptanes/EtOAc), the product was obtained as a 
white solid (70% yield). 
 
Molecular Formula: C12H13N3O2 
MW: 231.25 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ3.85 (s, 3H, H15), 4.08 (s, 3H, H14), 4.80 (bs, 
2H, -NH2), 6.95 (d, J = 8 Hz, 2H, H2,6), 7.84 (d, J = 8Hz, 2H, H3,5), 7.97 (s, 1H, 
H13). 
 
7.4  Synthesis of Peptidomimetics 
 
7.4.1 CO precursor synthesis 
 
2,4,6-Trichlorophenyl formate (4.16) 
 
Formic acid (9.71mL, 253mmol) and acetic anhydride (19.11mL, 203mmol) were 
mixed and stirred at 60°C for 1h. Afterwards the mixture was allowed to cool to 
RT. Sodium acetate (2.077 g, 25.3 mmol) and 2,4,6-trichlorophenol (5 g, 25.3 
mmol) were added to the solution and the mixture was stirred for 4 hours at RT. 
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The solution was then diluted with toluene (75 mL), washed with H2O, dried and 
evaporated in vacuo to give the product as a white solid (4.15 g, 72% yield). 
Molecular Formula: C7H3Cl3O2 
MW: 226.46 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 7.41 (s, 2H, H1,3) 8.29 (s, 1H, H8). 
13C-NMR (75MHz, CDCl3, ppm): δ  128.8 (C1,3), 129.3 (C4,6), 132.6 (C2), 141.9 
(C5), 156.2 (C7). 
HR-MS:Calculated mass: 195.9250, Found mass: 195.9249 (M – CO) 
FT-IR (cm-1): 1730 (s, ester) 
Tm: 73.6-75.1°C 
Pentafluorophenyl formate (4.14) 
 
  
Pentafluorophenol (1 g, 5.43 mmol) was dissolved in 6 mL of dry chloroform. The 
solution was cooled to 0°C, DCC (1.35 g, 6.52 mmol) and formic acid (0.25 mL, 
6.52 mmol) was added slowly while keeping the temperature at 0°C. Afterwards 
the reaction was stirred for an additional 90 minutes at 0°C. The suspension was 
then filtered and the filtrate was evaporated in vacuo. The residue was redissolved 
in Et2O and the organic phase was washed with 5% aq. NaHCO3, water and brine. 
It was then dried over MgSO4, filtered and the filtrate was evaporated in vacuo to 
give the product as a colorless oil (1 g, 87% yield). The product is not stable and 
decomposes on standing, even at -20°C 
Molecular Formula: C7HF5O2 
MW: 212.07 g/mol 
Analysis could not be performed due to the instability of the product. 
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7.4.2 Stable CO Precursors in Flow 
 
General flow procedure. 
Two solutions: A) Pd(OAc)2 (3 mol %), Xantphos (6 mol %), halide (1 equiv, 
0.24M), Et3N (1.3equiv) in THF/ DMF (1:1) and B) 2,4,6-trichlorophenyl formate 
(1.3 equiv, 0.31M) in DMF were pumped at 0.2 mL/min (each one) using R2+R4 
system. The mixed solution was driven to a 2 mL coil at 150ºC, Rt = 5 min. The 
outlet solution was concentrated in vacuo and the residue was purified by silica gel 
column chromatography. 
2,4,6-Trichlorophenyl benzoate (4.19, 4.21b-c).White crystal m.p: 54-55.  
1H-NMR (400 MHz, CDCl3) δ:7.44 (s, 2H), 7.56 (t, J =7.7 Hz, 2H), 7.70 (t, J =7.6 
Hz, 1H), 8.25 (dd, J =7.2, 1.2 Hz, 2H). 
13C-NMR (100 MHz, CDCl3) δ: 127.8, 128.6, 128.7, 129.8, 130.5, 132.0, 134.2, 
143.2, 162.9 
m/z  calc.299.95, found (EI) 299.86. 
(2,4,6-trichlorophenyl)3-Methylimidazole-4-carboxylate(4.21c).White crystal.m.p.: 
132-134°C 
1H-NMR (400 MHz, CDCl3) δ: 3.96 (s, 3H), 7.42 (s, 2H), 7.69 (s, 1H), 8.07 (s, 1H) 
13C-NMR (100 MHz, CDCl3) δ: 34.6, 121.5, 129.1, 130.4, 132.7, 140.6, 142.7, 
144.2, 156.6  
m/z  calc. 303.96, found (EI) 303.87. 
2,4,6-trichlorophenyl tiophene-3-carboxylate (4.21e). White solid m.p.: 42-43.  
1H-NMR (400 MHz, CDCl3) δ: 7.39-7.41 (m, 3H), 7.69 (dd, J = 5.1,1.4 Hz, 1H), 
8.40 (dd, J = 3.1, 1.2,1H)  
13C-NMR (100 MHz, CDCl3) δ: 53.0, 129.1, 130.0, 130.3, 130.9, 132.7, 135.5, 
143.4, 162.6, 166.4  
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m/z  calc. 305.91, found (EI) 305.92. 
2,4,6-trichlorophenyl pyrimidine-5-carboxylate (4.21f). White solid m.p.: 78-79. 
1H-NMR (400 MHz, CDCl3) δ: 7.46 (s, 2H), 7.49 (s, 2H), 7.50 (s, 1H)  
13C-NMR (100 MHz, CDCl3) δ: 123.0, 129.3, 129.9, 133.3, 142.6, 159.1, 160.6, 
162.8  
m/z calc. 301.94, found (EI) 301.85. 
2,4,6-trichlorophenyl 4-bromobenzoate (4.21g). White solid m.p.: 75-76.  
1H-NMR (500 MHz, CDCl3) δ: 7.42 (s, 2H), 7.69 (d,J = 8.7Hz, 2H), 8.09 (d, J = 
8.4Hz, 2H)  
13C-NMR (100 MHz, CDCl3) δ: 127.2, 129.1, 129.2, 132.4, 132.6, 133.2, 143.3, 
162.4  
m/z calc. 377.86, found (EI) 377.93. 
2,4,6-trichlorophenyl 4-bromothiophene-3-carboxylate (4.21h). White solid m.p.: 
115-117. 
1H-NMR (400 MHz, CDCl3) δ: 7.42-7.43 (m, 3H), 8.47 (dd,J = 3.7Hz, 1H) 
13C-NMR (100 MHz, CDCl3) δ: 112.0, 126.4, 129.05, 130.3, 132.7, 137.3, 143.1, 
157.4  
m/z calc. 383.82, found (EI) 383.69. 
7.4.3 Unstable CO precursors in Flow 
 
Procedure for aminocarbonylation in flow using a Teflon coilreactor 
Three solutions were prepared: A) Tosyl Chloride (0.3 M) and DIPEA (0.4 M), B) 
Formic acid (0.3 M) and C) PhBr (0.2 M), aniline (0.3 M), Pd(OAc)2 (0.01 M), 
Xantphos (0.02 M) in the solvent of choice (see table 4.3). Solutions A and B were 
loaded in separate syringes and pumped, using a Chemyx Fusion 200 syringe 
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pump. The solutions were mixed in an ETFE T-tube fitting (Dolomite109 part  Nr. 
3000397) and passed through a Chemtrix glass reactor chip (GRC) (residence time 
20 sec), heated using the Chemtrix Start Unit, with temperature control provided 
by a Laird Technologies MTTC1410 unit. After the GRC, the reagent stream was 
mixed with solution C (pumped via a separate syringe pump) in another T-tube 
fitting before being passed through a Teflon coil reactor (T-CR, residence time 4 
min 45 sec). The product was then collected at the outlet and subjected to GC-MS 
analysis to determine conversion. 
Procedure for aminocarbonylation using a Tube-in-Tube reactor 
A) Tosyl Chloride (0.5 M) and DIPEA (1 M), B) Formic acid (0.5 M) and C) PhBr 
(0.2 M), benzylamine (0.4 M), Pd(OAc)2 (0.01 M), Xantphos (0.02 M) and DIPEA 
(0.6 M) inthe solvent of choice (see table 4.4). Solutions A and B were loaded in 
separate syringes and pumped, using a Chemyx Fusion 200 syringe pump. The 
solutions were mixed in an ETFE T-tube fitting (Dolomite109 part  Nr. 3000397) 
and passed through the inner tube of the Tube-in-Tube reactor (residence time 1 
min). Simultaneously, solution C was passed through the outer tube of the Tube-
in-Tube reactor (residence time 10 min). The outlet stream of the inner tube was 
disposed as waste, the outlet stream of the outer tube was collected and subjected 
to GC-MS analysis to determine conversion.  
 
7.4.4 Amine Deprotection Step 
 
Procedure I: Reduction of the nitro group of the pyridine building blocks (2.51): 
The nitropyridine monomer 2.51 (1 eq.)was suspended in a 2 w% TPGS-740-M 
solution in water (0.37 M). NH4Cl (1.2 eq.) was added in one portion and the 
suspension was stirred vigorously under an argon atmosphere. Zinc powder 
(particle size <10µm) (5 eq.) was then added in one portion and the mixture was 
stirred at RT for 2 hours. The blue suspension is then filtered over a pad of silica 
and eluted with copious amounts of EtOAc. The filtrate is dried over Na2SO4, 
filtered and evaporated in vacuo. The then obtained blue oil is used immediately in 
the next step without further purification. The free amine (4.27) is not stable and 
should be used promptly. 
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Methyl 5-amino-6-methoxypyrazine-2-carboxylate (4.29a) 
 
 
di-tert-Butyl (5-bromo-3-methoxypyrazin-2-yl)imidodicarbonate(2.31a)(800 mg, 
2.087 mmol) was dissolved in 10 mL of dry DCM  and the solution was cooled in 
an icebath. To this TFA (3.215 ml, 41.7 mmol) was added dropwise while stirring. 
After the addition of TFA, the reaction was stirred at RT . for 6 hours. Afterwards, 
the solvent was evaporated in vacuo. The residue was purified using MPLC (70/30 
EtOAc/heptane) to obtain the pure product as off-white crystals(350 mg, 92 % 
yield). 
 
Molecular Formula: C7H9N3O3 
MW: 183.16 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 3.93 (s, 3H, H8), 4.11 (s, 3H, H9), 5.81 (bs, 2H, 
-NH2), 8.35 (s, 1H, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 52.18 (C8), 54.02 (C9), 128.63 (C6), 138.05 
(C5), 147.34 (C3), 147.81 (C2), 165.28 (C7). 
FT-IR (cm-1): 3338, 3111, 2953, 2876, 1715, 1551, 1447 
Tm: 87°C 
 
HR-MS:Calculated mass: 183.0644,  Found mass: 183.0650 
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Methyl 5-amino-6-isobutoxypyrazine-2-carboxylate (2.31b) 
 
 
 
di-tert-Butyl (5-bromo-3-isobutoxypyrazin-2-yl)imidodicarbonate (2.63g) (220 mg, 
0.517 mmol) was suspended in 15 mL of water, in a sealed vessel under an argon 
atmosphere. The mixture was stirred vigorously while heating to 100°C for 24 
hours. The suspension was then allowed to cool to RT and extracted three times 
with EtOAc. The combined organic phases were washed with water, brine and 
dried over MgSO4. After filtration the filtrate was evaporated in vacuo to give the 
pure product as white crystals (90 mg, 77% yield). 
Molecular Formula:C10H15N3O3 
MW: 225.24 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.04 (d, J = 6.6 Hz, H11,12), 2.13 (m, 1H, 
H10), 3.92 (s, 3H, H8), 4.25 (d, J = 6.6 Hz, 2H, H9), 5.32 (bs, 2H, -NH2), 8.37 (s, 
1H, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 52.18 (C8), 54.02 (C9), 128.63 (C6), 138.05 
(C5), 147.34 (C3), 147.81 (C2), 165.28 (C7). 
 
7.4.5 Dimerisation using Carbonylation 
 
Procedure J:Aminocarbonylative coupling of monomers 
All solid reagents: monomer A (1 eq.), monomer B (1 eq), Pd(OAc)2 (5 mol%), 
Na2CO3 (10 eq.) and Xantphos (5 mol%) were brought in a dry two-necked flask 
with a cooler and a septum, under an atmosphere of argon. The flask was 
evacuated and subsequently purged with argon. This was repeated 2 times. Dry 
and degassed Toluene (0.2 M) was added via a syringe. The mixture was purged 
with carbon monoxide for 2 minutes via a needle through the septum. (Caution! 
Carbon monoxide is a highly toxic and flammable gas). Then a carbon monoxide 
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atmosphere was created by means of a balloon. The mixture was stirred at 80°C, 
for 24 hours. Afterwards, the reaction was cooled to room temperature, diluted 
with EtOAc and filtered over a plug of Celite. The filtrate was evaporated to give 
the crude product which was purified by MPLC. 
Methyl 5-[((5-[bis(tert-butoxycarbonyl)amino]-6-methoxypyrazin-2-yl)11-
carbonyl)amino]-6-methoxypyrazine-2-carboxylate (4.30) 
 
Using procedure I, after purification using MPLC (9/1 heptanes/EtOAc), the 
product was obtained as white crystals (60% yield). 
Molecular Formula: C23H30N6O9 
MW: 534.52 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 2.17 (s, 18H, H23-28)), 3.99 (s, 3H, H16), 4.17 (s, 
3H, H17), 4.21 (s, 3H, H18), 8.81 (s, 1H, H5), 8.98 (s, 1H, H14), 10.53 (s, 1H, H7). 
13C-NMR (75MHz, CDCl3, ppm): δ 27.83 (C23-28), 52.72 (C16), 54.22 (C17), 55.00 
(C18), 84.02 (C22,21), 134.02 (C12), 135.39 (C14), 137.58 (C5), 139.13 (C6), 140.34 
(C3), 142.09 (C9), 149.06 (C2), 149.67 (C19,20), 154.21 (C11), 159.66 (C8), 164.30 
(C15). 
Tm: 242°C (decomposition) 
HR-MS:Calculated mass: 534.2074,  Found mass: 534.2103 
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Methyl 5-([3-(2-ethoxy-2-oxoethoxy)-4-nitrobenzoyl]amino)-6-methoxypyrazine-2-
carboxylate (4.31) 
 
 
Using procedure I, after purification using MPLC (9/1 heptanes/EtOAc), the 
product was obtained as a yellow solid (29% yield). 
Molecular Formula: C18H18N4O9 
MW: 434.36 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.31 (t, J = 6.9 Hz, 3H, H21), 3.99 (s, 3H, H17), 
4.20 (s, 3H, H16), 4.27 (q, 2H, H20), 4.87 (s, 2H, H18), 7.51 (d, J = 9 Hz, 1H, H14), 
7.62 (s, 1H, H10), 7.97 (d, J = 9Hz, 1H, H13), 8.72 (bs, 1H, H7), 8.77 (s, 1H, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ14.10, 52.75, 54.95, 62.00, 66.39, 115.40, 
119.18, 126.18, 134.63, 137.30, 138.67, 140.19, 142.61, 149.03, 151.57, 162.36, 
164.15, 167.20. 
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Methyl 5-[((5-[bis(tert-butoxycarbonyl)amino]-6-isobutoxypyrazin-2-
yl)carbonyl)amino]-6-isobutoxypyrazine-2-carboxylate (4.32) 
 
 
Using procedure I, after purification using MPLC (1/1 heptanes/EtOAc), the 
product was obtained as a yellow oil (59% yield). 
Molecular Formula:C29H42N6O9 
MW: 618.86 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.07 (d, J = 7 Hz, 6H, H31,32), 1.10 (d, J = 7Hz, 
6H, H33,34), 1.43 (s, 18H, H23-28), 2.18 (bm, 2H, H29,30), 3.99 (s, 3H, H16), 4.25 (d, J 
= 6.4 Hz, 2H, H17), 4.37 (d, J = 6.4 Hz, 2H, H18), 8.80 (s, 1H, H5), 8.98 (s, 1H, H14), 
10.39 (s, 1H, H7). 
13C-NMR (75MHz, CDCl3, ppm): δ 19.19 (C31,32), 19.43(C33,34), 21.06 (C29,30), 
28.05 (C23-28), 52.69 (C16), 73.49 (C17), 73.87 (C18), 83.93 (C21,22), 134.00 (C12), 
135.37 (C14), 137.30 (C5), 139.44 (C6), 140.30 (C3), 142.15 (C9), 148.91 (C2), 
149.76 (C19,20), 154.51 (C11), 159.89 (C8), 164.35 (C15). 
Tm: Oil. 
HR-MS:Calculated mass: 618.3013,  Found mass: 618.3000 
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Methyl 5-[(3-isobutoxy-4-nitrobenzoyl)amino]-6-methoxypyrazine-2-carboxylate 
(4.33) 
 
 
 
Using procedure I, after purification using MPLC (6/4 heptanes/EtOAc), the 
product was obtained as a yellow solid (38% yield). 
Molecular Formula: C18H20N4O7 
MW: 404.37 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.07 (d; J = 6.8 Hz, 6H, H20,21), 2.18 (m, 1H, 
H19), 3.96 (d, J = 6.8 Hz, 2H, H18), 3.99 (s, 3H, H16), 4.20 (s, 3H, H17), 7.41 (dd, J 
= 8.2 Hz, 1.8 Hz, 1H, H14), 7.68 (d, J = 1.8 Hz, 1H, H10), 7.91 (d, J = 8.3 Hz, 1H, 
H13), 8.70 (bs, 1H, H7), 8.78 (s, 1H, H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 18.99, 28.17, 52.76, 54.96, 76.12, 114.55, 
117.63, 125.77, 134.54, 137.28, 138.68, 140.30, 142.15, 149.10, 152.79, 162.81, 
164.17. 
HR-MS: Calculated mass: 404.1332,  Found mass: 404.1339 
3-isoButoxy-N-[3-methoxy-5-(4-methoxyphenyl)pyrazin-2-yl]-4-nitrobenzamide 
(4.34) 
 
Using procedure I, after purification using MPLC (6/4 heptanes/EtOAc), the 
product was obtained as a yellow solid (8% yield). 
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Molecular Formula: C23H24N4O6 
MW: 452.17 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.07 (d; J = 6.8 Hz, 6H, H20,21), 2.17 (m, 1H, 
H19), 3.88 (s, 3H, H27), 3.96 (d, J = 6.8 Hz, 2H, H18), 4.16 (s, 3H, H17), 7.00 (d, J = 
8.5 Hz, 1H, H23,25), 7.44 (dd, J = 8 Hz, 1.6 Hz, 1H, H14), 7.69 (d, J = 1.3 Hz, 1H, 
H10), 7.90 (d, J = 8.4 Hz, 1H , H13), 7.95 (dd, J = 8.9 Hz, 1.7 Hz, 2H, H22,26), 8.42 
(s, 1H, H5), 8.55 (bs, 1H, H7). 
13C-NMR (75MHz, CDCl3, ppm): δ 19.00, 28.19, 54.12, 55.42, 76.06, 114.36, 
75.47, 125.70, 127.84, 128.38, 129.95, 134.82, 139.28, 141.84, 145.30, 150.00, 
152.75, 160.82, 163.12. 
HR-MS: Calculated mass: 452.1696,  Found mass: 452.1680 
tert-Butyl 3-((3-[((5-[bis(tert-butoxycarbonyl)amino]-6-isobutoxypyrazin-2-
yl)carbonyl)amino]-6-morpholin-4-ylpyridin-2-yl)oxy)propanoate (4.35) 
 
 
 
Using procedure I, after purification using MPLC (4/6 heptanes/EtOAc), the 
product was obtained as yellow crystals (24% yield). 
Molecular Formula: C35H52N6O10 
MW: 716.82 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.10 (d, J = 6.9 Hz, 6H, H20,21), 1.39 (s, 9H, 
H25-27), 1.41 (s, 18H, H36-51), 2.19 (m, 1H, H19), 2.75 (t, J = 6.86 Hz, 2H, H22), 3.46 
(m, 4H, H28,31), 3.84 (m, 4H, H29,30), 4.31 (d, J = 6.86 Hz, 2H, H18), 4.64 (t, J = 6.9 
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Hz, 2H, H17), 6.25 (d, J = 8.7 Hz, 1H, H5), 8.68 (d, J = 8.7 Hz, 1H, H4), 8.86 (s, 1H, 
H14), 9.70 (s, 1H, H7). 
13C-NMR (75MHz, CDCl3, ppm): δ 16.22, 27.86, 27,97, 28.03, 35.63, 45.88, 
61.78,66.79, 73.47, 80.95, 83.62, 98.33, 112.80, 129.85, 134.02, 140.57, 140.93, 
149.75, 151.39, 154.07, 154.30, 159.90, 169.95. 
2-(Benzyloxy)-N-[2-(benzyloxy)-6-morpholin-4-ylpyridin-3-yl]-5-isobutoxy-4-
nitrobenzamide  (4.36) 
 
 
 
Using procedure I, after purification using MPLC (8/2 heptanes/EtOAc), the 
product was obtained as a yellow oil (15% yield). 
Molecular Formula: C34H36N4O7 
MW: 612.67 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.01 (d, J = 6.7 Hz, 6H, H35,36), 2.11 (m, 1H, 
H34), 3.46 (m, 4H, H15,18), 3.84 (m, 4H, H16,17), 3.89 (d, J = 6.7 Hz, 2H, H33), 4.76 
(s, 2H, H26), 5.25 (s, 2H, H19), 6.23 (d, J = 7.8 Hz, 1H, H5), 7.16-7.21 (bm, 6H, 
H21,23,25,28,30,32), 7.26-7.32 (bm, 4H, H22,24,29,32), 7.37 (s, 1H, H10), 8.00 (s, 1H, H13), 
8.72 (d, J = 8.9 Hz, 1H, H4), 10.47 (s, 1H, H7). 
Tm: oil. 
HR-MS:Calculated mass: 612.2584,  Found mass: 612.2563 
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3-[(4-Fluorobenzyl)oxy]-N-(3-methoxy-5-[(trimethylsilyl)ethynyl]pyrazin-2-yl)-4-
nitrobenzamide(4.37) 
 
 
Using procedure I, after purification using MPLC (8/2 heptanes/EtOAc), the 
product was obtained as a yellow solid (21% yield). 
Molecular Formula: C24H23FN4O5Si 
MW: 494.55 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 0.29 (s, 9H, H18-20), 3.99 (s, 3H, H15), 5.18 (s, 
2H, H21), 7.07 (t, J = 8.5 Hz, 2H, H23,27), 7.23 (dd, J = 8.2 Hz, 1.7 Hz, 1H, H10), 
7.39 (m, 2H, H24,26), 7.49 (d, J = 1.5 Hz, 1H, H14), 7.76 (d, J = 8.5 Hz, 1H, H11) , 
8.00 (s, 1H, H5). 
 
tert-Butyl 3-([3-((5-methoxy-4-nitro-2-[(1-trityl-1H-imidazol-4-
yl)methoxy]benzoyl)amino)-6-morpholin-4-ylpyridin-2-yl]oxy)propanoate (4.38) 
 
 
Using procedure I, after purification using MPLC (1/1 heptanes/EtOAc), the 
product was obtained as a yellow oil (15% yield). 
Molecular Formula:C47H48N6O9 
MW: 840.92 g/mol 
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1H-NMR (300MHz, CDCl3, ppm):δ 1.41 (s, 9H, H23-25), 2.76 (t, J = 6.6 Hz, 2H, 
H20), 3.45 (m, 4H, H15,18), 3.89 (m, 4H, H16,17), 4.11 (s, 3H, H49), 4.68 (t, J = 6.3 Hz, 
2H, H19), 5.22 (s, 2H, H26), 6.22 (d, J = 9Hz, 1H, H5), 6.97 (d, J = 1.3 Hz, 1H, 
H28), 7.11-7.14 (bm, 6H, H35,37,40,42,45,47), 7.31-7.33 (bm, 9H, H34,36,38,39,41,43,44,46,48), 
7.44 (d, J = 1.4 Hz, 1H, H29), 7.51 (s, 1H, H10), 8.23 (s, 1H, H13), 8.68 (d, J = 
8.9Hz, 1H, H4), 10.20 (s, 1H, H7). 
Tm: oil 
N-(6-Isopropoxy-5-nitropyridin-2-yl)-3-methoxy-5-(2-methoxyphenyl)pyrazin-2-
amine (4.40cII) 
 
3-methoxy-5-(2-methoxyphenyl)pyrazin-2-amine (300 mg, 1.297 mmol), 6-
chloro-2-isopropoxy-3-nitropyridine (281 mg, 1.297 mmol), Pd(OAc)2 (15 mg, 
0.065 mmol), Xantphos (37.5 mg, 0.065 mmol) and NaOAc (1375 mg, 12.97 
mmol) were brought in a dry two-necked flask with a cooler and a septum, under 
an atmosphere of argon. The flask was evacuated and subsequently purged with 
argon. This was repeated 2 times. 7 mL of dry and degassed toluene was added via 
a syringe. The mixture was subsequently stirred at 80°C for 48hours. It was then 
allowed to cool to RT. Afterwards the mixture was diluted with EtOAc (50mL) 
and filtered over Celite. The filtrate was evaporated in vacuo. Purification was 
performed using MPLC (1/1 Heptane/EtOAc) to yield the product as a yellow 
solid (306 mg, 57% yield). 
 
Molecular Formula: C20H21N5O5 
MW: 411 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ 1.48 (d, J = 6Hz, 6H, H23,24), 3.97 (s, 3H, 
H14), 4.20 (s, 3H, H15), 5.55 (m, 1H, H22), 7.06 (d, J = 9Hz, 1H, H3), 7.12 (t, J = 
8Hz, 1H,H1), 7.39 (t, J = 8Hz, 1H, H2), 8.00 (d, J = 9Hz, 1H, H21), 8.22 (d, J = 
9Hz, 1H, H6),8.43 (d, J = 9Hz, 1H, H20),8.62 (s, 1H, H12). 
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13C-NMR (75MHz, CDCl3, ppm): δ 22.0 (C23,24), 53.9 (C15), 55.6 (C14), 70.7 (C22), 
103.1 (C21), 111.5 (C3), 121.0 (C1), 125.4 (C5), 127.8 (C19), 129.8 (C2), 130.3 (C9), 
132.4 (C20), 134.2 (C12), 137.3 (C10), 138.7 (C7), 139.5 (C4), 147.8 (C18), 157.2 
(C16). 
HR-MS:Calculated mass: 411.1512, Found mass: 411.1543 
FT-IR (cm-1):3381 (m, secondary amine) 
Tm: 155.0-156.3°C 
 
7.4.6 Trimerisation Using Carbonylation 
 
Methyl 5-[((5-[bis(tert-butoxycarbonyl)amino]-6-methoxypyrazin-2-
yl)carbonyl)amino]-6-methoxypyrazine-2-carboxylate (4.43) 
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Methyl-5-[((5-[bis(tert-butoxycarbonyl)amino]-6-isobutoxypyrazin-2-yl)carbonyl) 
amino]-6-isobutoxypyrazine-2-carboxylate (4.32) (200 mg, 0.374 mmol) was 
dissolved in 20 mL of DCM under an atmosphere of argon. The solution was 
cooled to 0°C in an ice bath and TFA (0.577 ml, 7.48 mmol) was slowly added 
while stirring. The reaction mixture was then stirred at RT for 4 hours. Afterwards, 
the solvent was evaporated in vacuo to give a white-yellow powder, which was 
washed with water, MeOH, heptane, EtOAc and DCM to afford  the product as an 
off-white powder (125 mg, 100 % yield). 
Molecular Formula: C13H14N6O5 
MW: 334.29 g/mol 
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Due to the poor solubility of this product in all solvents tried, analytical data are 
not available. 
Methyl 5-[((5-[((5-[bis(tert-butoxycarbonyl)amino]-6-methoxypyrazin-2-
yl)carbonyl)amino]-6-methoxypyrazin-2-yl)carbonyl)amino]-6-methoxypyrazine-
2-carboxylate (4.44) 
 
Using procedure I, after purification using MPLC (9/1 EtOAc/heptanes), the 
product was obtained as a white solid (17% yield). 
Molecular Formula: C29H35N9O11 
MW: 685.64 g/mol 
Peak assignments of the 13C and 1H NMR spectra were confirmed using 2D NMR 
experiments. 
1H-NMR (300MHz, CDCl3, ppm):δ 1.44 (s, 18H, H30-32, 34-37), 3.99 (s, 3H, H16), 
4.18 (s, 3H, H26), 4.21 (s, 3H, H18), 4.27 (s, 3H, H17), 8.81 (s, 1H, H14), 9.00 (s, 1H, 
H25), 9.04 (s, 1H, H5), 10.40 (s, 1H, H7), 10.50 (s, 1H, H37). 
13C-NMR (75MHz, CDCl3, ppm): δ 27.89 (C30-32, 34-36), 52.70 (C15), 54.24 (C18), 
54.70 (C17), 54.97 (C26), 84.08 (C29,33), 133.78 (C9), 134.54 (C6), 135.52 (C5), 
136.34 (C25), 137.64 (C14), 138.99 (C20), 140.52 (C12), 140.92 (C3), 142.20 (C23), 
148.01 (C2), 149.01 (C11), 149.71 (C27,28), 154.23 (C22), 159.55 (C8), 159.84 (C19), 
164.35 (C15). 
HR-MS: Calculated mass: 483.1266,  Found mass: 483.1278 (M-2Boc) 
-Chapter 7- Experimental 
 
-219- 
 
Methyl 5-[((5-[bis(tert-butoxycarbonyl)amino]-6-isobutoxypyrazin-2-
yl)carbonyl)amino]-6-isobutoxypyrazine-2-carboxylate (4.45) 
 
 
Methyl 5-[((5-[bis(tert-butoxycarbonyl)amino]-6-isobutoxypyrazin-2-yl)carbonyl) 
amino]-6-isobutoxypyrazine-2-carboxylate (4.32) (115 mg, 0.186 mmol) was 
suspended in 7 mL of water, in a sealed vessel under an argon atmosphere. The 
mixture was stirred vigorously while heating to 100°C for 72 hours. The 
suspension was then allowed to cool to RT and extracted three times with EtOAc. 
The combined organic phases were washed with water, brine and dried over 
MgSO4. After filtration the filtrate was evaporated in vacuo to give the pure 
product as white crystals (72 mg, 92% yield). 
Molecular Formula: C19H26N6O5 
MW: 418.45 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.095 (d, J = 6.8 Hz, 6H, H20,22), 1.10 (d, J = 
6.8 Hz, 6H, H18,20), 2.19 (m, 2H, H19,21), 3.97 (s, 3H, H16), 4.23 (d, J = 6 Hz, 2H, 
H19), 4.35 (d, J = 6Hz, 2H, H17), 5.60 (bs, 2H, -NH2), 8.59 (s, 1H, H14), 8.77 (s, 1H, 
H5). 
13C-NMR (75MHz, CDCl3, ppm): δ 19.34 (C20,22), 19.46 (C18,20), 27.98 (C21), 
28.06 (C19), 52.59 (C16), 72.87 (C19), 73.69 (C17), 129.51 (C3), 133.04 (C9), 136.75 
(C14), 137.44 (C5), 141.04 (C12), 145.98 (C6), 148.45 (C11), 148.76 (C2), 161.25 
(C8), 164.90 (C15). 
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Methyl 5-[((5-[((5-[bis(tert-butoxycarbonyl)amino]-6-isobutoxypyrazin-2-
yl)carbonyl)amino]-6-isobutoxypyrazin-2-yl)carbonyl)amino]-6-
isobutoxypyrazine-2-carboxylate (4.46) 
 
 
 
Using procedure I, after purification using MPLC (8/2 EtOAc/heptanes), the 
product was obtained as a white solid (19% yield). 
Molecular Formula: C38H53N9O11 
MW: 811.88 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.08 (d, J = 7 Hz, 6H, H45,46), 1.11 (d, J = 7 Hz, 
6H, H42,43), 1.16 (d, J = 7Hz, H39,40), 1.44 (s, 18H, H30-32,34-36), 2.19 (bm, 3H, 
H38,51,44), 3.99 (s, 3H, H16), 4.26 (d, J = 5.6 Hz, 2H, H26), 4.35 (d, J = 5.6 Hz, 2H, 
H18), 4.37 (d, J = 5.6, 2H, H17), 8.79 (s, 1H, H14), 9.00 (s, 1H, H25), 9.06 (s, 1H, H5), 
10.26 (s, 1H, H37), 10.37 (s, 1H, H7). 
13C-NMR (75MHz, CDCl3, ppm): δ 19.21 (C45,46), 19.48 (C42,43), 19.50 (C39,40), 
27.89 (C30-32,34-36), 28.06 (C44), 28.09 (C41), 28.16 (C38), 52.67 (C16), 73.47 (C26), 
73.76 (C17,18), 84.00 (C29,33), 133.77 (C9), 134.64 (C6), 135.51 (C5), 136.33 (C25), 
137.38 (C14), 139.32 (C20), 140.49 (C12), 141.01 (C3), 142.25 (C23), 147.90 (C2), 
148.85 (C11), 149.82 (C27,28), 154.52 (C22), 159.76 (C8), 160.04 (C19), 164.40 (C15). 
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7.4.7 Hybrid Multimers 
 
di-tert-Butyl [3-methoxy-5-(([3-methoxy-5-(2-methoxyphenyl)pyrazin-2-
yl]amino}carbonyl)pyrazin-2-yl]imidodicarbonate (4.47) 
 
 
 
Using procedure I, after purification using MPLC (8/2 EtOAc/heptanes), the 
product was obtained as a yellow solid (37% yield). 
Molecular Formula: C28H34N6O8 
MW: 582.60 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.43 (s, 18H, H28-29,31-33), 3.92 (s, 3H, H22), 
4.17 (s, 6H, H21,23), 7.04 (d, J = 7.4 Hz, 1H, H3), 7.10 (t, J = 7.4 Hz, 1H, H1), 7.39 
(t, J = 7.5 Hz, 1H, H2), 7.98 (d, J = 8.3 Hz, 1H, H6), 8.84 (s, 1H, H12), 8.99 (s, 1H, 
H20), 10.23 (s, 1H, H13). 
13C-NMR (75MHz, CDCl3, ppm): δ 27.85 (C28-29,31-33), 54.13 (C21), 54.17 (C23), 
55.57 (C22), 83.88 (C26,30),  111.58 (C3), 120.98 (C1), 125.21 (C5), 130.30 (C6), 
130.52(C10), 135.19 (C12), 135.91 (C7), 139.84 (C20), 141.57 (C17), 149.72 (C26,30), 
154.14 (C9), 157.38 (C4), 159.63 (C14). 
HR-MS: Calculated mass: 582.2438,  Found mass: 582.2428 
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tert-Butyl(2-[5-((3-[2-(tert-butylamino)-2-oxoethoxy]-4-nitrobenzoyl)amino)-6-
methoxypyrazin-2-yl]phenoxy)acetate (4.48) 
 
 
 
Using procedure I, after purification using MPLC (7/3 EtOAc/heptanes), the 
product was obtained as a yellow oil (39% yield). 
Molecular Formula: C30H35N5O9 
MW: 609.63 g/mol 
1H-NMR (300MHz, CDCl3, ppm):δ 1.45 (s, 9H, H27-29), 1.47 (s, 9H, H32-34), 4.11 (s, 
3H, H23), 4.62 (s, 4H, H22, 21), 6.86 (d, J = 9 Hz, 1H, H3), 7.07 (s, 1H, H16), 7.12 (t, 
J = 7.8 Hz, 1H, H1), 7.35 (t, J = 7.8 Hz, 1H, H2), 7.61 (d, J = 9Hz, 1H, H6), 7.97 (d, 
J = 7.8 Hz, 1H, H20), 8.12 (d, J = 9 Hz, 1H, H19), 8.74 (s, 1H, H12), 8.90 (s, 1H, H13) 
13C-NMR (75MHz, CDCl3, ppm): δ 28.03 (C27-29), 28.68 (C32-34), 51.53 (C26), 
54.09 (C23), 65.91 (C21), 68.14 (C22), 82.63 (C31), 112.09, 114.71, 119.93, 
121.85, 125.36, 126.95, 130.33, 130.99, 134.65, 135.85, 140.54, 140.63, 150.14, 
151.13, 155.54, 162.65, 165.32, 167.54. 
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tert-Butyl[2-methoxy-6-([[3-methoxy-5-(2-methoxyphenyl)pyrazin-2-
yl]amino]carbonyl)pyridine-3-yl]carbamate (4.49) 
 
 
Using procedure I, after purification using MPLC (8/2 EtOAc/heptanes), the 
product was obtained as a yellow solid (39% yield). 
Molecular Formula: C24H27N5O6 
MW: 482.50 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ 1.55 (s, 9H, H26,27,28), 3.90 (s, 3H, H29), 4.14 
(s, 3H, H8), 4.16 (s, 3H, H21), 7.01 (d, J = 7Hz, 1H, H3), 7.17 (s, 1H, H29), 7.08 (t, J 
= 7Hz, 1H, H6), 7.37 (t, J = 7Hz, 1H, H2), 7.97 (t, J = 7Hz, 2H, H12), 8.49 (d, J = 
8Hz, 1H, H19),8.80 (s, 1H,H12), 10.53 (s, 1H, H13). 
13C-NMR (75MHz, CDCl3, ppm): δ 28.3 (C26,27,28), 53.7 (C21), 54.0 (C22), 55.6 
(C23), 161.6 (C7),81.7 (C25), 111.6 (C3), 118.0 (C20), 120.9 (C1), 124.6 (C15), 125.6 
(C5), 127.1 (C6), 130.0 (C2), 130.4 (C19), 135.8 (C12), 136.0 (C10), 138.7 (C3), 
141.3 (C17), 149.2 (C15), 150.8 (C9), 152.2 (C24), 157.4 (C14). 
FT-IR (cm-1): 1734 (d, carbamate) 
Tm: 166.2-168.6°C 
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7.5  G6 Derivatives and Fragment Synthesis  
 
2-(4-Methoxyphenyl)quinoline-4-carboxylic acid 
 
 
1-(4-methoxyphenyl)ethanone (5 g, 33.3 mmol) and indoline-2,3-dione (4.90 g, 
33.3 mmol) were mixed with a 30% potassium hydroxide (29.9 g, 160 mmol) 
solution. The resulting suspension was refluxed for 24 hours, under an atmosphere 
of argon. The mixture was then cooled to RT and diluted with water (50 ml). 
Subsequently, AcOH was added dropwise until a pH of 5-6 was reached, upon 
which a large volume of yellow precipitate was formed. This precipitate was then 
filtered of and air dried. Further drying was achieved by storing the product over 
P2O5 in an dessicator. The product was obtained as a yellow solid(7.7 g, 83 % 
yield). 
Molecular Formula: C17H13NO3 
MW: 279.29 g/mol 
1H-NMR (300MHz, d6-DMSO, ppm): δ 3.85 (s, 3H, H17), 7.10 (d, J = 8.4 Hz, 2H, 
H13,15), 7.55 (t, J = 8.5 Hz, 1H, H9), 7.73 (t, J = 8.5 Hz, 1H, H8), 8.03 (d, J = 7.7 
Hz, 1H, H10), 8.19 (s, 1H, H1), 8.23 (d, J = 8.5 Hz, 2H, H12,16), 8.59 (d, J = 8.4 Hz, 
1H, H7). 
2-Morpholin-4-yl-ethanol 
 
2-bromoethanol (1.5 mL, 21.15 mmol) and morpholine (3.87 mL, 44.4 mmol) 
were dissolved in 15 mL of toluene. The solution was stirred at 80°C for 2 hours. 
The mixture was cooled to RT and the white precipitate was filtered of. The 
filtrate was evaporated in vacuo to obtain a yellow oil which was vacuum distilled 
to obtain the product  as a light-yellow oil(1.8 g, 64.9 % yield). 
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Molecular Formula: C6H13NO2 
MW: 131.17 g/mol 
All analytical data were found  to be in accordance with the literature. 
2-Morpholin-4-ylethyl 2-(4-methoxyphenyl)quinoline-4-carboxylate (G6) 
 
 
2-(4-methoxyphenyl)quinoline-4-carboxylic acid (700 mg, 2.506 mmol), 1H-
benzo[d][1,2,3]triazol-1-ol (339 mg, 2.506 mmol) and NMM (0.276 ml, 2.506 
mmol) were dissolved in dry THF (Volume: 10 ml), under an atmosphere of argon. 
The mixture was cooled to 0°C and DCC (543 mg, 2.63 mmol) was slowly added. 
Afterwards, 2-morpholinoethanol (362 mg, 2.76 mmol) was added while cooling 
and the reaction was stirred for 1 hour at 0°C. After this period, the reaction was 
allowed to warm to R.T. and stirred for another 12 hours. The mixture was filtered 
and the filtrate evaporated. To the evaporated filtrate was added  EtOAc and sat. 
NaHCO3 (2:1), the organic phase was separated and further washed with water. 
The EtOAc was then dried with MgSO4 and the solvent evaporated in vacuo. The 
crude product was purified by MPLC (70/30 EtOAc/heptane) to obtain the product 
as a yellow oil (477 mg, 49 % yield). 
Molecular Formula: C23H24N2O4 
MW: 392.45 g/mol 
1H-NMR (300MHz, d6-DMSO, ppm): δ 3.59 (bm, 4H, H21,24), 3.86 (s, 3H, H17), 
4.04 (bm, 4H, H22,23), 4.07 (bm, 2H, H20), 4.95 (bm, 2H, H19),  7.09 (d, J = 8.4 Hz, 
2H, H13,15), 7.66 (t, J = 8.5 Hz, 1H, H9), 7.83 (t, J = 8.5 Hz, 1H, H8), 7.89 (d, J = 
7.7 Hz, 1H, H10), 8.06 (d, J = 8.5 Hz, 2H, H12,16), 8.14 (s, 1H, H1), 8.49 (d, J = 8.4 
Hz, 1H, H7). 
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4-[2-(([2-(4-Methoxyphenyl)quinolin-4-yl]carbonyl)oxy)ethyl]-4-
methylmorpholin-4-ium. (G6 salt) 
 
 
2-morpholinoethyl 2-(4-methoxyphenyl)quinoline-4-carboxylate (G6) (290 mg, 
0.739 mmol) was dissolved in 5 mL of DCM. To this solution iodomethane (0.460 
ml, 7.39 mmol) was added dropwise while stirring. The reaction was subsequently 
refluxed for 12 hours. The mixture was then cooled to RT and a yellow precipitate 
was formed. This precipitate was filtered of and air dried to give the product  as a 
yellow solid (243 mg, 81% yield). The product can be recrystallized from 
acetone/heptane. 
Molecular Formula: C24H27N2O4+I- 
MW: 534.39 g/mol 
1H-NMR (300MHz, d6-DMSO, ppm): δ 3.60 (m, 4H, H21,24), 3.87 (s, 3H, H17), 
3.98 (m, 4H, H22,23), 4.10 (m, 2H, H19), 4.91 (bm, 2H, H20), 7.16 (d, J = 8.4 Hz, 
2H, H13,15), 7.72 (t, J = 8.5 Hz, 1H, H9), 7.88 (t, J = 8.5 Hz, 1H, H8), 8.16 (d, J = 
7.7 Hz, 1H, H10), 8.26 (d, J = 8.5 Hz, 2H, H12,16), 8.48 (s, 1H, H1), 8.63 (d, J = 8.4 
Hz, 1H, H7). 
1,4-Dichloro-2-[(3-nitrobenzyl)thio]benzene 
 
 
K2CO3 (134 mg, 0.942 mmol) and NaH (23 mg, 0.972 mmol) were suspended in 2 
mL of dry DMF, under an argon atmosphere. The ssuspension was cooled to 0°C 
and 2,5-dichlorobenzenethiol (166 mg, 0.926 mmol) was slowly added while 
stirring, keeping the temperature at 0°C. After this addition, the mixture was 
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stirred for another 20 min at 0°C. 3-nitro-benzylbromide (200 mg, 0.926 mmol), 
dissolved in 1 mL of dry DMF, was then slowly added, keeping the temperature at 
0°C. The reaction mixture was then allowed to warm to RT and stirred for 18 
hours. Afterwards, 10 mL of water were added and the mixture was extracted three 
times with DCM. The combined organic layers were washed with aq. 1M HCl, 
water and brine. The organic phase was then dried over MgSO4, filtered and 
evaporated in vacuo. The crude product was purified using MPLC (91/9 
heptanes/EtOAc) to give the product as a white solid (50 mg, 17% yield). 
Molecular Formula: C13H9Cl2NO2S 
MW: 314.19 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ 4.22 (s, 2H, H7), 7.13 (dd, J = 9Hz, 2.6 Hz, 
1H, H11), 7.20 (d, J = 2.5 Hz, 1H, H6), 7.31 (d, J = 9Hz, 1H, H10), 7.50 (t, J = 8.2 
Hz, 1H, H3), 7.66 (d, J = 8.4 Hz, 1H, H4), 8.14 (d, J = 8.4 Hz, 1H, H2), 8.19 (s, 1H, 
H6). 
(3-([(2,5-Dichlorophenyl)thio]methyl)phenyl)amine 
 
 
1,4-Dichloro-2-[(3-nitrobenzyl)thio]benzene (30 mg, 0.095 mmol) was dissolved 
in 1 mL of EtOH. FeSO4.7H2O (80 mg, 0.286 mmol), NH4Cl (41 mg, 0.764 mmol) 
and 0.2 mL of water were added. The mixture was stirred and zinc powder (19 mg, 
0.286 mmol) was slowly added. The grey suspension was then stirred at 50°C for 
4 hours. The yellow suspension was allowed to cool to RT and filtered over Celite, 
rinsing with EtOH. The filtrate was evaporated and the residue was redissolved in 
EtOAc. The organic phase was washed with aq. 25% NH4Cl, sat. aq. NaHCO3, 
water and brine. The EtOAc phase was then dried over MgSO4, filtered and 
evaporated in vacuo. The residue was purified using MPLC (8/2 heptanes/EtOAc) 
to obtain the pure product as a white solid (10 mg, 37%). 
 
Molecular Formula: C13H11Cl2NS 
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MW: 284.20 g/mol 
1H-NMR (300MHz, CDCl3, ppm): δ 3.68 (bs, 2H, -NH2), 4.06 (s, 2H, H7), 6.60 (d, 
J = 9Hz, 1H, H2), 6.72 (s, 1H, H6), 6.75 (d, J = 8.4 Hz, 1H, H4), 7.06 (d, J = 8.4 
Hz, 1H, H13), 7.11 (t, J = 8.2 Hz, 1H, H3), 7.21 (s, 1H, H13), 7.28 (s, 1H, H10). 
13C-NMR (75MHz, CDCl3, ppm): δ 37.29, 114.49, 115.37, 126.22, 127.45, 129.65, 
130.32, 130.87, 132.92, 136.54, 138.46, 146.77. 
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